US20140221333A1 - Btk inhibitors - Google Patents
Btk inhibitors Download PDFInfo
- Publication number
- US20140221333A1 US20140221333A1 US14/233,478 US201214233478A US2014221333A1 US 20140221333 A1 US20140221333 A1 US 20140221333A1 US 201214233478 A US201214233478 A US 201214233478A US 2014221333 A1 US2014221333 A1 US 2014221333A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- amino
- pyrazin
- imidazo
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [3*]C([4*])(C)c1cc(C2=B(#B)B=C(C(=O)Nc3cc([5*])[y]cn3)B(=BB)=B2B(B)B)c2c(N)nccc12.[KH] Chemical compound [3*]C([4*])(C)c1cc(C2=B(#B)B=C(C(=O)Nc3cc([5*])[y]cn3)B(=BB)=B2B(B)B)c2c(N)nccc12.[KH] 0.000 description 54
- KUZNEHVVLNEUIP-HXUWFJFHSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 KUZNEHVVLNEUIP-HXUWFJFHSA-N 0.000 description 3
- LFXCFKCQTRPVEM-UAPYVXQJSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 LFXCFKCQTRPVEM-UAPYVXQJSA-N 0.000 description 3
- UEUTVBADLGWTOZ-GOSISDBHSA-N *.COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)CCO4)=NC(Br)=C23)C(OC)=C1 Chemical compound *.COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)CCO4)=NC(Br)=C23)C(OC)=C1 UEUTVBADLGWTOZ-GOSISDBHSA-N 0.000 description 2
- LIJRGAPLARCXAV-LJQANCHMSA-N CC(=O)N1CCC[C@@H](NC2=C(C(=N)C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C(N)=NC=C2)C1 Chemical compound CC(=O)N1CCC[C@@H](NC2=C(C(=N)C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C(N)=NC=C2)C1 LIJRGAPLARCXAV-LJQANCHMSA-N 0.000 description 2
- ZABIUEPYWNCVOV-OAQYLSRUSA-N CC(C)C(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound CC(C)C(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 ZABIUEPYWNCVOV-OAQYLSRUSA-N 0.000 description 2
- WDZMYKJOFRYQQR-IBGZPJMESA-N CC1(C(=O)N2CCO[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCO[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 WDZMYKJOFRYQQR-IBGZPJMESA-N 0.000 description 2
- ZZSBFVCUMVRXBD-UHFFFAOYSA-N CC1(C)OB(C2=C(F)C=C(C(=O)NC3=NC=CC(OC4CC4)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=C(F)C=C(C(=O)NC3=NC=CC(OC4CC4)=C3)C=C2)OC1(C)C ZZSBFVCUMVRXBD-UHFFFAOYSA-N 0.000 description 2
- VXWIOPIIVPUSED-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC=N3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC=N3)C=C2)OC1(C)C VXWIOPIIVPUSED-UHFFFAOYSA-N 0.000 description 2
- YPOASKGAGZUSMT-HXUWFJFHSA-N CC1(CN2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(CN2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 YPOASKGAGZUSMT-HXUWFJFHSA-N 0.000 description 2
- CBMWAKBYAHNXAQ-HXUWFJFHSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 CBMWAKBYAHNXAQ-HXUWFJFHSA-N 0.000 description 2
- JTIQZUXOIISYIH-OAQYLSRUSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(C)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(C)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 JTIQZUXOIISYIH-OAQYLSRUSA-N 0.000 description 2
- JYMSYZYLZZYJNK-HXUWFJFHSA-N CC1=NOC(C)=C1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC1=NOC(C)=C1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 JYMSYZYLZZYJNK-HXUWFJFHSA-N 0.000 description 2
- VZHNEWMQGBQLEK-DLSAPELLSA-N CC1CCC2=C(C1)SC(NC(=O)C1=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C1)=N2 Chemical compound CC1CCC2=C(C1)SC(NC(=O)C1=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C1)=N2 VZHNEWMQGBQLEK-DLSAPELLSA-N 0.000 description 2
- HQHOXYKMEPIABV-QGZVFWFLSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 HQHOXYKMEPIABV-QGZVFWFLSA-N 0.000 description 2
- JVAIUVQDIWVFDI-PKOBYXMFSA-N CCC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CCC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F JVAIUVQDIWVFDI-PKOBYXMFSA-N 0.000 description 2
- YGUNMVVWZMFSSN-UHFFFAOYSA-N CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)S1 Chemical compound CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)S1 YGUNMVVWZMFSSN-UHFFFAOYSA-N 0.000 description 2
- AOVHAFXKCAKXJQ-KESTWPANSA-N CCCC1=CC(NC(=O)C2=C(OC)C=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=C(OC)C=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 AOVHAFXKCAKXJQ-KESTWPANSA-N 0.000 description 2
- VMTDRSYMPBBEAP-UHFFFAOYSA-N CCN(CC)C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound CCN(CC)C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 VMTDRSYMPBBEAP-UHFFFAOYSA-N 0.000 description 2
- PTTYLOUVAYDICT-UHFFFAOYSA-N CCNC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CCNC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=NN23)C1 PTTYLOUVAYDICT-UHFFFAOYSA-N 0.000 description 2
- UZTYCLSPYCVSBO-GOSISDBHSA-N CCNC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound CCNC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)C3=C2N=CN=C3N)C1 UZTYCLSPYCVSBO-GOSISDBHSA-N 0.000 description 2
- DTCQIMAAJSRPDP-SFHVURJKSA-N CCNC(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCNC(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 DTCQIMAAJSRPDP-SFHVURJKSA-N 0.000 description 2
- OXNPEEDBKZMHHI-VQIMIIECSA-N CCNC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C Chemical compound CCNC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C OXNPEEDBKZMHHI-VQIMIIECSA-N 0.000 description 2
- NFJZXNZEBYEXRF-PKOBYXMFSA-N CN(C)C(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CN(C)C(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F NFJZXNZEBYEXRF-PKOBYXMFSA-N 0.000 description 2
- ZJOIUBBNYSWXQK-UHFFFAOYSA-N CN1CCC(C2=NC(Br)=C3C(N)=NC=CN23)CC1=O Chemical compound CN1CCC(C2=NC(Br)=C3C(N)=NC=CN23)CC1=O ZJOIUBBNYSWXQK-UHFFFAOYSA-N 0.000 description 2
- MQEBDZLGYIMWOO-NHCUHLMSSA-N CN1CC[C@@H](C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 Chemical compound CN1CC[C@@H](C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 MQEBDZLGYIMWOO-NHCUHLMSSA-N 0.000 description 2
- OIBWKQGQMMSGAN-PKOBYXMFSA-N COC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 Chemical compound COC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 OIBWKQGQMMSGAN-PKOBYXMFSA-N 0.000 description 2
- OPHSZSZDICRBPP-MRXNPFEDSA-N COCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 OPHSZSZDICRBPP-MRXNPFEDSA-N 0.000 description 2
- VTJGMNANVAUMBW-HXUWFJFHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC(C)=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC(C)=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 VTJGMNANVAUMBW-HXUWFJFHSA-N 0.000 description 2
- WWRFQZSNDYLAPM-UHFFFAOYSA-N COCCC(=O)N1CCOC(C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound COCCC(=O)N1CCOC(C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 WWRFQZSNDYLAPM-UHFFFAOYSA-N 0.000 description 2
- BISLLWYETURXRJ-UHFFFAOYSA-N COCCC(=O)N1CCOC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCOC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 BISLLWYETURXRJ-UHFFFAOYSA-N 0.000 description 2
- APZYKMWKIRHYTG-GOSISDBHSA-N COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 APZYKMWKIRHYTG-GOSISDBHSA-N 0.000 description 2
- YLWXMIXPUMCEFM-MGBGTMOVSA-N COCCOCCOCCOCCOCCOCCOCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 YLWXMIXPUMCEFM-MGBGTMOVSA-N 0.000 description 2
- XLGPEIWISJFRIT-FXAWDEMLSA-N CO[C@@H](C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CO[C@@H](C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 XLGPEIWISJFRIT-FXAWDEMLSA-N 0.000 description 2
- LXODDGXVRDYSAY-GHTZIAJQSA-N CO[C@@H](C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CO[C@@H](C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 LXODDGXVRDYSAY-GHTZIAJQSA-N 0.000 description 2
- HSQJFEIZBPINIK-GOSISDBHSA-N CS(=O)(=O)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CS(=O)(=O)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 HSQJFEIZBPINIK-GOSISDBHSA-N 0.000 description 2
- PCOLOYPWINOFOU-UHFFFAOYSA-N CS(=O)(=O)CCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CS(=O)(=O)CCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 PCOLOYPWINOFOU-UHFFFAOYSA-N 0.000 description 2
- HZXUNZHPPMIPIR-LJQANCHMSA-N CS(=O)(=O)N1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 Chemical compound CS(=O)(=O)N1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 HZXUNZHPPMIPIR-LJQANCHMSA-N 0.000 description 2
- JOXWEHPRYRAPNQ-YLJYHZDGSA-N C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 JOXWEHPRYRAPNQ-YLJYHZDGSA-N 0.000 description 2
- WTKAFKUTHUGWNG-DYESRHJHSA-N C[C@@H]1[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CCCN1C(=O)C1(C)COC1 Chemical compound C[C@@H]1[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CCCN1C(=O)C1(C)COC1 WTKAFKUTHUGWNG-DYESRHJHSA-N 0.000 description 2
- YKPUQDZTHCIYQB-QFBILLFUSA-N C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 YKPUQDZTHCIYQB-QFBILLFUSA-N 0.000 description 2
- YPJZDVZONFFXGI-HNAYVOBHSA-N C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 YPJZDVZONFFXGI-HNAYVOBHSA-N 0.000 description 2
- GWPYMFNGRUKTRJ-UQBPGWFLSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1 GWPYMFNGRUKTRJ-UQBPGWFLSA-N 0.000 description 2
- YFSWTEABEACXRB-PGRDOPGGSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1 YFSWTEABEACXRB-PGRDOPGGSA-N 0.000 description 2
- VTCAHPJXFSJRAX-GHTZIAJQSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(C)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(C)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 VTCAHPJXFSJRAX-GHTZIAJQSA-N 0.000 description 2
- RVOKBSXJDCUWLK-HXUWFJFHSA-N N=C(C1=CC=C(C(=O)NC2=NC=CC(C(F)(F)F)=C2)C=C1)C1=C(N[C@@H]2CCCN(C(=O)C3CC3)C2)C=CN=C1N Chemical compound N=C(C1=CC=C(C(=O)NC2=NC=CC(C(F)(F)F)=C2)C=C1)C1=C(N[C@@H]2CCCN(C(=O)C3CC3)C2)C=CN=C1N RVOKBSXJDCUWLK-HXUWFJFHSA-N 0.000 description 2
- FVBMGSBINGLPSX-SSDOTTSWSA-N NC1=NC=CC2=C1C(Br)=NN2[C@@H]1CCCNC1 Chemical compound NC1=NC=CC2=C1C(Br)=NN2[C@@H]1CCCNC1 FVBMGSBINGLPSX-SSDOTTSWSA-N 0.000 description 2
- XBKPVMNAHXZYQC-SAABIXHNSA-N NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC4=C(CCCC4)S3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC4=C(CCCC4)S3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 XBKPVMNAHXZYQC-SAABIXHNSA-N 0.000 description 2
- SYRJZYXLLNMEGR-HSZRJFAPSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CN4CCOC4=O)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CN4CCOC4=O)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 SYRJZYXLLNMEGR-HSZRJFAPSA-N 0.000 description 2
- CHEXHPZYSCYLBS-LJQANCHMSA-N NC1=NC=CN2C([C@@H]3CCCN(CCC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CCC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 CHEXHPZYSCYLBS-LJQANCHMSA-N 0.000 description 2
- QGLCSLZVDSCXFQ-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(S(=O)(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(S(=O)(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 QGLCSLZVDSCXFQ-GOSISDBHSA-N 0.000 description 2
- OZTWWLIIXKMFEY-DLBZAZTESA-N NC1=NC=CN2C([C@H]3CN[C@@H](CO)CO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CN[C@@H](CO)CO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 OZTWWLIIXKMFEY-DLBZAZTESA-N 0.000 description 2
- NMPXPFJCSQUCPH-LJQANCHMSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CC(F)(F)C2)C1 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CC(F)(F)C2)C1 NMPXPFJCSQUCPH-LJQANCHMSA-N 0.000 description 2
- CZUMWIWICUZYBB-FQEVSTJZSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=NN(CCO)C=C21 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=NN(CCO)C=C21 CZUMWIWICUZYBB-FQEVSTJZSA-N 0.000 description 2
- VFRDWTLULUGRRD-AREMUKBSSA-N NCCOCCOCCOCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound NCCOCCOCCOCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 VFRDWTLULUGRRD-AREMUKBSSA-N 0.000 description 2
- WSUXQWHDOBRQOF-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N(CC)CC)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N(CC)CC)=N3)C=C2)=NC=C1 WSUXQWHDOBRQOF-UHFFFAOYSA-N 0.000 description 2
- ONOCSAPGXSRCCT-ZMONIFLSSA-N [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(Br)=C2C(N)=NC=CN12 Chemical compound [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(Br)=C2C(N)=NC=CN12 ONOCSAPGXSRCCT-ZMONIFLSSA-N 0.000 description 2
- IRAGHCCFOVNYPT-KXTWHKPSSA-N [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC(CCC)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC(CCC)=C3)C=C2)=C2C(N)=NC=CN12 IRAGHCCFOVNYPT-KXTWHKPSSA-N 0.000 description 2
- WPQFPUDXKSLEOT-FBZVSCGNSA-N *.*.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CN(CCO)CCO4)=N3)C=C2)=NC=C1.COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound *.*.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CN(CCO)CCO4)=N3)C=C2)=NC=C1.COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 WPQFPUDXKSLEOT-FBZVSCGNSA-N 0.000 description 1
- OYIVUCDIEYJXII-ANHUGMMASA-N *.*.COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)[C@@H](CO[Si](C5=CC=CC=C5)(C5=CC=CC=C5)C(C)(C)C)CO4)=NC(Br)=C23)C(OC)=C1 Chemical compound *.*.COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)[C@@H](CO[Si](C5=CC=CC=C5)(C5=CC=CC=C5)C(C)(C)C)CO4)=NC(Br)=C23)C(OC)=C1 OYIVUCDIEYJXII-ANHUGMMASA-N 0.000 description 1
- VNAYLOJPBXKVGV-UHFFFAOYSA-N *.CC1(C(=O)N2CCCC(C3=NC(Br)=C4C(N)=NC=CN34)C2)COC1 Chemical compound *.CC1(C(=O)N2CCCC(C3=NC(Br)=C4C(N)=NC=CN34)C2)COC1 VNAYLOJPBXKVGV-UHFFFAOYSA-N 0.000 description 1
- XYFZVVYVIFJBIS-UHFFFAOYSA-N *.CC1(C(=O)N2CCCC(C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound *.CC1(C(=O)N2CCCC(C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 XYFZVVYVIFJBIS-UHFFFAOYSA-N 0.000 description 1
- WMGIPIPKYBGHCT-CYBMUJFWSA-N *.NC1=NC=C(F)N2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound *.NC1=NC=C(F)N2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 WMGIPIPKYBGHCT-CYBMUJFWSA-N 0.000 description 1
- AZIXBIWQUQBDMQ-GPZAVNNXSA-N C/C(O)=C/C(=N)CC(=O)C1=CC=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=C1 Chemical compound C/C(O)=C/C(=N)CC(=O)C1=CC=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=C1 AZIXBIWQUQBDMQ-GPZAVNNXSA-N 0.000 description 1
- BWPJHIFJHWKZPB-HXUWFJFHSA-N C/C1=C/N=C(/N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C4(C)COC4)CCO3)N21 Chemical compound C/C1=C/N=C(/N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C4(C)COC4)CCO3)N21 BWPJHIFJHWKZPB-HXUWFJFHSA-N 0.000 description 1
- RHZDJFXFKKAXDE-HXUWFJFHSA-N C=CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound C=CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 RHZDJFXFKKAXDE-HXUWFJFHSA-N 0.000 description 1
- HHWGSQIAXKSLGF-JOCHJYFZSA-N C=CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound C=CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 HHWGSQIAXKSLGF-JOCHJYFZSA-N 0.000 description 1
- QXJKNTDAYCNRPR-GVQGPWJCSA-N C=CCN.C=CCN(CCC(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.C=CCN(CCC(=O)O)C(=O)OCC1=CC=CC=C1.C=CCN(CCC(=O)OCC)C(=O)OCC1=CC=CC=C1.C=CCNCCC(=O)OCC.C=CC[C@H](CN(CC=C)C(=O)OCC1=CC=CC=C1)C(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1.O=C(O)C1CCCCCC1.O=C(O)[C@@H]1CC=CCN(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@@H]1CCCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(OCC1=CC=CC=C1)N1CC=CC[C@@H](C(=O)N2C(=O)OC[C@H]2CC2=CC=CC=C2)C1 Chemical compound C=CCN.C=CCN(CCC(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1.C=CCN(CCC(=O)O)C(=O)OCC1=CC=CC=C1.C=CCN(CCC(=O)OCC)C(=O)OCC1=CC=CC=C1.C=CCNCCC(=O)OCC.C=CC[C@H](CN(CC=C)C(=O)OCC1=CC=CC=C1)C(=O)N1C(=O)OC[C@H]1CC1=CC=CC=C1.O=C(O)C1CCCCCC1.O=C(O)[C@@H]1CC=CCN(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@@H]1CCCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(OCC1=CC=CC=C1)N1CC=CC[C@@H](C(=O)N2C(=O)OC[C@H]2CC2=CC=CC=C2)C1 QXJKNTDAYCNRPR-GVQGPWJCSA-N 0.000 description 1
- NIEVVQLSADZHHE-RKUIPQSKSA-N CB[2H]NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=NC(C3=C(F)C=C(C(N)=O)C=C3)=C12 Chemical compound CB[2H]NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=NC(C3=C(F)C=C(C(N)=O)C=C3)=C12 NIEVVQLSADZHHE-RKUIPQSKSA-N 0.000 description 1
- MMWMOBIAEDHTQU-CNAGDHGJSA-N CB[2H]NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=NC(C3=CC=C(C(=O)O)C=C3)=C12 Chemical compound CB[2H]NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=NC(C3=CC=C(C(=O)O)C=C3)=C12 MMWMOBIAEDHTQU-CNAGDHGJSA-N 0.000 description 1
- QPJUETALHVYUHP-CDCCEJPBSA-N CB[2H]NC1=NC=CN2C([C@@H]3CC[C@@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.CB[2H]NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound CB[2H]NC1=NC=CN2C([C@@H]3CC[C@@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.CB[2H]NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 QPJUETALHVYUHP-CDCCEJPBSA-N 0.000 description 1
- QPJUETALHVYUHP-CHKXIFKOSA-N CB[2H]NC1=NC=CN2C([C@@H]3CC[C@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.CB[2H]NC1=NC=CN2C([C@H]3CC[C@@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound CB[2H]NC1=NC=CN2C([C@@H]3CC[C@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.CB[2H]NC1=NC=CN2C([C@H]3CC[C@@H](C(F)(F)F)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 QPJUETALHVYUHP-CHKXIFKOSA-N 0.000 description 1
- ZLHGQMNVFNZSSE-QIWPBUTGSA-N CB[2H]NC1=NC=CN2C([C@H]3CC[C@@H](COC(C)=O)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound CB[2H]NC1=NC=CN2C([C@H]3CC[C@@H](COC(C)=O)N(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 ZLHGQMNVFNZSSE-QIWPBUTGSA-N 0.000 description 1
- VKXBHTAWXSYHEP-MRXNPFEDSA-N CC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 VKXBHTAWXSYHEP-MRXNPFEDSA-N 0.000 description 1
- UEZSIGFKTHGMMY-HXUWFJFHSA-N CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 UEZSIGFKTHGMMY-HXUWFJFHSA-N 0.000 description 1
- BBTIIBODMBNXAF-QGZVFWFLSA-N CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 BBTIIBODMBNXAF-QGZVFWFLSA-N 0.000 description 1
- NRADWHTUODTZMT-PKOBYXMFSA-N CC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F NRADWHTUODTZMT-PKOBYXMFSA-N 0.000 description 1
- YNPLJKAWICKPOY-IFXJQAMLSA-N CC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)CC[C@@H]1C Chemical compound CC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)CC[C@@H]1C YNPLJKAWICKPOY-IFXJQAMLSA-N 0.000 description 1
- QNJQXTDGHOQWGM-KBXCAEBGSA-N CC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C QNJQXTDGHOQWGM-KBXCAEBGSA-N 0.000 description 1
- GPNFAGFTTLRRSP-ULHLBVPDSA-N CC(=O)O[C@H]1CC[C@H](C(=O)NCC2=NC=CN=C2Cl)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC(Br)=C3C(Cl)=NC=CN32)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC(Br)=C3C(N)=NC=CN32)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC=C3C(Cl)=NC=CN32)CC1.N#CC1=NC=CN=C1Cl.NC1=NC=CN2C1=C(Br)N=C2[C@H]1CC[C@H](O)CC1.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)[C@H]1CC[C@H](O)CC1 Chemical compound CC(=O)O[C@H]1CC[C@H](C(=O)NCC2=NC=CN=C2Cl)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC(Br)=C3C(Cl)=NC=CN32)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC(Br)=C3C(N)=NC=CN32)CC1.CC(=O)O[C@H]1CC[C@H](C2=NC=C3C(Cl)=NC=CN32)CC1.N#CC1=NC=CN=C1Cl.NC1=NC=CN2C1=C(Br)N=C2[C@H]1CC[C@H](O)CC1.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)[C@H]1CC[C@H](O)CC1 GPNFAGFTTLRRSP-ULHLBVPDSA-N 0.000 description 1
- MJSPWDFSDZHHCE-WIYYLYMNSA-N CC(C)(C#N)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(C#N)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 MJSPWDFSDZHHCE-WIYYLYMNSA-N 0.000 description 1
- JOVLHYYYIGJMBQ-HXUWFJFHSA-N CC(C)(C#N)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(C#N)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 JOVLHYYYIGJMBQ-HXUWFJFHSA-N 0.000 description 1
- DZRWRJQFWSXGHP-OAQYLSRUSA-N CC(C)(C#N)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 Chemical compound CC(C)(C#N)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 DZRWRJQFWSXGHP-OAQYLSRUSA-N 0.000 description 1
- IFEPDUJCGFNFFZ-LJQANCHMSA-N CC(C)(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 IFEPDUJCGFNFFZ-LJQANCHMSA-N 0.000 description 1
- TYHPWOAUABSBAQ-UHFFFAOYSA-N CC(C)(C)C1(C)CCC1.CC(C)(C)C1(C)COC1.CC(C)(C)C1CC(F)(F)C1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)(C)CC1CCCO1.CC(C)C(C)(C)C.COCCC(C)(C)C Chemical compound CC(C)(C)C1(C)CCC1.CC(C)(C)C1(C)COC1.CC(C)(C)C1CC(F)(F)C1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)(C)CC1CCCO1.CC(C)C(C)(C)C.COCCC(C)(C)C TYHPWOAUABSBAQ-UHFFFAOYSA-N 0.000 description 1
- MIVYKXQJSZLTOH-UHFFFAOYSA-N CC(C)(C)C1(C)CCC1.CC(C)(C)C1(C)COC1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C.COCCC(C)(C)C Chemical compound CC(C)(C)C1(C)CCC1.CC(C)(C)C1(C)COC1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C.COCCC(C)(C)C MIVYKXQJSZLTOH-UHFFFAOYSA-N 0.000 description 1
- QSPRGKABVGHIEA-UHFFFAOYSA-N CC(C)(C)C1(C)CCC1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C Chemical compound CC(C)(C)C1(C)CCC1.CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C QSPRGKABVGHIEA-UHFFFAOYSA-N 0.000 description 1
- SXPJMQOVZOGPKU-OAQYLSRUSA-N CC(C)(C)C1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)S1 Chemical compound CC(C)(C)C1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)S1 SXPJMQOVZOGPKU-OAQYLSRUSA-N 0.000 description 1
- BRNJVWMDWXMVFH-UHFFFAOYSA-N CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C Chemical compound CC(C)(C)C1CC1.CC(C)(C)C1CCC1.CC(C)C(C)(C)C BRNJVWMDWXMVFH-UHFFFAOYSA-N 0.000 description 1
- CJKDHHBAYCYTSZ-UHFFFAOYSA-N CC(C)(C)NC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CC(C)(C)NC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 CJKDHHBAYCYTSZ-UHFFFAOYSA-N 0.000 description 1
- DRADDVGIWCKUKE-UHFFFAOYSA-N CC(C)(C)OC(=O)N1C=C(C2=CC=C3C(N)=NC=NN23)CCC1.CC(C)(C)OC(=O)N1CCCC(C2=CC(Br)=C3C(N)=NC=NN23)C1.CC(C)(C)OC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1.CC(C)(C)OC(=O)N1CCCC(C2=CC=C3C(N)=NC=NN32)C1.NC1=NC=NN2C(Br)=CC=C12 Chemical compound CC(C)(C)OC(=O)N1C=C(C2=CC=C3C(N)=NC=NN23)CCC1.CC(C)(C)OC(=O)N1CCCC(C2=CC(Br)=C3C(N)=NC=NN23)C1.CC(C)(C)OC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1.CC(C)(C)OC(=O)N1CCCC(C2=CC=C3C(N)=NC=NN32)C1.NC1=NC=NN2C(Br)=CC=C12 DRADDVGIWCKUKE-UHFFFAOYSA-N 0.000 description 1
- MFAFTLAYCNBLAQ-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CCC2=C(C1)SC(CC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 Chemical compound CC(C)(C)OC(=O)N1CCC2=C(C1)SC(CC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 MFAFTLAYCNBLAQ-UHFFFAOYSA-N 0.000 description 1
- NMYAOBZUEBGEFJ-SNVBAGLBSA-N CC(C)(C)OC(=O)N1CCC[C@@H](N2C=C(Br)C3=C2N=CN=C3N)C1 Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N2C=C(Br)C3=C2N=CN=C3N)C1 NMYAOBZUEBGEFJ-SNVBAGLBSA-N 0.000 description 1
- SCPNUQNYHNKTOS-DCJLRIFMSA-N CC(C)(C)OC(=O)N1CCC[C@@H](N2N=C(Br)C3=C2N=CN=C3N)C1.CC(C)(C)OC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1.NC1=NC=NC2=C1C(Br)=NN2.NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCNC1.NC1=NC=NC2=C1C=NN2 Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N2N=C(Br)C3=C2N=CN=C3N)C1.CC(C)(C)OC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1.NC1=NC=NC2=C1C(Br)=NN2.NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCNC1.NC1=NC=NC2=C1C=NN2 SCPNUQNYHNKTOS-DCJLRIFMSA-N 0.000 description 1
- BAKOMMNRNKVCAE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)Cc2c1nc(NC(c1ccc(B3OC(C)(C)C(C)(C)O3)cc1)=O)[s]2)=O Chemical compound CC(C)(C)OC(N(CC1)Cc2c1nc(NC(c1ccc(B3OC(C)(C)C(C)(C)O3)cc1)=O)[s]2)=O BAKOMMNRNKVCAE-UHFFFAOYSA-N 0.000 description 1
- QIMPIZBUXGFIBN-LJQANCHMSA-N CC(C)(CO)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(CO)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 QIMPIZBUXGFIBN-LJQANCHMSA-N 0.000 description 1
- UJQGZOWRRLAHNO-YLJYHZDGSA-N CC(C)(F)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(F)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 UJQGZOWRRLAHNO-YLJYHZDGSA-N 0.000 description 1
- WFXNNRRGDVWJTR-QGZVFWFLSA-N CC(C)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CC(C)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 WFXNNRRGDVWJTR-QGZVFWFLSA-N 0.000 description 1
- MLWMXQVVXVGHQL-JOCHJYFZSA-N CC(C)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 MLWMXQVVXVGHQL-JOCHJYFZSA-N 0.000 description 1
- GCNWRKXSKAXVSR-GOSISDBHSA-N CC(C)(F)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound CC(C)(F)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 GCNWRKXSKAXVSR-GOSISDBHSA-N 0.000 description 1
- MGHUYESUNINXPC-SFHVURJKSA-N CC(C)(F)C(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(F)C(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 MGHUYESUNINXPC-SFHVURJKSA-N 0.000 description 1
- QVWITDFAZGOTFB-LJQANCHMSA-N CC(C)(O)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)(O)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 QVWITDFAZGOTFB-LJQANCHMSA-N 0.000 description 1
- ZTVSRSQBFVWRHB-WIYYLYMNSA-N CC(C)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 ZTVSRSQBFVWRHB-WIYYLYMNSA-N 0.000 description 1
- ZTVSRSQBFVWRHB-GHTZIAJQSA-N CC(C)C(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 ZTVSRSQBFVWRHB-GHTZIAJQSA-N 0.000 description 1
- KBEOGAKCDYQRFJ-UHFFFAOYSA-N CC(C)C(=O)N1CCC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CC1 Chemical compound CC(C)C(=O)N1CCC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CC1 KBEOGAKCDYQRFJ-UHFFFAOYSA-N 0.000 description 1
- IZHONLLHVJUMQN-LJQANCHMSA-N CC(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 IZHONLLHVJUMQN-LJQANCHMSA-N 0.000 description 1
- SHEXJWJVISIOMP-OAQYLSRUSA-N CC(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 SHEXJWJVISIOMP-OAQYLSRUSA-N 0.000 description 1
- XTFFWESTTATUAY-LJQANCHMSA-N CC(C)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound CC(C)C(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 XTFFWESTTATUAY-LJQANCHMSA-N 0.000 description 1
- MUCDMPIVIYYHAQ-IBGZPJMESA-N CC(C)C(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)N1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 MUCDMPIVIYYHAQ-IBGZPJMESA-N 0.000 description 1
- KHIGKAVIGMDFSL-LJQANCHMSA-N CC(C)C(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)C(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 KHIGKAVIGMDFSL-LJQANCHMSA-N 0.000 description 1
- LPCYBQTZRVYWNH-GHTZIAJQSA-N CC(C)C(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CC(C)C(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C LPCYBQTZRVYWNH-GHTZIAJQSA-N 0.000 description 1
- ULKIHPPIGXACIB-UHFFFAOYSA-N CC(C)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC(C)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 ULKIHPPIGXACIB-UHFFFAOYSA-N 0.000 description 1
- GLXHXZSLXQOZPQ-XGAFWQRZSA-N CC(C)C1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 Chemical compound CC(C)C1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 GLXHXZSLXQOZPQ-XGAFWQRZSA-N 0.000 description 1
- KBVZGIHVEWRANK-DDRJZQQSSA-N CC(C)C1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 Chemical compound CC(C)C1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)C1 KBVZGIHVEWRANK-DDRJZQQSSA-N 0.000 description 1
- YFHCDFDZLUZKOD-XMMPIXPASA-N CC(C)CNC(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(C)CNC(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 YFHCDFDZLUZKOD-XMMPIXPASA-N 0.000 description 1
- MZVOXRLIRDHKNL-XUZZJYLKSA-N CC(C)COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC(C)COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 MZVOXRLIRDHKNL-XUZZJYLKSA-N 0.000 description 1
- SVOLZHXBAICRNN-OAQYLSRUSA-N CC(C)N1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C1 Chemical compound CC(C)N1CC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C1 SVOLZHXBAICRNN-OAQYLSRUSA-N 0.000 description 1
- AZQLVGLODOSPSK-LJQANCHMSA-N CC(CO)(CO)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC(CO)(CO)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 AZQLVGLODOSPSK-LJQANCHMSA-N 0.000 description 1
- KAKJSQVSPOUASV-GOSISDBHSA-N CC(F)(F)C1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC(F)(F)C1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 KAKJSQVSPOUASV-GOSISDBHSA-N 0.000 description 1
- OAARHRYICILICR-UHFFFAOYSA-N CC(F)(F)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C(F)=C2)=NC=C1 Chemical compound CC(F)(F)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C(F)=C2)=NC=C1 OAARHRYICILICR-UHFFFAOYSA-N 0.000 description 1
- MNFDAFRPHHOIEN-UHFFFAOYSA-N CC(F)(F)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC(F)(F)C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 MNFDAFRPHHOIEN-UHFFFAOYSA-N 0.000 description 1
- UYVRXLFDDMYBEC-HXUWFJFHSA-N CC(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(Nc2nccc(OC)c2)=O)c2[n]1c(C)cnc2N)=O Chemical compound CC(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(Nc2nccc(OC)c2)=O)c2[n]1c(C)cnc2N)=O UYVRXLFDDMYBEC-HXUWFJFHSA-N 0.000 description 1
- NFOLKKBTNRGEEZ-WIYYLYMNSA-N CC1(C(=O)C[C@@H]2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)C[C@@H]2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 NFOLKKBTNRGEEZ-WIYYLYMNSA-N 0.000 description 1
- NFOLKKBTNRGEEZ-GHTZIAJQSA-N CC1(C(=O)C[C@H]2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)C[C@H]2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 NFOLKKBTNRGEEZ-GHTZIAJQSA-N 0.000 description 1
- FRACNZPVMOGITA-UHFFFAOYSA-N CC1(C(=O)N2CCCC(C3=CC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=NN34)C2)COC1 Chemical compound CC1(C(=O)N2CCCC(C3=CC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=NN34)C2)COC1 FRACNZPVMOGITA-UHFFFAOYSA-N 0.000 description 1
- SPIMYQRTHNJFOY-HXUWFJFHSA-N CC1(C(=O)N2CCCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4/C(N)=N\C=C/N34)C2)COC1 Chemical compound CC1(C(=O)N2CCCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4/C(N)=N\C=C/N34)C2)COC1 SPIMYQRTHNJFOY-HXUWFJFHSA-N 0.000 description 1
- JZWWXZZALUYFOO-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C#N)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C#N)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 JZWWXZZALUYFOO-LJQANCHMSA-N 0.000 description 1
- PPZYKYWZZXAADM-MRXNPFEDSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 PPZYKYWZZXAADM-MRXNPFEDSA-N 0.000 description 1
- DYDGQEDVYCTGMO-GOSISDBHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 DYDGQEDVYCTGMO-GOSISDBHSA-N 0.000 description 1
- XIVKWXYVAQWEDB-QGZVFWFLSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(Cl)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(Cl)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 XIVKWXYVAQWEDB-QGZVFWFLSA-N 0.000 description 1
- VONKFEMUWRJVRF-QGZVFWFLSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(OC(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(OC(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 VONKFEMUWRJVRF-QGZVFWFLSA-N 0.000 description 1
- SDFINNXRAFPGPH-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(OC6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(OC6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 SDFINNXRAFPGPH-LJQANCHMSA-N 0.000 description 1
- PLYCDYCABTZOTF-QGZVFWFLSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC(Cl)=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC(Cl)=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 PLYCDYCABTZOTF-QGZVFWFLSA-N 0.000 description 1
- ZECBQBFHNONJLH-QGZVFWFLSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC(F)=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC(F)=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 ZECBQBFHNONJLH-QGZVFWFLSA-N 0.000 description 1
- SMYIGSRBQRVQSL-GOSISDBHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)C/C(S)=N/C=N)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)C/C(S)=N/C=N)C=C4)=C4C(N)=NC=CN34)C2)COC1 SMYIGSRBQRVQSL-GOSISDBHSA-N 0.000 description 1
- IKLQEVHTIMJZSD-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=CC=C(F)C=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=CC=C(F)C=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 IKLQEVHTIMJZSD-HXUWFJFHSA-N 0.000 description 1
- HYVFHHNLGVEBET-JOCHJYFZSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC6=C(C=N5)CCC6)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC6=C(C=N5)CCC6)C=C4)=C4C(N)=NC=CN34)C2)COC1 HYVFHHNLGVEBET-JOCHJYFZSA-N 0.000 description 1
- LMDIXDVIIGYQBP-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=C(C(F)(F)F)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=C(C(F)(F)F)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 LMDIXDVIIGYQBP-HXUWFJFHSA-N 0.000 description 1
- ZWLWPEDYRJCKTA-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=C(Cl)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=C(Cl)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 ZWLWPEDYRJCKTA-HXUWFJFHSA-N 0.000 description 1
- NSQARQAKOHTQAW-RUZDIDTESA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=CC(C6CCC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)CC5=NC=CC(C6CCC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 NSQARQAKOHTQAW-RUZDIDTESA-N 0.000 description 1
- KXHHRMMVLWOADQ-NRUCVBPESA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)N/C(C=N)=C/S)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)N/C(C=N)=C/S)C=C4)=C4C(N)=NC=CN34)C2)COC1 KXHHRMMVLWOADQ-NRUCVBPESA-N 0.000 description 1
- VQVFWVQQUAGYAM-GKRLRZCASA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC(=N)/C=C\C=N)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC(=N)/C=C\C=N)C=C4)=C4C(N)=NC=CN34)C2)COC1 VQVFWVQQUAGYAM-GKRLRZCASA-N 0.000 description 1
- BTQZZDZOAZNEHS-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C#N)=CC=N5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C#N)=CC=N5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 BTQZZDZOAZNEHS-HXUWFJFHSA-N 0.000 description 1
- RUBNWSHROPIOMF-FQCFFEASSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(/C=C/C5=CC=C(F)C=C5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(/C=C/C5=CC=C(F)C=C5)N34)C2)COC1 RUBNWSHROPIOMF-FQCFFEASSA-N 0.000 description 1
- HEKGJUNELNFLMR-XMMPIXPASA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5=CC=CC=C5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5=CC=CC=C5)N34)C2)COC1 HEKGJUNELNFLMR-XMMPIXPASA-N 0.000 description 1
- HXNVRPWMDKIFQI-HSZRJFAPSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5=CCOCC5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5=CCOCC5)N34)C2)COC1 HXNVRPWMDKIFQI-HSZRJFAPSA-N 0.000 description 1
- HHXGGSONBPCZOS-OAQYLSRUSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5CC5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(C5CC5)N34)C2)COC1 HHXGGSONBPCZOS-OAQYLSRUSA-N 0.000 description 1
- QDUKHYXZAZMUJW-AREMUKBSSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(CCC5=CC=CC=C5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(CCC5=CC=CC=C5)N34)C2)COC1 QDUKHYXZAZMUJW-AREMUKBSSA-N 0.000 description 1
- BATBAWRDXILGBJ-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 BATBAWRDXILGBJ-HXUWFJFHSA-N 0.000 description 1
- AHBFBRPGNOVEBK-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 AHBFBRPGNOVEBK-LJQANCHMSA-N 0.000 description 1
- HWYCTEFGXKKVQU-OAQYLSRUSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC=C(C#N)C=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC=C(C#N)C=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 HWYCTEFGXKKVQU-OAQYLSRUSA-N 0.000 description 1
- GWPFCPBHGVAONT-GOSISDBHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CSC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CSC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 GWPFCPBHGVAONT-GOSISDBHSA-N 0.000 description 1
- KNVXLLJNXBYZTE-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=C(C(F)F)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=C(C(F)F)C=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 KNVXLLJNXBYZTE-HXUWFJFHSA-N 0.000 description 1
- PODALRDYFAZFDR-OAQYLSRUSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C#N)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C#N)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 PODALRDYFAZFDR-OAQYLSRUSA-N 0.000 description 1
- JRASZWYZYHKACJ-OYGPHJITSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(/C=C/C5=CC=CC=C5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(/C=C/C5=CC=CC=C5)N34)C2)COC1 JRASZWYZYHKACJ-OYGPHJITSA-N 0.000 description 1
- RRRNXYNOQFZILZ-GOSISDBHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C(F)(F)F)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C(F)(F)F)N34)C2)COC1 RRRNXYNOQFZILZ-GOSISDBHSA-N 0.000 description 1
- WOCWBOMKUXGMAR-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C5(O)COC5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C5(O)COC5)N34)C2)COC1 WOCWBOMKUXGMAR-HXUWFJFHSA-N 0.000 description 1
- FWNAENNCHBJSNE-OAQYLSRUSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C5=CC=CO5)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C5=CC=CO5)N34)C2)COC1 FWNAENNCHBJSNE-OAQYLSRUSA-N 0.000 description 1
- SYDPWQJCNNZXJT-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C=O)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C=O)N34)C2)COC1 SYDPWQJCNNZXJT-LJQANCHMSA-N 0.000 description 1
- QXSYFQHBMWCXDI-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(CO)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(CO)N34)C2)COC1 QXSYFQHBMWCXDI-LJQANCHMSA-N 0.000 description 1
- WNUIGBZFPCDGCP-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=NN34)C2)CCC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=NN34)C2)CCC1 WNUIGBZFPCDGCP-LJQANCHMSA-N 0.000 description 1
- PSKUOQICSVMPEY-GOSISDBHSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=NN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=NN34)C2)COC1 PSKUOQICSVMPEY-GOSISDBHSA-N 0.000 description 1
- XZLPYIMFAHAEHH-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CN=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CN=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 XZLPYIMFAHAEHH-LJQANCHMSA-N 0.000 description 1
- FPLZDJUZRCBQAF-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](N3C=C(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C3N=CN=C4N)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](N3C=C(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C3N=CN=C4N)C2)COC1 FPLZDJUZRCBQAF-HXUWFJFHSA-N 0.000 description 1
- DTGZHNDIRNJALQ-JOCHJYFZSA-N CC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)CC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C(N)N=CN=C43)C2)CCC1 Chemical compound CC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)CC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C(N)N=CN=C43)C2)CCC1 DTGZHNDIRNJALQ-JOCHJYFZSA-N 0.000 description 1
- GGTALNDTBFVEEA-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)C4=C3N=CN=C4N)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)C4=C3N=CN=C4N)C2)COC1 GGTALNDTBFVEEA-LJQANCHMSA-N 0.000 description 1
- NVMWPOFCHUDZLI-HXUWFJFHSA-N CC1(C(=O)N2CCC[C@@H](NC3=C(C(=N)C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C(N)=NC=C3)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](NC3=C(C(=N)C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C(N)=NC=C3)C2)COC1 NVMWPOFCHUDZLI-HXUWFJFHSA-N 0.000 description 1
- VFHJKEUNTZVOSU-LJQANCHMSA-N CC1(C(=O)N2CCC[C@@H](NN3=C(C(=N)C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C(N)=NC=C3Cl)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@H](NN3=C(C(=N)C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C(N)=NC=C3Cl)C2)COC1 VFHJKEUNTZVOSU-LJQANCHMSA-N 0.000 description 1
- FMQTYLQTJYYYIW-MUUNZHRXSA-N CC1(C(=O)N2CCC[C@@](C)(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@](C)(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 FMQTYLQTJYYYIW-MUUNZHRXSA-N 0.000 description 1
- MIBUWCOKXIRFOE-NDEPHWFRSA-N CC1(C(=O)N2CCC[C@@](O)(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCC[C@@](O)(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 MIBUWCOKXIRFOE-NDEPHWFRSA-N 0.000 description 1
- MFKXMGVLUDJTRJ-LJQANCHMSA-N CC1(C(=O)N2CCN[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 Chemical compound CC1(C(=O)N2CCN[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 MFKXMGVLUDJTRJ-LJQANCHMSA-N 0.000 description 1
- OEZOQUNDNHZFPI-UHFFFAOYSA-N CC1(C(=O)N2CCOC(C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCOC(C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 OEZOQUNDNHZFPI-UHFFFAOYSA-N 0.000 description 1
- KIDZKZMLPUWSLF-LJQANCHMSA-N CC1(C(=O)N2CCO[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4/C(N)=N\C=C/N34)C2)COC1 Chemical compound CC1(C(=O)N2CCO[C@@H](C3=NC(C4=C(F)C=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4/C(N)=N\C=C/N34)C2)COC1 KIDZKZMLPUWSLF-LJQANCHMSA-N 0.000 description 1
- SUEPGNXEXXNPJO-HXUWFJFHSA-N CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C#N)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(C#N)N34)C2)COC1 SUEPGNXEXXNPJO-HXUWFJFHSA-N 0.000 description 1
- OEZOQUNDNHZFPI-GOSISDBHSA-N CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 Chemical compound CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=C(Cl)N34)C2)COC1 OEZOQUNDNHZFPI-GOSISDBHSA-N 0.000 description 1
- WDZMYKJOFRYQQR-LJQANCHMSA-N CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 WDZMYKJOFRYQQR-LJQANCHMSA-N 0.000 description 1
- YSILLBSTYXZXSY-LJQANCHMSA-N CC1(C(=O)N2CC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2CC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 YSILLBSTYXZXSY-LJQANCHMSA-N 0.000 description 1
- GPIZYTXYJFBFSI-QUCCMNQESA-N CC1(C(=O)N2C[C@@H](O)C[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N2C[C@@H](O)C[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)COC1 GPIZYTXYJFBFSI-QUCCMNQESA-N 0.000 description 1
- URFHXAXQLKNBDS-DENIHFKCSA-N CC1(C(=O)N2C[C@H](C3=NC(C4=CC=C(C(=O)CC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)CC[C@@H]2C(F)F)COC1 Chemical compound CC1(C(=O)N2C[C@H](C3=NC(C4=CC=C(C(=O)CC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)CC[C@@H]2C(F)F)COC1 URFHXAXQLKNBDS-DENIHFKCSA-N 0.000 description 1
- XVLBZULPAAJBBU-GOSISDBHSA-N CC1(C(=O)N2C[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)CC(F)(F)C2)COC1 Chemical compound CC1(C(=O)N2C[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)CC(F)(F)C2)COC1 XVLBZULPAAJBBU-GOSISDBHSA-N 0.000 description 1
- GTMFOPNUMQWLRQ-FQEVSTJZSA-N CC1(C(=O)N[C@H]2CCCN(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(C(=O)N[C@H]2CCCN(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 GTMFOPNUMQWLRQ-FQEVSTJZSA-N 0.000 description 1
- BUGIOJPYMNMWKP-UHFFFAOYSA-N CC1(C)CC(C2=NC(Br)=C3C(N)=NC=CN23)CCO1 Chemical compound CC1(C)CC(C2=NC(Br)=C3C(N)=NC=CN23)CCO1 BUGIOJPYMNMWKP-UHFFFAOYSA-N 0.000 description 1
- YBVGPUNVKQAFCO-UHFFFAOYSA-N CC1(C)CC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CCO1 Chemical compound CC1(C)CC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CCO1 YBVGPUNVKQAFCO-UHFFFAOYSA-N 0.000 description 1
- JVYJANIAKXKDPE-UHFFFAOYSA-N CC1(C)OB(C2=C(F)C=C(C(=O)NC3=NC=CC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=C(F)C=C(C(=O)NC3=NC=CC=C3)C=C2)OC1(C)C JVYJANIAKXKDPE-UHFFFAOYSA-N 0.000 description 1
- BDWYBNFVRXJQPY-UHFFFAOYSA-N CC1(C)OB(C2=C3C=CC=CC3=C(C(=O)CC3=NC=CC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=C3C=CC=CC3=C(C(=O)CC3=NC=CC=C3)C=C2)OC1(C)C BDWYBNFVRXJQPY-UHFFFAOYSA-N 0.000 description 1
- GRKQXSSJOOAONZ-UHFFFAOYSA-N CC1(C)OB(C2=CC(Cl)=C(C(=O)CC3=NC=CC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC(Cl)=C(C(=O)CC3=NC=CC=C3)C=C2)OC1(C)C GRKQXSSJOOAONZ-UHFFFAOYSA-N 0.000 description 1
- OESWRQLCODGCAP-UHFFFAOYSA-N CC1(C)OB(C2=CC(F)=C(C(=O)NC3=NC=CC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC(F)=C(C(=O)NC3=NC=CC=C3)C=C2)OC1(C)C OESWRQLCODGCAP-UHFFFAOYSA-N 0.000 description 1
- YIRRRSCSHFDKQH-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(C(F)F)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(C(F)F)=C3)C=C2)OC1(C)C YIRRRSCSHFDKQH-UHFFFAOYSA-N 0.000 description 1
- AHMOCKLDLRBJBR-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(C4=CC=CC=C4)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(C4=CC=CC=C4)=C3)C=C2)OC1(C)C AHMOCKLDLRBJBR-UHFFFAOYSA-N 0.000 description 1
- QLBBJAZDMCLOSY-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(N4CCCC4)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(N4CCCC4)=C3)C=C2)OC1(C)C QLBBJAZDMCLOSY-UHFFFAOYSA-N 0.000 description 1
- FHCXRCUBKQRPIH-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(OC4CC4)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)CC3=NC=CC(OC4CC4)=C3)C=C2)OC1(C)C FHCXRCUBKQRPIH-UHFFFAOYSA-N 0.000 description 1
- HQOTUVBYKQCUQJ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)Cl)C=C2)OC1(C)C.CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(F)=C3)C=C2)OC1(C)C.CC1(C)OB(C2=CC=C(C(=O)O)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)Cl)C=C2)OC1(C)C.CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(F)=C3)C=C2)OC1(C)C.CC1(C)OB(C2=CC=C(C(=O)O)C=C2)OC1(C)C HQOTUVBYKQCUQJ-UHFFFAOYSA-N 0.000 description 1
- JUBRGMQDJPWDCD-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC4=C(CCCC4)S3)C=C2)OC1(C)C.O=C(Cl)C1=CC=C(Br)C=C1.O=C(NC1=NC2=C(CCCC2)S1)C1=CC=C(Br)C=C1 Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC4=C(CCCC4)S3)C=C2)OC1(C)C.O=C(Cl)C1=CC=C(Br)C=C1.O=C(NC1=NC2=C(CCCC2)S1)C1=CC=C(Br)C=C1 JUBRGMQDJPWDCD-UHFFFAOYSA-N 0.000 description 1
- DVQXIJVZKVJELS-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC4=C(COCC4)S3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC4=C(COCC4)S3)C=C2)OC1(C)C DVQXIJVZKVJELS-UHFFFAOYSA-N 0.000 description 1
- QGMYWOHXZMRAHQ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)OC1(C)C QGMYWOHXZMRAHQ-UHFFFAOYSA-N 0.000 description 1
- FTVCJSCKBANBQE-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2F)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2F)OC1(C)C FTVCJSCKBANBQE-UHFFFAOYSA-N 0.000 description 1
- QTXNLCFMPWAOCZ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)F)=C3)C=C2F)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C(F)F)=C3)C=C2F)OC1(C)C QTXNLCFMPWAOCZ-UHFFFAOYSA-N 0.000 description 1
- SDQLVWGMLJYQEQ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C4(F)COC4)=C3)C=C2)OC1(C)C.ClC1=NC=CC(I)=C1.FC1(C2=CC(Cl)=NC=C2)COC1.OC1(C2=CC(Cl)=NC=C2)COC1 Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C4(F)COC4)=C3)C=C2)OC1(C)C.ClC1=NC=CC(I)=C1.FC1(C2=CC(Cl)=NC=C2)COC1.OC1(C2=CC(Cl)=NC=C2)COC1 SDQLVWGMLJYQEQ-UHFFFAOYSA-N 0.000 description 1
- OEMNIGMYXMDGJQ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C4CC4)=C3)C=C2)OC1(C)C.NC1=NC=CC(Br)=C1.NC1=NC=CC(C2CC2)=C1 Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=CC(C4CC4)=C3)C=C2)OC1(C)C.NC1=NC=CC(Br)=C1.NC1=NC=CC(C2CC2)=C1 OEMNIGMYXMDGJQ-UHFFFAOYSA-N 0.000 description 1
- APCITVGUELDPGZ-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NC=NC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NC=NC=C3)C=C2)OC1(C)C APCITVGUELDPGZ-UHFFFAOYSA-N 0.000 description 1
- FFBLZKPPZGSYND-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NN=CC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NN=CC=C3)C=C2)OC1(C)C FFBLZKPPZGSYND-UHFFFAOYSA-N 0.000 description 1
- FFMHUJMEJVPGOH-UHFFFAOYSA-N CC1(C)OB(C2=CC=C(C(=O)NC3=NOC=C3)C=C2)OC1(C)C Chemical compound CC1(C)OB(C2=CC=C(C(=O)NC3=NOC=C3)C=C2)OC1(C)C FFMHUJMEJVPGOH-UHFFFAOYSA-N 0.000 description 1
- UJBLTPWEXCXFHP-UHFFFAOYSA-N CC1(C)OB(c(cc2)ccc2C(Nc2cc(OC)ccn2)=O)OC1(C)C Chemical compound CC1(C)OB(c(cc2)ccc2C(Nc2cc(OC)ccn2)=O)OC1(C)C UJBLTPWEXCXFHP-UHFFFAOYSA-N 0.000 description 1
- VDYZSEXELXDNGE-HXUWFJFHSA-N CC1(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 Chemical compound CC1(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)COC1 VDYZSEXELXDNGE-HXUWFJFHSA-N 0.000 description 1
- PFFZEHNCYNOAGH-ZBTAVZRMSA-N CC1(COC1)C(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(NC(/C=C\NC)=N)=O)c2[n]1ccnc2N)=O Chemical compound CC1(COC1)C(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(NC(/C=C\NC)=N)=O)c2[n]1ccnc2N)=O PFFZEHNCYNOAGH-ZBTAVZRMSA-N 0.000 description 1
- SCCOZXCEDOZQRU-XMMPIXPASA-N CC1(COC1)C(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(Nc2nccc(C3CCC3)c2)=O)c2[n]1ccnc2N)=O Chemical compound CC1(COC1)C(N(CCC1)C[C@@H]1c1nc(-c(cc2)ccc2C(Nc2nccc(C3CCC3)c2)=O)c2[n]1ccnc2N)=O SCCOZXCEDOZQRU-XMMPIXPASA-N 0.000 description 1
- XWYUUNPTRWMYME-UHFFFAOYSA-N CC1=C(B2OC(C)(C)C(C)(C)O2)C=CC(C(=O)NC2=NC=CC=C2)=C1 Chemical compound CC1=C(B2OC(C)(C)C(C)(C)O2)C=CC(C(=O)NC2=NC=CC=C2)=C1 XWYUUNPTRWMYME-UHFFFAOYSA-N 0.000 description 1
- ZXSDGZVBUHSFCD-LJQANCHMSA-N CC1=C(C(=O)NC2=NC=CC(C(F)(F)F)=C2)C=CC(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)=C1 Chemical compound CC1=C(C(=O)NC2=NC=CC(C(F)(F)F)=C2)C=CC(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)=C1 ZXSDGZVBUHSFCD-LJQANCHMSA-N 0.000 description 1
- UKJOACITVMWWIC-HHHXNRCGSA-N CC1=C(C)C=C(NC(=O)C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=C1 Chemical compound CC1=C(C)C=C(NC(=O)C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=C1 UKJOACITVMWWIC-HHHXNRCGSA-N 0.000 description 1
- CTKSOMJAXZUHJJ-OAQYLSRUSA-N CC1=C(C)SC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=N1 Chemical compound CC1=C(C)SC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=N1 CTKSOMJAXZUHJJ-OAQYLSRUSA-N 0.000 description 1
- PCLBCSGANGKMKL-LJQANCHMSA-N CC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 Chemical compound CC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 PCLBCSGANGKMKL-LJQANCHMSA-N 0.000 description 1
- HLXFENUNSACAHV-SAABIXHNSA-N CC1=C(C2=C3C(N)=NC=CN3C([C@H]3CC[C@H](O)CC3)=N2)C=CC(C(=O)NC2=NC=CC=C2)=C1 Chemical compound CC1=C(C2=C3C(N)=NC=CN3C([C@H]3CC[C@H](O)CC3)=N2)C=CC(C(=O)NC2=NC=CC=C2)=C1 HLXFENUNSACAHV-SAABIXHNSA-N 0.000 description 1
- ZRIPEKYHTBDFRN-OAQYLSRUSA-N CC1=C(F)C=NC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=C1 Chemical compound CC1=C(F)C=NC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=C1 ZRIPEKYHTBDFRN-OAQYLSRUSA-N 0.000 description 1
- APODTENNDIAIQG-JOCHJYFZSA-N CC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 APODTENNDIAIQG-JOCHJYFZSA-N 0.000 description 1
- JATPVBYIEXDGAC-UHFFFAOYSA-N CC1=CC(NC(=O)C2=C(F)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=C(F)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 JATPVBYIEXDGAC-UHFFFAOYSA-N 0.000 description 1
- YSWPPOHENQSJMO-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC(F)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC(F)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 YSWPPOHENQSJMO-UHFFFAOYSA-N 0.000 description 1
- RISOCWSPGQLPCE-GOSISDBHSA-N CC1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 RISOCWSPGQLPCE-GOSISDBHSA-N 0.000 description 1
- SRNLWGKIMGETIM-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 SRNLWGKIMGETIM-UHFFFAOYSA-N 0.000 description 1
- YXLYJHFJNDNYBP-OAQYLSRUSA-N CC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 YXLYJHFJNDNYBP-OAQYLSRUSA-N 0.000 description 1
- ASCWHHDJZJSXSM-OAQYLSRUSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C#N)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C#N)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 ASCWHHDJZJSXSM-OAQYLSRUSA-N 0.000 description 1
- QSYWXGKEXQGBHN-HXUWFJFHSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C(=O)O)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C(=O)O)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 QSYWXGKEXQGBHN-HXUWFJFHSA-N 0.000 description 1
- KWCJTOXBXIQIBM-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C(C)CN)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C(C)CN)=N3)C=C2)=NC=C1 KWCJTOXBXIQIBM-UHFFFAOYSA-N 0.000 description 1
- IAOCEGDSMWREJV-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCCC4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCCC4)=N3)C=C2)=NC=C1 IAOCEGDSMWREJV-UHFFFAOYSA-N 0.000 description 1
- NDPDAIQARMZYOM-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 NDPDAIQARMZYOM-UHFFFAOYSA-N 0.000 description 1
- LGQZLGFPMFVVKG-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 LGQZLGFPMFVVKG-UHFFFAOYSA-N 0.000 description 1
- UHBBHNJBJFCAQJ-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCO4)=N3)C=C2)=NC=C1.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCO4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCO4)=N3)C=C2)=NC=C1.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCO4)=N3)C=C2)=NC=C1 UHBBHNJBJFCAQJ-UHFFFAOYSA-N 0.000 description 1
- YHCMFSZXYXYVSW-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCS4)=N3)C=C2)=NC=C1.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCS4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCS4)=N3)C=C2)=NC=C1.CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CNCCS4)=N3)C=C2)=NC=C1 YHCMFSZXYXYVSW-UHFFFAOYSA-N 0.000 description 1
- UEIAFRCXIIDKHR-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCCC(C(=O)CC(C)C)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCCC(C(=O)CC(C)C)C4)=N3)C=C2)=NC=C1 UEIAFRCXIIDKHR-UHFFFAOYSA-N 0.000 description 1
- ZMYXBAZWBRCFAK-UHFFFAOYSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCCC(C(=O)O)C4)=N3)C=C2)=NC=C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(N)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCCC(C(=O)O)C4)=N3)C=C2)=NC=C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(N)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 ZMYXBAZWBRCFAK-UHFFFAOYSA-N 0.000 description 1
- XRLSAFHKMZMDBR-VQCQRNETSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC(O)CO)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC(O)CO)C4)=N3)C=C2)=NC=C1 XRLSAFHKMZMDBR-VQCQRNETSA-N 0.000 description 1
- ZOQUZCMFNUQEEI-XMMPIXPASA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5=CC=NC=C5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5=CC=NC=C5)C4)=N3)C=C2)=NC=C1 ZOQUZCMFNUQEEI-XMMPIXPASA-N 0.000 description 1
- LBDWCVVRPZKDJS-JOCHJYFZSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5CC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5CC5)C4)=N3)C=C2)=NC=C1 LBDWCVVRPZKDJS-JOCHJYFZSA-N 0.000 description 1
- MFAXEFWLCKTJMV-GWQXNCQPSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5CCOC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(CC5CCOC5)C4)=N3)C=C2)=NC=C1 MFAXEFWLCKTJMV-GWQXNCQPSA-N 0.000 description 1
- YHOPNUQXBVKAAG-RTBURBONSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCC[C@@H](N)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCC[C@@H](N)C4)=N3)C=C2)=NC=C1 YHOPNUQXBVKAAG-RTBURBONSA-N 0.000 description 1
- YHOPNUQXBVKAAG-MOPGFXCFSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCC[C@H](N)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCC[C@H](N)C4)=N3)C=C2)=NC=C1 YHOPNUQXBVKAAG-MOPGFXCFSA-N 0.000 description 1
- BOWFLNKDPVUXBX-SIKLNZKXSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 BOWFLNKDPVUXBX-SIKLNZKXSA-N 0.000 description 1
- LCWDVKGYKGHSSH-LEWJYISDSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](C(F)(F)F)N(C(=O)C5CC5)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](C(F)(F)F)N(C(=O)C5CC5)C4)=N3)C=C2)=NC=C1 LCWDVKGYKGHSSH-LEWJYISDSA-N 0.000 description 1
- PGTCEUASCQLWAN-MSOLQXFVSA-N CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CNC[C@@H](O)C4)=N3)C=C2)=NC=C1 Chemical compound CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CNC[C@@H](O)C4)=N3)C=C2)=NC=C1 PGTCEUASCQLWAN-MSOLQXFVSA-N 0.000 description 1
- MYKUXZLRGWMWRO-UHFFFAOYSA-N CC1=CC=C(C(=O)NC2=CC=CC=N2)C=N1 Chemical compound CC1=CC=C(C(=O)NC2=CC=CC=N2)C=N1 MYKUXZLRGWMWRO-UHFFFAOYSA-N 0.000 description 1
- MICPQWWMSPKMLQ-UHFFFAOYSA-N CC1=CC=NC(NC(=O)C2=C(Cl)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=C1 Chemical compound CC1=CC=NC(NC(=O)C2=C(Cl)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=C1 MICPQWWMSPKMLQ-UHFFFAOYSA-N 0.000 description 1
- UNJDBYCQOLDEAB-UHFFFAOYSA-N CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=C1 Chemical compound CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=C1 UNJDBYCQOLDEAB-UHFFFAOYSA-N 0.000 description 1
- XNSSYABBPKQHID-PGRDOPGGSA-N CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5CC5)C4)=N3)C=C2)=C1 Chemical compound CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5CC5)C4)=N3)C=C2)=C1 XNSSYABBPKQHID-PGRDOPGGSA-N 0.000 description 1
- IMLARQGZDSRRBT-BEUBQONESA-N CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5CCCO5)C4)=N3)C=C2)=C1 Chemical compound CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5CCCO5)C4)=N3)C=C2)=C1 IMLARQGZDSRRBT-BEUBQONESA-N 0.000 description 1
- BPIOVFWFXTWUHJ-JOCHJYFZSA-N CC1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 Chemical compound CC1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 BPIOVFWFXTWUHJ-JOCHJYFZSA-N 0.000 description 1
- PTMALSDGXQQBQK-OAHLLOKOSA-N CC1=CN=C(N)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12 PTMALSDGXQQBQK-OAHLLOKOSA-N 0.000 description 1
- PKHWDSMTQJZPFA-OXJNMPFZSA-N CC1=CN=C(N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)N=C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)N=C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)N12 PKHWDSMTQJZPFA-OXJNMPFZSA-N 0.000 description 1
- JTCBLJJIQQVPAA-QGZVFWFLSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C(F)F)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C(F)F)CCO3)N12 JTCBLJJIQQVPAA-QGZVFWFLSA-N 0.000 description 1
- YYZDFEAIVGKYCB-HXUWFJFHSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C4(C)COC4)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)C4(C)COC4)CCO3)N12 YYZDFEAIVGKYCB-HXUWFJFHSA-N 0.000 description 1
- FZDZOMGNAHTHMA-DNVCBOLYSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)[C@@H](C)O)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)[C@@H](C)O)CCO3)N12 FZDZOMGNAHTHMA-DNVCBOLYSA-N 0.000 description 1
- FZDZOMGNAHTHMA-HNAYVOBHSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)[C@H](C)O)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(C(=O)[C@H](C)O)CCO3)N12 FZDZOMGNAHTHMA-HNAYVOBHSA-N 0.000 description 1
- CACKZJYCRAAWHB-JOCHJYFZSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(CC4=CN(C)N=C4)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(CC4=CN(C)N=C4)CCO3)N12 CACKZJYCRAAWHB-JOCHJYFZSA-N 0.000 description 1
- ZOBPBTZEGKQZJX-LJQANCHMSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(CCO)CCO3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@H]3CN(CCO)CCO3)N12 ZOBPBTZEGKQZJX-LJQANCHMSA-N 0.000 description 1
- YUEZUSYHVDJXRZ-OAQYLSRUSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 YUEZUSYHVDJXRZ-OAQYLSRUSA-N 0.000 description 1
- FZPBJFBENFRYLR-JOCHJYFZSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 FZPBJFBENFRYLR-JOCHJYFZSA-N 0.000 description 1
- SSDUZJOPMADTMD-JOCHJYFZSA-N CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4CC4)C3)N12 Chemical compound CC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4CC4)C3)N12 SSDUZJOPMADTMD-JOCHJYFZSA-N 0.000 description 1
- ZQJIQIGLMMIZIR-OAQYLSRUSA-N CC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 Chemical compound CC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 ZQJIQIGLMMIZIR-OAQYLSRUSA-N 0.000 description 1
- UOLSVAVHNMZQPY-UHFFFAOYSA-N CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)N(C)C)N12 Chemical compound CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)N(C)C)N12 UOLSVAVHNMZQPY-UHFFFAOYSA-N 0.000 description 1
- HTCUASLFNXBKRW-UHFFFAOYSA-N CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NC3CCN(C)CC3)N12 Chemical compound CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NC3CCN(C)CC3)N12 HTCUASLFNXBKRW-UHFFFAOYSA-N 0.000 description 1
- AYADLLNNWVFLJX-UHFFFAOYSA-N CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CC=CC=C3)N12 Chemical compound CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CC=CC=C3)N12 AYADLLNNWVFLJX-UHFFFAOYSA-N 0.000 description 1
- XZPVSKBGPOXNDM-UHFFFAOYSA-N CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CN=CC=C3)N12 Chemical compound CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CN=CC=C3)N12 XZPVSKBGPOXNDM-UHFFFAOYSA-N 0.000 description 1
- JUHARXQQZQZICM-UHFFFAOYSA-N CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CN=CO3)N12 Chemical compound CC1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=C(C(=O)NCC3=CN=CO3)N12 JUHARXQQZQZICM-UHFFFAOYSA-N 0.000 description 1
- MUQRPPVWYSPQPZ-UHFFFAOYSA-N CC1=NC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CC1=NC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 MUQRPPVWYSPQPZ-UHFFFAOYSA-N 0.000 description 1
- MUYUFHHOOFYLES-JOCHJYFZSA-N CC1=NN=C(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)O1 Chemical compound CC1=NN=C(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)O1 MUYUFHHOOFYLES-JOCHJYFZSA-N 0.000 description 1
- CHFWEUKUKJLFNU-HJNYFJLDSA-N CC1=NOC([C@H]2C[C@@H]2C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)=N1 Chemical compound CC1=NOC([C@H]2C[C@@H]2C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)=N1 CHFWEUKUKJLFNU-HJNYFJLDSA-N 0.000 description 1
- GPNMGMUEDIILGH-WHKWTHTOSA-N CC1CC1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC1CC1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 GPNMGMUEDIILGH-WHKWTHTOSA-N 0.000 description 1
- MHJGOFRPYXDHHP-UHFFFAOYSA-N CC1CCC2=C(C1)SC(NC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 Chemical compound CC1CCC2=C(C1)SC(NC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 MHJGOFRPYXDHHP-UHFFFAOYSA-N 0.000 description 1
- MWPRAMQDGAXUMW-JOCHJYFZSA-N CCC(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 MWPRAMQDGAXUMW-JOCHJYFZSA-N 0.000 description 1
- COIGUNZVVFAKMC-GHTZIAJQSA-N CCC(=O)C(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCC(=O)C(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C COIGUNZVVFAKMC-GHTZIAJQSA-N 0.000 description 1
- RKVOWBNDYMWISR-YLJYHZDGSA-N CCC(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 RKVOWBNDYMWISR-YLJYHZDGSA-N 0.000 description 1
- RKVOWBNDYMWISR-FXAWDEMLSA-N CCC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 RKVOWBNDYMWISR-FXAWDEMLSA-N 0.000 description 1
- PTCCDBKMTDKBKO-UHFFFAOYSA-N CCC(=O)N1C2CCC1C(C1=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN13)C2 Chemical compound CCC(=O)N1C2CCC1C(C1=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN13)C2 PTCCDBKMTDKBKO-UHFFFAOYSA-N 0.000 description 1
- AHKDDLYVVSUZAL-HXUWFJFHSA-N CCC(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound CCC(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 AHKDDLYVVSUZAL-HXUWFJFHSA-N 0.000 description 1
- QVHFKWHBJNRKLA-MRXNPFEDSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 QVHFKWHBJNRKLA-MRXNPFEDSA-N 0.000 description 1
- WLCSZJLWGMRJDU-QGZVFWFLSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=C(OC)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=C(OC)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 WLCSZJLWGMRJDU-QGZVFWFLSA-N 0.000 description 1
- JGENXHKXPWAKMS-LJQANCHMSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(OC)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(OC)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 JGENXHKXPWAKMS-LJQANCHMSA-N 0.000 description 1
- SCOLUPVNCZJDBX-UUSAFJCLSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC5=C(CC(C)CC5)S4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC5=C(CC(C)CC5)S4)C=C3)=C3C(N)=NC=CN23)C1 SCOLUPVNCZJDBX-UUSAFJCLSA-N 0.000 description 1
- SFFUOIXDCRKVNK-HXUWFJFHSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 SFFUOIXDCRKVNK-HXUWFJFHSA-N 0.000 description 1
- ZGHIAUFLTVYJOQ-JOCHJYFZSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 ZGHIAUFLTVYJOQ-JOCHJYFZSA-N 0.000 description 1
- YBYIDWNOKQAKIK-LJQANCHMSA-N CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 YBYIDWNOKQAKIK-LJQANCHMSA-N 0.000 description 1
- SESKTYSFDOAGCV-GOSISDBHSA-N CCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound CCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 SESKTYSFDOAGCV-GOSISDBHSA-N 0.000 description 1
- XGQYAEVUTPLHKJ-UHFFFAOYSA-N CCC(=O)N1CCSC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(=O)N1CCSC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 XGQYAEVUTPLHKJ-UHFFFAOYSA-N 0.000 description 1
- OEHZXWKNBGJHOZ-DOTOQJQBSA-N CCC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C OEHZXWKNBGJHOZ-DOTOQJQBSA-N 0.000 description 1
- DXEPVOIQQOZRDS-FXAWDEMLSA-N CCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C DXEPVOIQQOZRDS-FXAWDEMLSA-N 0.000 description 1
- HXCULWWWBHQXBJ-UHFFFAOYSA-N CCC(=O)NCC(C)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound CCC(=O)NCC(C)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 HXCULWWWBHQXBJ-UHFFFAOYSA-N 0.000 description 1
- FDHOZKZIIPUHCP-LJQANCHMSA-N CCC(F)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(F)(F)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 FDHOZKZIIPUHCP-LJQANCHMSA-N 0.000 description 1
- VUQDROMZUWCILP-QSVWIEALSA-N CCC(O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCC(O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 VUQDROMZUWCILP-QSVWIEALSA-N 0.000 description 1
- AQXPPGIWLDXWBN-UHFFFAOYSA-N CCC1=CC(CC(=O)C2=CC(F)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCC1=CC(CC(=O)C2=CC(F)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 AQXPPGIWLDXWBN-UHFFFAOYSA-N 0.000 description 1
- DILHMKBGYAPTHO-HSZRJFAPSA-N CCC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CCC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 DILHMKBGYAPTHO-HSZRJFAPSA-N 0.000 description 1
- POXWLIUOSSDFLB-UHFFFAOYSA-N CCC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 POXWLIUOSSDFLB-UHFFFAOYSA-N 0.000 description 1
- PCUMUZOYQFIUEV-JOCHJYFZSA-N CCC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 Chemical compound CCC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 PCUMUZOYQFIUEV-JOCHJYFZSA-N 0.000 description 1
- HVTFMFOCNFMMOB-HSZRJFAPSA-N CCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 HVTFMFOCNFMMOB-HSZRJFAPSA-N 0.000 description 1
- FCYFNJHKEHOCIA-KESTWPANSA-N CCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C2)=NC=C1 Chemical compound CCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C2)=NC=C1 FCYFNJHKEHOCIA-KESTWPANSA-N 0.000 description 1
- MSVNQHVZWZEHHI-JOCHJYFZSA-N CCC1=CC(NC(=O)C2=CC=C(C3=CN([C@@H]4CCCN(C(=O)C5(C)COC5)C4)C4=C3C(N)=NC=N4)C=C2)=NC=C1 Chemical compound CCC1=CC(NC(=O)C2=CC=C(C3=CN([C@@H]4CCCN(C(=O)C5(C)COC5)C4)C4=C3C(N)=NC=N4)C=C2)=NC=C1 MSVNQHVZWZEHHI-JOCHJYFZSA-N 0.000 description 1
- BLODPKXFDWIUIY-OAQYLSRUSA-N CCC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(O)CC5)C4)=N3)C=C2)=C1 Chemical compound CCC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(O)CC5)C4)=N3)C=C2)=C1 BLODPKXFDWIUIY-OAQYLSRUSA-N 0.000 description 1
- YBZPQJFZYJNRLC-HXUWFJFHSA-N CCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 YBZPQJFZYJNRLC-HXUWFJFHSA-N 0.000 description 1
- HUSLRPLMILKAIB-UHFFFAOYSA-N CCC1=CN=C(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)S1 Chemical compound CCC1=CN=C(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)S1 HUSLRPLMILKAIB-UHFFFAOYSA-N 0.000 description 1
- OHGLMEMZLXIAJX-MAEOIBBWSA-N CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)S1 Chemical compound CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)S1 OHGLMEMZLXIAJX-MAEOIBBWSA-N 0.000 description 1
- SYSKBXANQVWGNR-UAPYVXQJSA-N CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](OC(C)=O)CC4)=N3)C=C2)S1 Chemical compound CCC1=CN=C(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](OC(C)=O)CC4)=N3)C=C2)S1 SYSKBXANQVWGNR-UAPYVXQJSA-N 0.000 description 1
- NHCYDZJWKSBDDK-JCNLHEQBSA-N CCC1=CN=C(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)S1 Chemical compound CCC1=CN=C(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)S1 NHCYDZJWKSBDDK-JCNLHEQBSA-N 0.000 description 1
- YGHJQDBGPCLERL-SFHVURJKSA-N CCCC(=O)C[C@@H]1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCCC(=O)C[C@@H]1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 YGHJQDBGPCLERL-SFHVURJKSA-N 0.000 description 1
- DLHOATXJYCPMEP-HXUWFJFHSA-N CCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 DLHOATXJYCPMEP-HXUWFJFHSA-N 0.000 description 1
- HDVCSUISVSMRKG-SIKLNZKXSA-N CCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C HDVCSUISVSMRKG-SIKLNZKXSA-N 0.000 description 1
- HEBDHWXXIKSQAD-GHTZIAJQSA-N CCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C HEBDHWXXIKSQAD-GHTZIAJQSA-N 0.000 description 1
- OULJSBRFSFRWPJ-IBGZPJMESA-N CCCC(N1C[C@@H](c2nc(-c(cc3)ccc3C(Nc3cc(C(F)(F)F)ccn3)=O)c3[n]2ccnc3N)OCC1)=O Chemical compound CCCC(N1C[C@@H](c2nc(-c(cc3)ccc3C(Nc3cc(C(F)(F)F)ccn3)=O)c3[n]2ccnc3N)OCC1)=O OULJSBRFSFRWPJ-IBGZPJMESA-N 0.000 description 1
- YIEXRFKBCJZZSF-UHFFFAOYSA-N CCCC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=NC=C1 YIEXRFKBCJZZSF-UHFFFAOYSA-N 0.000 description 1
- RVPRNBGWBVAKKK-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=C(F)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=C(F)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 RVPRNBGWBVAKKK-UHFFFAOYSA-N 0.000 description 1
- JPMUABWOGKKBNV-UAPYVXQJSA-N CCCC1=CC(NC(=O)C2=C(F)C=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=C(F)C=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C2)=NC=C1 JPMUABWOGKKBNV-UAPYVXQJSA-N 0.000 description 1
- JYRUHTNWLIEPII-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=C(OC)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=C(OC)C=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 JYRUHTNWLIEPII-UHFFFAOYSA-N 0.000 description 1
- ZBGSXMADIPILEN-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC(C)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC(C)=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 ZBGSXMADIPILEN-UHFFFAOYSA-N 0.000 description 1
- BOWGLJZQGRTCGX-XUTJKUGGSA-N CCCC1=CC(NC(=O)C2=CC(C)=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC(C)=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 BOWGLJZQGRTCGX-XUTJKUGGSA-N 0.000 description 1
- KISMNQBEJRZEOW-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 KISMNQBEJRZEOW-UHFFFAOYSA-N 0.000 description 1
- BQBBBFWUUJQWEG-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C(=O)NCCCOC)N4C(C)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C(=O)NCCCOC)N4C(C)=N3)C=C2)=NC=C1 BQBBBFWUUJQWEG-UHFFFAOYSA-N 0.000 description 1
- XYBWMQNYNWGDPO-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C(C4CCOCC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C(C4CCOCC4)=N3)C=C2)=NC=C1 XYBWMQNYNWGDPO-UHFFFAOYSA-N 0.000 description 1
- AWTKOUJXDSLIPI-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 AWTKOUJXDSLIPI-UHFFFAOYSA-N 0.000 description 1
- SXTWHONRQLNRCE-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 SXTWHONRQLNRCE-UHFFFAOYSA-N 0.000 description 1
- JSYULDRIUZCULG-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N(CC)CC)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N(CC)CC)=N3)C=C2)=NC=C1 JSYULDRIUZCULG-UHFFFAOYSA-N 0.000 description 1
- IICPJODJSICBPZ-UHFFFAOYSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCOCC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCOCC4)=N3)C=C2)=NC=C1 IICPJODJSICBPZ-UHFFFAOYSA-N 0.000 description 1
- FSKCBJSJSQJTBE-GRGXKFILSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)=NC=C1 FSKCBJSJSQJTBE-GRGXKFILSA-N 0.000 description 1
- CBSGDXFXXBMJIP-XUTJKUGGSA-N CCCC1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 Chemical compound CCCC1=CC(NC(=O)C2=CC=C(C3=C4\C(N)=NC=CN4/C([C@H]4CC[C@H](O)CC4)=N\3)C=C2)=NC=C1 CBSGDXFXXBMJIP-XUTJKUGGSA-N 0.000 description 1
- KNMKHQCMZSGXEO-HXUWFJFHSA-N CCCOC1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CCCOC1=CC(NC(=O)C2=CC(F)=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 KNMKHQCMZSGXEO-HXUWFJFHSA-N 0.000 description 1
- FKLSJZRQUNTOFS-UHFFFAOYSA-N CCN(CC)C(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CCN(CC)C(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 FKLSJZRQUNTOFS-UHFFFAOYSA-N 0.000 description 1
- IXRCHARRJVOMQY-UHFFFAOYSA-N CCN(CC)C(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CCN(CC)C(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 IXRCHARRJVOMQY-UHFFFAOYSA-N 0.000 description 1
- NOLNPRZZGSAKOZ-UHFFFAOYSA-N CCN(CC)C1=NC(Br)=C2C(N)=NC=CN12 Chemical compound CCN(CC)C1=NC(Br)=C2C(N)=NC=CN12 NOLNPRZZGSAKOZ-UHFFFAOYSA-N 0.000 description 1
- ORZQDEWPYPOOKO-FQEVSTJZSA-N CCN1C=C2C(=N1)CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N Chemical compound CCN1C=C2C(=N1)CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N ORZQDEWPYPOOKO-FQEVSTJZSA-N 0.000 description 1
- JNJGJRIACMWCQN-UHFFFAOYSA-N CCN1CCC(C2=NC(Br)=C3C(N)=NC=CN23)CC1=O Chemical compound CCN1CCC(C2=NC(Br)=C3C(N)=NC=CN23)CC1=O JNJGJRIACMWCQN-UHFFFAOYSA-N 0.000 description 1
- SCJFWSFZXBIKRX-UHFFFAOYSA-N CCN1CCC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC1=O Chemical compound CCN1CCC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC1=O SCJFWSFZXBIKRX-UHFFFAOYSA-N 0.000 description 1
- QCEJFTMRZBBVAU-HXUWFJFHSA-N CCN1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCN1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN23)C1 QCEJFTMRZBBVAU-HXUWFJFHSA-N 0.000 description 1
- MWBLDGJKPGLMAO-LJQANCHMSA-N CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 MWBLDGJKPGLMAO-LJQANCHMSA-N 0.000 description 1
- MMJHHOIVLASGRE-QGZVFWFLSA-N CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 MMJHHOIVLASGRE-QGZVFWFLSA-N 0.000 description 1
- AZIWGOLZVJPZRH-GOSISDBHSA-N CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 AZIWGOLZVJPZRH-GOSISDBHSA-N 0.000 description 1
- AZIWGOLZVJPZRH-SFHVURJKSA-N CCN1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCN1CCO[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 AZIWGOLZVJPZRH-SFHVURJKSA-N 0.000 description 1
- XOXUNHOVNIYDJR-PKOBYXMFSA-N CCN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CCN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F XOXUNHOVNIYDJR-PKOBYXMFSA-N 0.000 description 1
- CNUBVEBMHZBEBQ-GRTNUQQKSA-N CCN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)F.CF Chemical compound CCN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)F.CF CNUBVEBMHZBEBQ-GRTNUQQKSA-N 0.000 description 1
- LNKCASWSILDHQR-RBUKOAKNSA-N CCN1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)OC[C@@H]1CO Chemical compound CCN1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)OC[C@@H]1CO LNKCASWSILDHQR-RBUKOAKNSA-N 0.000 description 1
- XUGLPQLPXHJNHB-HXUWFJFHSA-N CCN1N=CC2=C1CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N Chemical compound CCN1N=CC2=C1CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N XUGLPQLPXHJNHB-HXUWFJFHSA-N 0.000 description 1
- KLMJQQUOJFVRPG-UHFFFAOYSA-N CCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 KLMJQQUOJFVRPG-UHFFFAOYSA-N 0.000 description 1
- RAFNQZLQOKJSAA-FXAWDEMLSA-N CCNC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCNC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 RAFNQZLQOKJSAA-FXAWDEMLSA-N 0.000 description 1
- ZHJWWXFLYXDYAZ-HXUWFJFHSA-N CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 ZHJWWXFLYXDYAZ-HXUWFJFHSA-N 0.000 description 1
- BKAFFDQKRWFTCY-QGZVFWFLSA-N CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 BKAFFDQKRWFTCY-QGZVFWFLSA-N 0.000 description 1
- VZRCFYQSAQPCIY-JOCHJYFZSA-N CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCNC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 VZRCFYQSAQPCIY-JOCHJYFZSA-N 0.000 description 1
- CGEMFXKSUGCEGH-ZOGSKTMCSA-N CCOC(=O)C1=CN=C(Cl)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.CCOC(=O)C1=CN=C(Cl)C2=CN=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.CCOC(=O)C1=CN=C(N)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC=C3C(Cl)=NC=CN32)C1 Chemical compound CCOC(=O)C1=CN=C(Cl)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.CCOC(=O)C1=CN=C(Cl)C2=CN=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.CCOC(=O)C1=CN=C(N)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC=C3C(Cl)=NC=CN32)C1 CGEMFXKSUGCEGH-ZOGSKTMCSA-N 0.000 description 1
- LZZWLHFZVFBLFO-JOCHJYFZSA-N CCOC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CCOC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 LZZWLHFZVFBLFO-JOCHJYFZSA-N 0.000 description 1
- AKLMDLYBAHTWSL-DDRJZQQSSA-N CCOC(=O)C1CC1CN1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCOC(=O)C1CC1CN1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 AKLMDLYBAHTWSL-DDRJZQQSSA-N 0.000 description 1
- SMURXAPBDWCTHD-UHFFFAOYSA-N CCOC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CCOC(=O)N1CCCC(C2=CC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=NN23)C1 SMURXAPBDWCTHD-UHFFFAOYSA-N 0.000 description 1
- IUGPQYBKUHJIKL-QGZVFWFLSA-N CCOC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CCOC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 IUGPQYBKUHJIKL-QGZVFWFLSA-N 0.000 description 1
- MVDHWBGXVDBULI-LJQANCHMSA-N CCOC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCOC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 MVDHWBGXVDBULI-LJQANCHMSA-N 0.000 description 1
- QFIPXXISTKDONR-GOSISDBHSA-N CCOC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound CCOC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)C3=C2N=CN=C3N)C1 QFIPXXISTKDONR-GOSISDBHSA-N 0.000 description 1
- DVLPNGDIAPHJBI-VQIMIIECSA-N CCOC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C Chemical compound CCOC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C DVLPNGDIAPHJBI-VQIMIIECSA-N 0.000 description 1
- ALSCXSLCIXZHCJ-FDDCHVKYSA-N CCOC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCOC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C ALSCXSLCIXZHCJ-FDDCHVKYSA-N 0.000 description 1
- JLFQUWSCGSIZDN-UHFFFAOYSA-N CCOC1=CC(CC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound CCOC1=CC(CC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 JLFQUWSCGSIZDN-UHFFFAOYSA-N 0.000 description 1
- KMYAEJFPNNGCKF-SIKLNZKXSA-N CCOC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound CCOC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 KMYAEJFPNNGCKF-SIKLNZKXSA-N 0.000 description 1
- WIBSZQQASAGHCI-LJQANCHMSA-N CCOCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCOCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 WIBSZQQASAGHCI-LJQANCHMSA-N 0.000 description 1
- LKWZDHVGJYPLQB-LJQANCHMSA-N CCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 LKWZDHVGJYPLQB-LJQANCHMSA-N 0.000 description 1
- YBPCMARLCFXQQE-HXUWFJFHSA-N CCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound CCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 YBPCMARLCFXQQE-HXUWFJFHSA-N 0.000 description 1
- KHILECXKNMDNFW-LJQANCHMSA-N CCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 Chemical compound CCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=NN23)C1 KHILECXKNMDNFW-LJQANCHMSA-N 0.000 description 1
- DIODCMDLOWOIJN-JOCHJYFZSA-N CCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 Chemical compound CCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 DIODCMDLOWOIJN-JOCHJYFZSA-N 0.000 description 1
- KVGRKZKSLHKDTJ-HXUWFJFHSA-N CCOCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CCOCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 KVGRKZKSLHKDTJ-HXUWFJFHSA-N 0.000 description 1
- MCTZMDXMOFFFKF-GHTZIAJQSA-N CCOCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCOCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C MCTZMDXMOFFFKF-GHTZIAJQSA-N 0.000 description 1
- ZEEKOIVETCTICW-SIKLNZKXSA-N CCOCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CCOCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C ZEEKOIVETCTICW-SIKLNZKXSA-N 0.000 description 1
- RYHATBFBQGADQN-OAQYLSRUSA-N CCOCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound CCOCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 RYHATBFBQGADQN-OAQYLSRUSA-N 0.000 description 1
- WYTNATIKTCESIR-GHTZIAJQSA-N CC[C@H](C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CC[C@H](C)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 WYTNATIKTCESIR-GHTZIAJQSA-N 0.000 description 1
- ORJOTQARKKLUMU-JOCHJYFZSA-N CN(C)C(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN(C)C(=O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 ORJOTQARKKLUMU-JOCHJYFZSA-N 0.000 description 1
- ZECFXDZLRPDLMI-HXUWFJFHSA-N CN(C)C1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CC1 Chemical compound CN(C)C1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CC1 ZECFXDZLRPDLMI-HXUWFJFHSA-N 0.000 description 1
- DAFKXKGAPUOBCV-OAQYLSRUSA-N CN(C)C1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 Chemical compound CN(C)C1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 DAFKXKGAPUOBCV-OAQYLSRUSA-N 0.000 description 1
- CARQWRFQAXMJBK-LJQANCHMSA-N CN(C)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN(C)CC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 CARQWRFQAXMJBK-LJQANCHMSA-N 0.000 description 1
- GZILCKGCTQIHBZ-JOCHJYFZSA-N CN(C)CCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN(C)CCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 GZILCKGCTQIHBZ-JOCHJYFZSA-N 0.000 description 1
- BSSIKISDPAWUIH-OAQYLSRUSA-N CN(C)CCCC(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN(C)CCCC(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 BSSIKISDPAWUIH-OAQYLSRUSA-N 0.000 description 1
- IVQKYOKOXLBYKZ-RHFBOYJTSA-N CN/C=C1\C(=N)CCC[C@@H]1NC1=C(C(=N)C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C(N)=NC=N1 Chemical compound CN/C=C1\C(=N)CCC[C@@H]1NC1=C(C(=N)C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C(N)=NC=N1 IVQKYOKOXLBYKZ-RHFBOYJTSA-N 0.000 description 1
- OYIMGHVNCSYQJI-JQORXCDHSA-N CN/C=C\C(=N)CC(=O)C1=CC=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=C1 Chemical compound CN/C=C\C(=N)CC(=O)C1=CC=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=C1 OYIMGHVNCSYQJI-JQORXCDHSA-N 0.000 description 1
- ZIYZAORNGWRFSO-JOCHJYFZSA-N CN1C=C(CN2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 Chemical compound CN1C=C(CN2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 ZIYZAORNGWRFSO-JOCHJYFZSA-N 0.000 description 1
- WLSAQYBDVIXUHM-OAQYLSRUSA-N CN1C=C(CN2CCN[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 Chemical compound CN1C=C(CN2CCN[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 WLSAQYBDVIXUHM-OAQYLSRUSA-N 0.000 description 1
- HYENHGHKVDBHRR-OAQYLSRUSA-N CN1C=C(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 Chemical compound CN1C=C(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 HYENHGHKVDBHRR-OAQYLSRUSA-N 0.000 description 1
- WQTJMWYCWZMTIQ-XMMPIXPASA-N CN1C=C(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 Chemical compound CN1C=C(CN2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 WQTJMWYCWZMTIQ-XMMPIXPASA-N 0.000 description 1
- NCNKFHPFLYEMML-UHFFFAOYSA-N CN1C=C(CN2CCSC(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1.O.O Chemical compound CN1C=C(CN2CCSC(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1.O.O NCNKFHPFLYEMML-UHFFFAOYSA-N 0.000 description 1
- DXXCRHYJCOVQMJ-FCHUYYIVSA-N CN1C=C(CN2C[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)OC[C@@H]2CO)C=N1 Chemical compound CN1C=C(CN2C[C@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)OC[C@@H]2CO)C=N1 DXXCRHYJCOVQMJ-FCHUYYIVSA-N 0.000 description 1
- PMTZBZSNTTWACN-IBGZPJMESA-N CN1C=C2C(=N1)CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N Chemical compound CN1C=C2C(=N1)CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N PMTZBZSNTTWACN-IBGZPJMESA-N 0.000 description 1
- PMTZBZSNTTWACN-LJQANCHMSA-N CN1C=C2C(=N1)CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N Chemical compound CN1C=C2C(=N1)CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C1N=CN=C2N PMTZBZSNTTWACN-LJQANCHMSA-N 0.000 description 1
- PNOPFUNEWUODFA-HXUWFJFHSA-N CN1CC(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C1 Chemical compound CN1CC(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)C1 PNOPFUNEWUODFA-HXUWFJFHSA-N 0.000 description 1
- HCYLFQZXPCJKTQ-UHFFFAOYSA-N CN1CCC2=C(C1)SC(NC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 Chemical compound CN1CCC2=C(C1)SC(NC(=O)C1=CC=C(B3OC(C)(C)C(C)(C)O3)C=C1)=N2 HCYLFQZXPCJKTQ-UHFFFAOYSA-N 0.000 description 1
- NRIOQGSHECFOLI-SAABIXHNSA-N CN1CCC2=C(C1)SC(NC(=O)C1=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C1)=N2 Chemical compound CN1CCC2=C(C1)SC(NC(=O)C1=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@H](O)CC4)=N3)C=C1)=N2 NRIOQGSHECFOLI-SAABIXHNSA-N 0.000 description 1
- LVCCPFRZAKNTJV-IRLDBZIGSA-N CN1CCC[C@H]1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN1CCC[C@H]1C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 LVCCPFRZAKNTJV-IRLDBZIGSA-N 0.000 description 1
- XCAUFJUHCZXLMU-GOSISDBHSA-N CN1CCN(C)[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN1CCN(C)[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 XCAUFJUHCZXLMU-GOSISDBHSA-N 0.000 description 1
- OURWFWYMBSWOOS-QGZVFWFLSA-N CN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 OURWFWYMBSWOOS-QGZVFWFLSA-N 0.000 description 1
- IICHIZQBMUSVAS-UHFFFAOYSA-N CN1CCSC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1.O.O Chemical compound CN1CCSC(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1.O.O IICHIZQBMUSVAS-UHFFFAOYSA-N 0.000 description 1
- ZHNALUZXLFZPLU-KBXCAEBGSA-N CN1C[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CN1C[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F ZHNALUZXLFZPLU-KBXCAEBGSA-N 0.000 description 1
- TWQXELZZGTYACH-FUHWJXTLSA-N CN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound CN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F TWQXELZZGTYACH-FUHWJXTLSA-N 0.000 description 1
- OSEALRLAQRYVDY-HKUYNNGSSA-N CN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C(C)(F)F Chemical compound CN1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C(C)(F)F OSEALRLAQRYVDY-HKUYNNGSSA-N 0.000 description 1
- AEBQAGLHKZCKHZ-UHFFFAOYSA-N CN1N=CC2=C1CCCC2(O)C1=NC(Br)=C2C(N)=NC=CN12 Chemical compound CN1N=CC2=C1CCCC2(O)C1=NC(Br)=C2C(N)=NC=CN12 AEBQAGLHKZCKHZ-UHFFFAOYSA-N 0.000 description 1
- GIQJSYRVSVLVMN-UHFFFAOYSA-N CN1N=CC2=C1CCCC2C1=NC(Br)=C2C(N)=NC=CN12 Chemical compound CN1N=CC2=C1CCCC2C1=NC(Br)=C2C(N)=NC=CN12 GIQJSYRVSVLVMN-UHFFFAOYSA-N 0.000 description 1
- SIMFVULLGBPDGX-IBGZPJMESA-N CN1N=CC2=C1CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C(N)N=CN=C21 Chemical compound CN1N=CC2=C1CCC[C@@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C(N)N=CN=C21 SIMFVULLGBPDGX-IBGZPJMESA-N 0.000 description 1
- SIMFVULLGBPDGX-LJQANCHMSA-N CN1N=CC2=C1CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C(N)N=CN=C21 Chemical compound CN1N=CC2=C1CCC[C@H]2N1N=C(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)C2=C(N)N=CN=C21 SIMFVULLGBPDGX-LJQANCHMSA-N 0.000 description 1
- SGNAITGJWQBGQD-KGSSHYSFSA-N COC(=O)C1=CC=C(C)N=C1.COC(=O)C1CCC(C)NC1.COC(=O)[C@@H]1CC[C@@H](C)N(C(=O)OCC2=CC=CC=C2)C1.COC(=O)[C@@H]1CC[C@H](C)N(C(=O)OCC2=CC=CC=C2)C1.C[C@@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1.C[C@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1.Cl Chemical compound COC(=O)C1=CC=C(C)N=C1.COC(=O)C1CCC(C)NC1.COC(=O)[C@@H]1CC[C@@H](C)N(C(=O)OCC2=CC=CC=C2)C1.COC(=O)[C@@H]1CC[C@H](C)N(C(=O)OCC2=CC=CC=C2)C1.C[C@@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1.C[C@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1.Cl SGNAITGJWQBGQD-KGSSHYSFSA-N 0.000 description 1
- BMHPQMDBDLHKTE-UHFFFAOYSA-N COC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 Chemical compound COC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 BMHPQMDBDLHKTE-UHFFFAOYSA-N 0.000 description 1
- NIFQVWDSWLHKPE-UHFFFAOYSA-N COC(=O)C1CC12CCN(C(=O)OCC1=CC=CC=C1)CC2.COC(=O)C=C1CCN(C(=O)OCC2=CC=CC=C2)CC1.O=C(O)C1CC12CCN(C(=O)OCC1=CC=CC=C1)CC2.O=C1CCN(C(=O)OCC2=CC=CC=C2)CC1 Chemical compound COC(=O)C1CC12CCN(C(=O)OCC1=CC=CC=C1)CC2.COC(=O)C=C1CCN(C(=O)OCC2=CC=CC=C2)CC1.O=C(O)C1CC12CCN(C(=O)OCC1=CC=CC=C1)CC2.O=C1CCN(C(=O)OCC2=CC=CC=C2)CC1 NIFQVWDSWLHKPE-UHFFFAOYSA-N 0.000 description 1
- NKJIUDRXCHKKSS-UHFFFAOYSA-N COC(=O)C1CC=C(N2CCOCC2)CC1.COC(=O)C1CCC(=O)C(C(=O)C2CC2)C1.COC(=O)C1CCC(=O)CC1.COC(=O)C1CCC2=C(C1)C(C1CC1)=NN2.O=C(O)C1CCC2=C(C1)C(C1CC1)=NN2 Chemical compound COC(=O)C1CC=C(N2CCOCC2)CC1.COC(=O)C1CCC(=O)C(C(=O)C2CC2)C1.COC(=O)C1CCC(=O)CC1.COC(=O)C1CCC2=C(C1)C(C1CC1)=NN2.O=C(O)C1CCC2=C(C1)C(C1CC1)=NN2 NKJIUDRXCHKKSS-UHFFFAOYSA-N 0.000 description 1
- NFDQSZHMAFKHBP-UHFFFAOYSA-N COC(=O)C1CCCN(C(=O)NCC2=NC=CN=C2Cl)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(Cl)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(N)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(NCC4=CC=C(OC)C=C4)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC=C3C(Cl)=NC=CN32)C1.NCC1=NC=CN=C1Cl Chemical compound COC(=O)C1CCCN(C(=O)NCC2=NC=CN=C2Cl)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(Cl)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(N)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC(Br)=C3C(NCC4=CC=C(OC)C=C4)=NC=CN23)C1.COC(=O)C1CCCN(C2=NC=C3C(Cl)=NC=CN32)C1.NCC1=NC=CN=C1Cl NFDQSZHMAFKHBP-UHFFFAOYSA-N 0.000 description 1
- YTTPVZDDZOGPSM-FUHWJXTLSA-N COC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F Chemical compound COC(=O)N1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C(F)(F)F YTTPVZDDZOGPSM-FUHWJXTLSA-N 0.000 description 1
- ZYAQNCRDVLRUDG-ZWWIKEPDSA-N COC(=O)[C@@H]1CC[C@@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1 Chemical compound COC(=O)[C@@H]1CC[C@@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1 ZYAQNCRDVLRUDG-ZWWIKEPDSA-N 0.000 description 1
- SRONQHMTQRQNBN-UHFFFAOYSA-N COC1=C(B2OC(C)(C)C(C)(C)O2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 Chemical compound COC1=C(B2OC(C)(C)C(C)(C)O2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 SRONQHMTQRQNBN-UHFFFAOYSA-N 0.000 description 1
- KREQPZHVZLRARY-UHFFFAOYSA-N COC1=C(C(=O)NC2=NC=CC=C2)C=CC(B2OC(C)(C)C(C)(C)O2)=C1 Chemical compound COC1=C(C(=O)NC2=NC=CC=C2)C=CC(B2OC(C)(C)C(C)(C)O2)=C1 KREQPZHVZLRARY-UHFFFAOYSA-N 0.000 description 1
- KZFQCCGYALYEKM-JCNLHEQBSA-N COC1=C(C(=O)NC2=NC=CC=C2)C=CC(C2=C3\C(N)=NC=CN3/C([C@H]3CC[C@H](O)CC3)=N\2)=C1 Chemical compound COC1=C(C(=O)NC2=NC=CC=C2)C=CC(C2=C3\C(N)=NC=CN3/C([C@H]3CC[C@H](O)CC3)=N\2)=C1 KZFQCCGYALYEKM-JCNLHEQBSA-N 0.000 description 1
- NCZRTNRBHFRRIH-GOSISDBHSA-N COC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 Chemical compound COC1=C(C2=C3C(N)=NC=CN3C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)=N2)C=CC(C(=O)NC2=NC=CC(C(F)(F)F)=C2)=C1 NCZRTNRBHFRRIH-GOSISDBHSA-N 0.000 description 1
- LOFLKNCRRTUXLC-JWQCQUIFSA-N COC1=C(CNC2=NC=CN3C([C@@H]4CC[C@H](COC(C)=O)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C=CC(C)=C1 Chemical compound COC1=C(CNC2=NC=CN3C([C@@H]4CC[C@H](COC(C)=O)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C=CC(C)=C1 LOFLKNCRRTUXLC-JWQCQUIFSA-N 0.000 description 1
- CBOAJVVAQUNVIK-UQIIZPHYSA-N COC1=C(CNC2=NC=CN3C([C@]4(O)CCCN(C(=O)OC(C)(C)C)C4)=NC(Br)=C23)C=CC(C)=C1.S Chemical compound COC1=C(CNC2=NC=CN3C([C@]4(O)CCCN(C(=O)OC(C)(C)C)C4)=NC(Br)=C23)C=CC(C)=C1.S CBOAJVVAQUNVIK-UQIIZPHYSA-N 0.000 description 1
- LKUSQTZCJYNSGH-UHFFFAOYSA-N COC1=CC(CC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound COC1=CC(CC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 LKUSQTZCJYNSGH-UHFFFAOYSA-N 0.000 description 1
- LLSRFUKRVCLUKH-OAQYLSRUSA-N COC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(C)=O)C4)=N3)C=C2)=NC=C1 Chemical compound COC1=CC(CC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(C)=O)C4)=N3)C=C2)=NC=C1 LLSRFUKRVCLUKH-OAQYLSRUSA-N 0.000 description 1
- DMYXOLSVVMFZQQ-UHFFFAOYSA-N COC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C(F)=C2)=NC=C1 Chemical compound COC1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C(F)=C2)=NC=C1 DMYXOLSVVMFZQQ-UHFFFAOYSA-N 0.000 description 1
- CQBUHWVEBOKYNA-HXUWFJFHSA-N COC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 Chemical compound COC1=CC(NC(=O)C2=CC=C(C(=N)C3=C(N[C@@H]4CCCN(C(=O)C5(C)COC5)C4)C=CN=C3N)C=C2)=NC=C1 CQBUHWVEBOKYNA-HXUWFJFHSA-N 0.000 description 1
- APKMCWQHEZQNPE-OAQYLSRUSA-N COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(C)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 APKMCWQHEZQNPE-OAQYLSRUSA-N 0.000 description 1
- YGFUEMVRUCKAIH-GHTZIAJQSA-N COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound COC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CC[C@H](C)N(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 YGFUEMVRUCKAIH-GHTZIAJQSA-N 0.000 description 1
- VXKMCPBZXDTCRR-HXUWFJFHSA-N COC1=CC(OC)=C(CNC2=NC=C(Cl)N3C([C@@H]4CCCN(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C=C1 Chemical compound COC1=CC(OC)=C(CNC2=NC=C(Cl)N3C([C@@H]4CCCN(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C=C1 VXKMCPBZXDTCRR-HXUWFJFHSA-N 0.000 description 1
- BRYNLDJTNIPXAQ-GOSISDBHSA-N COC1=CC=C(CNC2=NC=CC3=C2C(Br)=NN3[C@@H]2CCCN(C(=O)OC(C)(C)C)C2)C(C)=C1 Chemical compound COC1=CC=C(CNC2=NC=CC3=C2C(Br)=NN3[C@@H]2CCCN(C(=O)OC(C)(C)C)C2)C(C)=C1 BRYNLDJTNIPXAQ-GOSISDBHSA-N 0.000 description 1
- JDUXBQCIGNMCGH-UHFFFAOYSA-N COC1=CC=C(CNC2=NC=CN3C(C4CN(C(=O)OC(C)(C)C)CCS4(=O)=O)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C(C4CN(C(=O)OC(C)(C)C)CCS4(=O)=O)=NC(Br)=C23)C(OC)=C1 JDUXBQCIGNMCGH-UHFFFAOYSA-N 0.000 description 1
- GLENUWGJZHHFKX-IRLDBZIGSA-N COC1=CC=C(CNC2=NC=CN3C([C@@H]4CC[C@@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@@H]4CC[C@@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 GLENUWGJZHHFKX-IRLDBZIGSA-N 0.000 description 1
- GLENUWGJZHHFKX-IFMALSPDSA-N COC1=CC=C(CNC2=NC=CN3C([C@@H]4CC[C@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@@H]4CC[C@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 GLENUWGJZHHFKX-IFMALSPDSA-N 0.000 description 1
- GLENUWGJZHHFKX-UNMCSNQZSA-N COC1=CC=C(CNC2=NC=CN3C([C@H]4CC[C@@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@H]4CC[C@@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 GLENUWGJZHHFKX-UNMCSNQZSA-N 0.000 description 1
- GLENUWGJZHHFKX-RBBKRZOGSA-N COC1=CC=C(CNC2=NC=CN3C([C@H]4CC[C@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@H]4CC[C@H](C(F)F)N(C(=O)OCC5=CC=CC=C5)C4)=NC(Br)=C23)C(OC)=C1 GLENUWGJZHHFKX-RBBKRZOGSA-N 0.000 description 1
- VAXZTTZGLWMRSI-HXUWFJFHSA-N COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)CCN4C(=O)OC(C)(C)C)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)CCN4C(=O)OC(C)(C)C)=NC(Br)=C23)C(OC)=C1 VAXZTTZGLWMRSI-HXUWFJFHSA-N 0.000 description 1
- ZDWAPDQXRZXMLI-HNAYVOBHSA-N COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)[C@@H](C)CO4)=NC(Br)=C23)C(OC)=C1 Chemical compound COC1=CC=C(CNC2=NC=CN3C([C@H]4CN(C(=O)OC(C)(C)C)[C@@H](C)CO4)=NC(Br)=C23)C(OC)=C1 ZDWAPDQXRZXMLI-HNAYVOBHSA-N 0.000 description 1
- CQWUFGIUWVDAFE-XMMPIXPASA-N COC1=CC=CC(C2=CN=C(N)C3=C(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)N=C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)N23)=C1 Chemical compound COC1=CC=CC(C2=CN=C(N)C3=C(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)N=C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)N23)=C1 CQWUFGIUWVDAFE-XMMPIXPASA-N 0.000 description 1
- DPEVVGGOSIBTPF-LJQANCHMSA-N COC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=C1 Chemical compound COC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=C(Cl)N4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=C1 DPEVVGGOSIBTPF-LJQANCHMSA-N 0.000 description 1
- UQOSVQAULPIMIU-OAQYLSRUSA-N COC1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 Chemical compound COC1=CN=C(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)C=C1 UQOSVQAULPIMIU-OAQYLSRUSA-N 0.000 description 1
- NWJWGJBDZQQPRB-HXUWFJFHSA-N COC1=NC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 Chemical compound COC1=NC(CC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5(C)COC5)C4)=N3)C=C2)=NC=C1 NWJWGJBDZQQPRB-HXUWFJFHSA-N 0.000 description 1
- MAHYDCCJRJPOBN-UHFFFAOYSA-N COC1CN(C2=NC(Br)=C3C(N)=NC=CN23)C1 Chemical compound COC1CN(C2=NC(Br)=C3C(N)=NC=CN23)C1 MAHYDCCJRJPOBN-UHFFFAOYSA-N 0.000 description 1
- IWKHOZZGOVSDAB-UHFFFAOYSA-N COC1CN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COC1CN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 IWKHOZZGOVSDAB-UHFFFAOYSA-N 0.000 description 1
- HHCIAZMCENVUKX-QGZVFWFLSA-N COCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(COC)N23)C1 Chemical compound COCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(COC)N23)C1 HHCIAZMCENVUKX-QGZVFWFLSA-N 0.000 description 1
- QOHFVXUKSMZMKR-GOSISDBHSA-N COCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 QOHFVXUKSMZMKR-GOSISDBHSA-N 0.000 description 1
- QZUUBYSBWWORKZ-QGZVFWFLSA-N COCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound COCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 QZUUBYSBWWORKZ-QGZVFWFLSA-N 0.000 description 1
- SQVLODRKHTUXPF-LJQANCHMSA-N COCC(=O)N1CCC[C@@H](NC2=C(C(=N)C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C(N)=NC=C2)C1 Chemical compound COCC(=O)N1CCC[C@@H](NC2=C(C(=N)C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C(N)=NC=C2)C1 SQVLODRKHTUXPF-LJQANCHMSA-N 0.000 description 1
- LAUHLGUSVSJYCI-GOSISDBHSA-N COCC(=O)N1CCO[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCC(=O)N1CCO[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 LAUHLGUSVSJYCI-GOSISDBHSA-N 0.000 description 1
- PSVMTBKIHSAZFO-GOSISDBHSA-N COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 PSVMTBKIHSAZFO-GOSISDBHSA-N 0.000 description 1
- QXWTZMQFLKNYHE-LJQANCHMSA-N COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 QXWTZMQFLKNYHE-LJQANCHMSA-N 0.000 description 1
- XNLVRFHUMUTCMR-QGZVFWFLSA-N COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound COCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 XNLVRFHUMUTCMR-QGZVFWFLSA-N 0.000 description 1
- MNEZOIADNNVMMV-OAQYLSRUSA-N COCC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 Chemical compound COCC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=CC(C(F)(F)F)=CC=N5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 MNEZOIADNNVMMV-OAQYLSRUSA-N 0.000 description 1
- XDOUJWYKOZFZCR-HXUWFJFHSA-N COCC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 Chemical compound COCC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 XDOUJWYKOZFZCR-HXUWFJFHSA-N 0.000 description 1
- RMGANNYELGYLHA-OAQYLSRUSA-N COCC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C3N=CN=C4N)C2)CCC1 Chemical compound COCC1(C(=O)N2CCC[C@@H](N3N=C(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)C4=C3N=CN=C4N)C2)CCC1 RMGANNYELGYLHA-OAQYLSRUSA-N 0.000 description 1
- GFYBRHCOGFUSCC-OAQYLSRUSA-N COCC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 Chemical compound COCC1(C(=O)N2CCO[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CCC1 GFYBRHCOGFUSCC-OAQYLSRUSA-N 0.000 description 1
- YOVIPHVVRVPXPT-GOSISDBHSA-N COCC1=CN=C(N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound COCC1=CN=C(N)C2=C(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 YOVIPHVVRVPXPT-GOSISDBHSA-N 0.000 description 1
- BOTXZOPWSRLCSE-HXUWFJFHSA-N COCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound COCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 BOTXZOPWSRLCSE-HXUWFJFHSA-N 0.000 description 1
- LNZTXPWTQUOCSC-GHTZIAJQSA-N COCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)N12 Chemical compound COCC1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CC[C@H](C)N(C(=O)C4(C)COC4)C3)N12 LNZTXPWTQUOCSC-GHTZIAJQSA-N 0.000 description 1
- IXSUCKSPPMSRHW-JOCHJYFZSA-N COCC1=CN=C(NCC2=C(OC)C=C(OC)C=C2)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12 Chemical compound COCC1=CN=C(NCC2=C(OC)C=C(OC)C=C2)C2=C(Br)N=C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)N12 IXSUCKSPPMSRHW-JOCHJYFZSA-N 0.000 description 1
- KETHOAGETCHSLK-UHFFFAOYSA-N COCC1=NNC2=C1CC(C1=NC(Br)=C3C(N)=NC=CN13)CC2 Chemical compound COCC1=NNC2=C1CC(C1=NC(Br)=C3C(N)=NC=CN13)CC2 KETHOAGETCHSLK-UHFFFAOYSA-N 0.000 description 1
- JLBASQDIHUHMMK-UHFFFAOYSA-N COCC1=NNC2=C1CC(C1=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN13)CC2 Chemical compound COCC1=NNC2=C1CC(C1=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN13)CC2 JLBASQDIHUHMMK-UHFFFAOYSA-N 0.000 description 1
- LLFUYBXUEXOXAC-WIYYLYMNSA-N COCCC(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)C[C@@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 LLFUYBXUEXOXAC-WIYYLYMNSA-N 0.000 description 1
- LLFUYBXUEXOXAC-GHTZIAJQSA-N COCCC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)C[C@H]1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 LLFUYBXUEXOXAC-GHTZIAJQSA-N 0.000 description 1
- ANIKHMYOMXIDCP-UHFFFAOYSA-N COCCC(=O)N1C2CCC1C(C1=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN13)C2 Chemical compound COCCC(=O)N1C2CCC1C(C1=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN13)C2 ANIKHMYOMXIDCP-UHFFFAOYSA-N 0.000 description 1
- MUIARQGPXMXYBV-OAQYLSRUSA-N COCCC(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound COCCC(=O)N1CCC2(CC1)C[C@@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12 MUIARQGPXMXYBV-OAQYLSRUSA-N 0.000 description 1
- AKSJYRSZWLCCSW-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(C(F)(F)F)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(C(F)(F)F)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 AKSJYRSZWLCCSW-GOSISDBHSA-N 0.000 description 1
- QSTOILCGEDLZDI-HXUWFJFHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(C)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(C)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 QSTOILCGEDLZDI-HXUWFJFHSA-N 0.000 description 1
- MWFICOWMLGVLTD-QGZVFWFLSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 MWFICOWMLGVLTD-QGZVFWFLSA-N 0.000 description 1
- ASYGWMBWDHGEMG-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 ASYGWMBWDHGEMG-GOSISDBHSA-N 0.000 description 1
- KLLUNBKPHALPNX-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(O)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=C(O)C=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 KLLUNBKPHALPNX-GOSISDBHSA-N 0.000 description 1
- HDVJGUQUZNOJEX-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC(F)=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC(F)=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 HDVJGUQUZNOJEX-GOSISDBHSA-N 0.000 description 1
- BXAASMHLFNGBBY-LJQANCHMSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 BXAASMHLFNGBBY-LJQANCHMSA-N 0.000 description 1
- GEXLJKSQCNCFND-OAQYLSRUSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C#N)=C4)C=C3)=C3C(N)=NC=CN23)C1 GEXLJKSQCNCFND-OAQYLSRUSA-N 0.000 description 1
- DORSPQGRYZKJAO-OYGPHJITSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(/C=C/C4=CC=CC=C4)N23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(/C=C/C4=CC=CC=C4)N23)C1 DORSPQGRYZKJAO-OYGPHJITSA-N 0.000 description 1
- DRCLNLSUAZCLOA-HSZRJFAPSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)C1 DRCLNLSUAZCLOA-HSZRJFAPSA-N 0.000 description 1
- KKWARJYDRRCQNX-HXUWFJFHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 KKWARJYDRRCQNX-HXUWFJFHSA-N 0.000 description 1
- UWTCDSRULALDQF-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=CN=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=CN=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 UWTCDSRULALDQF-GOSISDBHSA-N 0.000 description 1
- YFCKJINRTUYLDN-GOSISDBHSA-N COCCC(=O)N1CCC[C@@H](C2=NC(C3=NC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCC[C@@H](C2=NC(C3=NC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 YFCKJINRTUYLDN-GOSISDBHSA-N 0.000 description 1
- MJTUPUWNJAFYBH-LJQANCHMSA-N COCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 Chemical compound COCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)C1 MJTUPUWNJAFYBH-LJQANCHMSA-N 0.000 description 1
- ZJGKSBNPQXOWJL-LJQANCHMSA-N COCCC(=O)N1CCN[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCN[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 ZJGKSBNPQXOWJL-LJQANCHMSA-N 0.000 description 1
- LJSKCAFJUJGYHM-HXUWFJFHSA-N COCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound COCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 LJSKCAFJUJGYHM-HXUWFJFHSA-N 0.000 description 1
- BISLLWYETURXRJ-LJQANCHMSA-N COCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 BISLLWYETURXRJ-LJQANCHMSA-N 0.000 description 1
- MMUUBQDBHIQDCJ-LJQANCHMSA-N COCCC(=O)N1CCS[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1.O.O Chemical compound COCCC(=O)N1CCS[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1.O.O MMUUBQDBHIQDCJ-LJQANCHMSA-N 0.000 description 1
- XYIZFHYMXWPMEC-LJQANCHMSA-N COCCC(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 XYIZFHYMXWPMEC-LJQANCHMSA-N 0.000 description 1
- DHLKZLCVABZRID-QUCCMNQESA-N COCCC(=O)N1C[C@@H](O)C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N1C[C@@H](O)C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 DHLKZLCVABZRID-QUCCMNQESA-N 0.000 description 1
- NRGKJUHDGAKVTP-FUHWJXTLSA-N COCCC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound COCCC(=O)N1C[C@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C NRGKJUHDGAKVTP-FUHWJXTLSA-N 0.000 description 1
- AYNDBUYDJNTERV-FUHWJXTLSA-N COCCC(=O)N1C[C@H](C2=NC(C3=CC(F)=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound COCCC(=O)N1C[C@H](C2=NC(C3=CC(F)=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C AYNDBUYDJNTERV-FUHWJXTLSA-N 0.000 description 1
- RDHFWEBHRFQPOX-YADARESESA-N COCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound COCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C RDHFWEBHRFQPOX-YADARESESA-N 0.000 description 1
- JLOJOEURZWKBLI-HXUWFJFHSA-N COCCC(=O)N[C@@H]1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCC(=O)N[C@@H]1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 JLOJOEURZWKBLI-HXUWFJFHSA-N 0.000 description 1
- CMWBOLDEGCDVDS-UHFFFAOYSA-N COCCCNC(=O)C1=CN=C(N)C2=C(Br)N=C(C)N12 Chemical compound COCCCNC(=O)C1=CN=C(N)C2=C(Br)N=C(C)N12 CMWBOLDEGCDVDS-UHFFFAOYSA-N 0.000 description 1
- GNULQYCQNUXLLK-UHFFFAOYSA-N COCCCNC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 Chemical compound COCCCNC(=O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 GNULQYCQNUXLLK-UHFFFAOYSA-N 0.000 description 1
- QVBVFFFVJGUBLZ-HXUWFJFHSA-N COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 Chemical compound COCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(C)N23)C1 QVBVFFFVJGUBLZ-HXUWFJFHSA-N 0.000 description 1
- JDNWWXVONNKYQL-UHFFFAOYSA-N COCCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound COCCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 JDNWWXVONNKYQL-UHFFFAOYSA-N 0.000 description 1
- HKVLMWNCIHXCGI-LJQANCHMSA-N COCCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound COCCOCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 HKVLMWNCIHXCGI-LJQANCHMSA-N 0.000 description 1
- DHTIEXOIWRAINO-OAQYLSRUSA-N COCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound COCCOCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 DHTIEXOIWRAINO-OAQYLSRUSA-N 0.000 description 1
- QJUFMJMHLVDNQH-HSZRJFAPSA-N COCCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 Chemical compound COCCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 QJUFMJMHLVDNQH-HSZRJFAPSA-N 0.000 description 1
- HPFOOBSFKDFFIG-HHHXNRCGSA-N COCCOCCOCCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 Chemical compound COCCOCCOCCOCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 HPFOOBSFKDFFIG-HHHXNRCGSA-N 0.000 description 1
- GQYQVRIIEZBKSL-KBPBESRZSA-N COC[C@@H]1CC[C@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1 Chemical compound COC[C@@H]1CC[C@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1 GQYQVRIIEZBKSL-KBPBESRZSA-N 0.000 description 1
- MJOCXNXJUGKEQV-ZEQRLZLVSA-N COC[C@@H]1CC[C@H](C2=NC(Br)=C3C(NCC4=C(OC)C=C(C)C=C4)=NC=CN23)CN1C(=O)OCC1=CC=CC=C1 Chemical compound COC[C@@H]1CC[C@H](C2=NC(Br)=C3C(NCC4=C(OC)C=C(C)C=C4)=NC=CN23)CN1C(=O)OCC1=CC=CC=C1 MJOCXNXJUGKEQV-ZEQRLZLVSA-N 0.000 description 1
- KCFAIKQKXCIXFO-URXFXBBRSA-N COC[C@@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound COC[C@@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 KCFAIKQKXCIXFO-URXFXBBRSA-N 0.000 description 1
- RRDZJAGJQXCYAF-VGOKPJQXSA-N COC[C@H](C)CC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound COC[C@H](C)CC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 RRDZJAGJQXCYAF-VGOKPJQXSA-N 0.000 description 1
- ZYMYVFNSWGDABI-LCQOSCCDSA-N COC[C@H](C)CC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound COC[C@H](C)CC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 ZYMYVFNSWGDABI-LCQOSCCDSA-N 0.000 description 1
- GQYQVRIIEZBKSL-ZIAGYGMSSA-N COC[C@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1 Chemical compound COC[C@H]1CC[C@@H](C(=O)O)CN1C(=O)OCC1=CC=CC=C1 GQYQVRIIEZBKSL-ZIAGYGMSSA-N 0.000 description 1
- MJOCXNXJUGKEQV-DNQXCXABSA-N COC[C@H]1CC[C@@H](C2=NC(Br)=C3C(NCC4=C(OC)C=C(C)C=C4)=NC=CN23)CN1C(=O)OCC1=CC=CC=C1 Chemical compound COC[C@H]1CC[C@@H](C2=NC(Br)=C3C(NCC4=C(OC)C=C(C)C=C4)=NC=CN23)CN1C(=O)OCC1=CC=CC=C1 MJOCXNXJUGKEQV-DNQXCXABSA-N 0.000 description 1
- KCFAIKQKXCIXFO-ZJSXRUAMSA-N COC[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound COC[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 KCFAIKQKXCIXFO-ZJSXRUAMSA-N 0.000 description 1
- XGHKNNUVLWWTSO-UHFFFAOYSA-N CONC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CONC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 XGHKNNUVLWWTSO-UHFFFAOYSA-N 0.000 description 1
- FOWLOPSMWLVVDQ-UHFFFAOYSA-N CONC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CONC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 FOWLOPSMWLVVDQ-UHFFFAOYSA-N 0.000 description 1
- LXODDGXVRDYSAY-WIYYLYMNSA-N CO[C@H](C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound CO[C@H](C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 LXODDGXVRDYSAY-WIYYLYMNSA-N 0.000 description 1
- ADPJJKJNMQBANC-DTORHVGOSA-N CO[C@H]1CC[C@@H](C2=NC(Br)=C3C(N)=NC=CN32)CC1 Chemical compound CO[C@H]1CC[C@@H](C2=NC(Br)=C3C(N)=NC=CN32)CC1 ADPJJKJNMQBANC-DTORHVGOSA-N 0.000 description 1
- IALIYUXJGMBUDT-PUZFROQSSA-N CO[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN32)CC1 Chemical compound CO[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C)=C4)C=C3)=C3C(N)=NC=CN32)CC1 IALIYUXJGMBUDT-PUZFROQSSA-N 0.000 description 1
- UYXYHDMJBYUYET-GOSISDBHSA-N CS(=O)(=O)CC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CS(=O)(=O)CC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 UYXYHDMJBYUYET-GOSISDBHSA-N 0.000 description 1
- VKHACTAKQGNIQR-LJQANCHMSA-N CS(=O)(=O)CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CS(=O)(=O)CCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 VKHACTAKQGNIQR-LJQANCHMSA-N 0.000 description 1
- JGLSZZIIGNOOLY-GOSISDBHSA-N CS(=O)(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CS(=O)(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 JGLSZZIIGNOOLY-GOSISDBHSA-N 0.000 description 1
- RKKNAGBDXIXUBR-LJQANCHMSA-N CSCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CSCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 RKKNAGBDXIXUBR-LJQANCHMSA-N 0.000 description 1
- YUCUJACGQWGVOR-OAQYLSRUSA-N CSCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 Chemical compound CSCCC(=O)N1CCC[C@@H](N2N=C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C(N)N=CN=C32)C1 YUCUJACGQWGVOR-OAQYLSRUSA-N 0.000 description 1
- YYZZVOAZISYFBP-LJQANCHMSA-N CSCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound CSCCC(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 YYZZVOAZISYFBP-LJQANCHMSA-N 0.000 description 1
- MYJPCXGZVQLMJC-YLJYHZDGSA-N CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C Chemical compound CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@H]1C MYJPCXGZVQLMJC-YLJYHZDGSA-N 0.000 description 1
- ATQILXCHJCZMQZ-SIKLNZKXSA-N CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C ATQILXCHJCZMQZ-SIKLNZKXSA-N 0.000 description 1
- XOXIBYBSNHKYGA-YADARESESA-N CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C Chemical compound CSCCC(=O)N1C[C@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CC[C@@H]1C XOXIBYBSNHKYGA-YADARESESA-N 0.000 description 1
- SEFUJPSMWCFTEJ-UHFFFAOYSA-N CSCCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 Chemical compound CSCCNC(=O)C1CCCN(C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)C1 SEFUJPSMWCFTEJ-UHFFFAOYSA-N 0.000 description 1
- GDOKPXKDBMNXCT-HNNXBMFYSA-N C[C@@H](CNC(=O)C1(C)COC1)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound C[C@@H](CNC(=O)C1(C)COC1)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 GDOKPXKDBMNXCT-HNNXBMFYSA-N 0.000 description 1
- VHQWXJDUVMROQP-SFHVURJKSA-N C[C@@H](CNC(=O)OCC1=CC=CC=C1)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound C[C@@H](CNC(=O)OCC1=CC=CC=C1)C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 VHQWXJDUVMROQP-SFHVURJKSA-N 0.000 description 1
- ZHLLAGZBFVQTJM-CRAIPNDOSA-N C[C@@H](O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound C[C@@H](O)C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 ZHLLAGZBFVQTJM-CRAIPNDOSA-N 0.000 description 1
- ZSYNRZMPLBXQNV-RDTXWAMCSA-N C[C@@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound C[C@@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 ZSYNRZMPLBXQNV-RDTXWAMCSA-N 0.000 description 1
- QUYDSIXJBFBWNR-CXAGYDPISA-N C[C@@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound C[C@@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 QUYDSIXJBFBWNR-CXAGYDPISA-N 0.000 description 1
- UUCBRZWIYUWJBE-YLJYHZDGSA-N C[C@@H](O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound C[C@@H](O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 UUCBRZWIYUWJBE-YLJYHZDGSA-N 0.000 description 1
- CGLUEJGNSBIWSY-PMQSLKNFSA-N C[C@@H]1CCC(N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)CN1.C[C@H]1CCC(N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)CN1 Chemical compound C[C@@H]1CCC(N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)CN1.C[C@H]1CCC(N2N=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)C3=C2N=CN=C3N)CN1 CGLUEJGNSBIWSY-PMQSLKNFSA-N 0.000 description 1
- WFAURZNSPGKTIO-UTKZUKDTSA-N C[C@@H]1CCN(C(=O)C2(C)COC2)C[C@@H]1C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound C[C@@H]1CCN(C(=O)C2(C)COC2)C[C@@H]1C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 WFAURZNSPGKTIO-UTKZUKDTSA-N 0.000 description 1
- YVKJHIKLYWBZCV-YPMHNXCESA-N C[C@@H]1CCN(C(=O)OCC2=CC=CC=C2)C[C@@H]1C(=O)O Chemical compound C[C@@H]1CCN(C(=O)OCC2=CC=CC=C2)C[C@@H]1C(=O)O YVKJHIKLYWBZCV-YPMHNXCESA-N 0.000 description 1
- FVODXSBICIHIGB-OXQOHEQNSA-N C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 Chemical compound C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 FVODXSBICIHIGB-OXQOHEQNSA-N 0.000 description 1
- AKHUIKHIDLUEJS-IKQMYLSPSA-N C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCCO1 Chemical compound C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCCO1 AKHUIKHIDLUEJS-IKQMYLSPSA-N 0.000 description 1
- IQLVYCQQGWGYEQ-CDAOEWRMSA-N C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1.C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1 Chemical compound C[C@@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1.C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1 IQLVYCQQGWGYEQ-CDAOEWRMSA-N 0.000 description 1
- AVHAICXACVBUTE-UTKZUKDTSA-N C[C@@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 Chemical compound C[C@@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 AVHAICXACVBUTE-UTKZUKDTSA-N 0.000 description 1
- SOYXQVSBDHHRLV-DGCLKSJQSA-N C[C@@H]1C[C@@H](C(=O)O)CN(C(=O)OCC2=CC=CC=C2)C1 Chemical compound C[C@@H]1C[C@@H](C(=O)O)CN(C(=O)OCC2=CC=CC=C2)C1 SOYXQVSBDHHRLV-DGCLKSJQSA-N 0.000 description 1
- FQPFRLRXIJWSEK-YLJYHZDGSA-N C[C@@H]1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN(C(=O)C2(C)COC2)C1 Chemical compound C[C@@H]1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN(C(=O)C2(C)COC2)C1 FQPFRLRXIJWSEK-YLJYHZDGSA-N 0.000 description 1
- YKJCJNIFIXVBBU-IFZUVJPXSA-N C[C@@H]1[C@H](C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1.C[C@H]1[C@H](C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1 Chemical compound C[C@@H]1[C@H](C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1.C[C@H]1[C@H](C(=O)O)CCCN1C(=O)OCC1=CC=CC=C1 YKJCJNIFIXVBBU-IFZUVJPXSA-N 0.000 description 1
- VTRVUNGMWPPWGP-OAHLLOKOSA-N C[C@@]1(C(=O)O)CCCN(C(=O)OCC2=CC=CC=C2)C1 Chemical compound C[C@@]1(C(=O)O)CCCN(C(=O)OCC2=CC=CC=C2)C1 VTRVUNGMWPPWGP-OAHLLOKOSA-N 0.000 description 1
- ZSYNRZMPLBXQNV-KBXCAEBGSA-N C[C@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound C[C@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)C1 ZSYNRZMPLBXQNV-KBXCAEBGSA-N 0.000 description 1
- QUYDSIXJBFBWNR-SUMWQHHRSA-N C[C@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound C[C@H](O)C(=O)N1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 QUYDSIXJBFBWNR-SUMWQHHRSA-N 0.000 description 1
- UUCBRZWIYUWJBE-FXAWDEMLSA-N C[C@H](O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound C[C@H](O)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 UUCBRZWIYUWJBE-FXAWDEMLSA-N 0.000 description 1
- WFAURZNSPGKTIO-UWJYYQICSA-N C[C@H]1CCN(C(=O)C2(C)COC2)C[C@@H]1C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound C[C@H]1CCN(C(=O)C2(C)COC2)C[C@@H]1C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C2)=C2C(N)=NC=CN12 WFAURZNSPGKTIO-UWJYYQICSA-N 0.000 description 1
- WUXCAVPIXFTUAB-FUHWJXTLSA-N C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 WUXCAVPIXFTUAB-FUHWJXTLSA-N 0.000 description 1
- JUSWPUDQOKINJO-MAUKXSAKSA-N C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 JUSWPUDQOKINJO-MAUKXSAKSA-N 0.000 description 1
- RUUKPEUJTMVALS-FUHWJXTLSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC(Cl)=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC(Cl)=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 RUUKPEUJTMVALS-FUHWJXTLSA-N 0.000 description 1
- PJESVHWTDVSWDE-FUHWJXTLSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC(F)=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC(F)=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 PJESVHWTDVSWDE-FUHWJXTLSA-N 0.000 description 1
- CVPZVCUAIRPBTK-FZWXSHBKSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1(F)F Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CCC1(F)F CVPZVCUAIRPBTK-FZWXSHBKSA-N 0.000 description 1
- FRAPHDQDRKHANO-YADARESESA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)CN1CCOC1=O Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)CN1CCOC1=O FRAPHDQDRKHANO-YADARESESA-N 0.000 description 1
- FGPLRGROXNPJHW-HFZDXXHNSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)N1CCCCC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC(C5CC5)=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)N1CCCCC1 FGPLRGROXNPJHW-HFZDXXHNSA-N 0.000 description 1
- CINSJOUQYPQGOC-FXAWDEMLSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC(F)(F)C1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC(F)(F)C1 CINSJOUQYPQGOC-FXAWDEMLSA-N 0.000 description 1
- AVHAICXACVBUTE-LAUBAEHRSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1CC1 AVHAICXACVBUTE-LAUBAEHRSA-N 0.000 description 1
- CIRCCHUEPAXNSC-PGRDOPGGSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)CC1CC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=CC=CC=N4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)CC1CC1 CIRCCHUEPAXNSC-PGRDOPGGSA-N 0.000 description 1
- JOXWEHPRYRAPNQ-FXAWDEMLSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 JOXWEHPRYRAPNQ-FXAWDEMLSA-N 0.000 description 1
- IZQXAVNCICXCLW-SIKLNZKXSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(OC5CC5)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 IZQXAVNCICXCLW-SIKLNZKXSA-N 0.000 description 1
- HJVBQWNEEVHOKR-GHTZIAJQSA-N C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(OCC(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(OCC(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 HJVBQWNEEVHOKR-GHTZIAJQSA-N 0.000 description 1
- JOXWEHPRYRAPNQ-PXNSSMCTSA-N C[C@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CC[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN1C(=O)C1(C)COC1 JOXWEHPRYRAPNQ-PXNSSMCTSA-N 0.000 description 1
- AIOWTBDHNQPSIB-OXJNMPFZSA-N C[C@H]1CO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)CN1C(=O)C1(C)COC1 Chemical compound C[C@H]1CO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)CN1C(=O)C1(C)COC1 AIOWTBDHNQPSIB-OXJNMPFZSA-N 0.000 description 1
- QSDILAZARCECIK-MGPUTAFESA-N C[C@H]1CO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)CN1C(=O)C1CC1 Chemical compound C[C@H]1CO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3/C(N)=N\C=C/N23)CN1C(=O)C1CC1 QSDILAZARCECIK-MGPUTAFESA-N 0.000 description 1
- SOYXQVSBDHHRLV-WCQYABFASA-N C[C@H]1C[C@@H](C(=O)O)CN(C(=O)OCC2=CC=CC=C2)C1 Chemical compound C[C@H]1C[C@@H](C(=O)O)CN(C(=O)OCC2=CC=CC=C2)C1 SOYXQVSBDHHRLV-WCQYABFASA-N 0.000 description 1
- FQPFRLRXIJWSEK-FXAWDEMLSA-N C[C@H]1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN(C(=O)C2(C)COC2)C1 Chemical compound C[C@H]1C[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CN(C(=O)C2(C)COC2)C1 FQPFRLRXIJWSEK-FXAWDEMLSA-N 0.000 description 1
- WTKAFKUTHUGWNG-LAUBAEHRSA-N C[C@H]1[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CCCN1C(=O)C1(C)COC1 Chemical compound C[C@H]1[C@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)CCCN1C(=O)C1(C)COC1 WTKAFKUTHUGWNG-LAUBAEHRSA-N 0.000 description 1
- PVEUHYXRYHGEFX-XDLSHKQYSA-N Cl.NC1=NN2C(=CN=C2[C@@H]2CCCN(C(=O)OCC3=CC=CC=C3)C2)C(=O)N1.NC1=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C2C(=O)N1.NC1=NN=C(CNC(=O)[C@@H]2CCCN(C(=O)OCC3=CC=CC=C3)C2)C(=O)N1.NCC1=NN=C(N)NC1=O.O=C(O)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(ON1C(=O)CCC1=O)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C1NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C12 Chemical compound Cl.NC1=NN2C(=CN=C2[C@@H]2CCCN(C(=O)OCC3=CC=CC=C3)C2)C(=O)N1.NC1=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C2C(=O)N1.NC1=NN=C(CNC(=O)[C@@H]2CCCN(C(=O)OCC3=CC=CC=C3)C2)C(=O)N1.NCC1=NN=C(N)NC1=O.O=C(O)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(ON1C(=O)CCC1=O)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C1NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C12 PVEUHYXRYHGEFX-XDLSHKQYSA-N 0.000 description 1
- DGHDLEHLKDCGPL-UHFFFAOYSA-N ClC1=CN=C(Cl)C2=C(I)N=C(C3CCOCC3)N12.ClC1=CN=C(Cl)C2=CN=C(C3CCOCC3)N12.ClC1=NC=CN2C1=CN=C2C1CCOCC1.NC1=NC=C(Cl)N2C(C3CCOCC3)=NC(I)=C12 Chemical compound ClC1=CN=C(Cl)C2=C(I)N=C(C3CCOCC3)N12.ClC1=CN=C(Cl)C2=CN=C(C3CCOCC3)N12.ClC1=NC=CN2C1=CN=C2C1CCOCC1.NC1=NC=C(Cl)N2C(C3CCOCC3)=NC(I)=C12 DGHDLEHLKDCGPL-UHFFFAOYSA-N 0.000 description 1
- MVWLKFTYIOWIIN-UHFFFAOYSA-N ClC1=NC=CN2C(N3CCC3)=NC(Br)=C12.ClC1=NC=CN2C1=CN=C2N1CCC1.NC1=NC=CN2C(N3CCC3)=NC(Br)=C12.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)N1CCC1 Chemical compound ClC1=NC=CN2C(N3CCC3)=NC(Br)=C12.ClC1=NC=CN2C1=CN=C2N1CCC1.NC1=NC=CN2C(N3CCC3)=NC(Br)=C12.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)N1CCC1 MVWLKFTYIOWIIN-UHFFFAOYSA-N 0.000 description 1
- JPFIRBLMVXFWFC-LJQANCHMSA-N N#CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 Chemical compound N#CC1(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1 JPFIRBLMVXFWFC-LJQANCHMSA-N 0.000 description 1
- RTKKNJCRRDGOPS-UHFFFAOYSA-N N#CC1(C(=O)N2CCSC(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1.O.O Chemical compound N#CC1(C(=O)N2CCSC(C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C(F)(F)F)=C5)C=C4)=C4C(N)=NC=CN34)C2)CC1.O.O RTKKNJCRRDGOPS-UHFFFAOYSA-N 0.000 description 1
- WUIQLHSYAMFPSM-UHFFFAOYSA-N N#CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCC5=C(C4)C(C4CC4)=NN5)=N3)C=C2)=NC=C1 Chemical compound N#CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCC5=C(C4)C(C4CC4)=NN5)=N3)C=C2)=NC=C1 WUIQLHSYAMFPSM-UHFFFAOYSA-N 0.000 description 1
- ONBQONDXZPPVNZ-OAQYLSRUSA-N N#CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5CC5)C4)=N3)C=C2)=NC=C1 Chemical compound N#CC1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@@H]4CCCN(C(=O)C5CC5)C4)=N3)C=C2)=NC=C1 ONBQONDXZPPVNZ-OAQYLSRUSA-N 0.000 description 1
- RTCDBOCHVVFLPS-RUZDIDTESA-N N#CC1=CC=C(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 Chemical compound N#CC1=CC=C(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)C=N1 RTCDBOCHVVFLPS-RUZDIDTESA-N 0.000 description 1
- FVMBTZROIBNVBG-UHFFFAOYSA-N N#CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=C1 Chemical compound N#CC1=CC=NC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(N4CCC4)=N3)C=C2)=C1 FVMBTZROIBNVBG-UHFFFAOYSA-N 0.000 description 1
- XGKKXGADCCMWBJ-XMMPIXPASA-N N#CC1=CSC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)=C1 Chemical compound N#CC1=CSC(C(=O)N2CCC[C@@H](C3=NC(C4=CC=C(C(=O)NC5=NC=CC(C6CC6)=C5)C=C4)=C4C(N)=NC=CN34)C2)=C1 XGKKXGADCCMWBJ-XMMPIXPASA-N 0.000 description 1
- ORTTYVUGTKRDJE-LJQANCHMSA-N N#CCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound N#CCCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 ORTTYVUGTKRDJE-LJQANCHMSA-N 0.000 description 1
- ULWXHDGRRSDUHD-QGZVFWFLSA-N N#CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 Chemical compound N#CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=C(Cl)N23)C1 ULWXHDGRRSDUHD-QGZVFWFLSA-N 0.000 description 1
- WROOBIBBKLUVKZ-GOSISDBHSA-N N#CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound N#CCN1CCO[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C3C(N)=NC=CN23)C1 WROOBIBBKLUVKZ-GOSISDBHSA-N 0.000 description 1
- CFOBXVGGKDOJHD-YMXDCFFPSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)C[C@@H]4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)C[C@@H]4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 CFOBXVGGKDOJHD-YMXDCFFPSA-N 0.000 description 1
- CFOBXVGGKDOJHD-ITUIMRKVSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)C[C@H]4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)C[C@H]4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 CFOBXVGGKDOJHD-ITUIMRKVSA-N 0.000 description 1
- GRDJRFCTCKDRGN-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCCC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCCC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 GRDJRFCTCKDRGN-UHFFFAOYSA-N 0.000 description 1
- KESAAMATNJDOJS-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 KESAAMATNJDOJS-UHFFFAOYSA-N 0.000 description 1
- QLPWITUJXGKHHP-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCOCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCOCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 QLPWITUJXGKHHP-UHFFFAOYSA-N 0.000 description 1
- NVEHODLHRLCOGC-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCOCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)N4CCOCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 NVEHODLHRLCOGC-UHFFFAOYSA-N 0.000 description 1
- HCCNMSRPCDWEBO-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NC4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NC4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 HCCNMSRPCDWEBO-UHFFFAOYSA-N 0.000 description 1
- IAPMDABQNNPCIW-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 IAPMDABQNNPCIW-UHFFFAOYSA-N 0.000 description 1
- XQOFVVNRQYKSKS-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 XQOFVVNRQYKSKS-UHFFFAOYSA-N 0.000 description 1
- SJXPRRAUVWWPSD-UHFFFAOYSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NCC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 SJXPRRAUVWWPSD-UHFFFAOYSA-N 0.000 description 1
- SXZKQLQYOZWLFT-IAXKEJLGSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NC[C@@H]4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NC[C@@H]4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 SXZKQLQYOZWLFT-IAXKEJLGSA-N 0.000 description 1
- XZAZTXYIANEELN-KEKNWZKVSA-N N/C1=N/C=C\N2C(N3CCCC(C(=O)NC[C@@H]4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C(N3CCCC(C(=O)NC[C@@H]4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 XZAZTXYIANEELN-KEKNWZKVSA-N 0.000 description 1
- FJABPRWLMFJGMH-LJQANCHMSA-N N/C1=N/C=C\N2C([C@H]3CN(C(=O)C4CC4)CCO3)=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound N/C1=N/C=C\N2C([C@H]3CN(C(=O)C4CC4)CCO3)=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 FJABPRWLMFJGMH-LJQANCHMSA-N 0.000 description 1
- PZPMJENCABNZQB-GOSISDBHSA-N NC1=C2C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@@H]3CCCN(C(=O)C(Cl)(Cl)Cl)C3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@@H]3CCCN(C(=O)C(Cl)(Cl)Cl)C3)C2=NC=N1 PZPMJENCABNZQB-GOSISDBHSA-N 0.000 description 1
- LWICARBWASYOSD-GOSISDBHSA-N NC1=C2C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@@H]3CCCN(C(=O)C(F)(F)F)C3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@@H]3CCCN(C(=O)C(F)(F)F)C3)C2=NC=N1 LWICARBWASYOSD-GOSISDBHSA-N 0.000 description 1
- UVHKWIWTUNHVNW-JKSUJKDBSA-N NC1=C2C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@H]3CC[C@H](C(F)(F)F)NC3)C2=NC=N1 Chemical compound NC1=C2C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=NN([C@H]3CC[C@H](C(F)(F)F)NC3)C2=NC=N1 UVHKWIWTUNHVNW-JKSUJKDBSA-N 0.000 description 1
- YAQFJLSWFSUMIF-NTEUORMPSA-N NC1=NC=C(/C=C/C2=CC=CC=C2)N2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=C(/C=C/C2=CC=CC=C2)N2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 YAQFJLSWFSUMIF-NTEUORMPSA-N 0.000 description 1
- UYNHCBOPZQTIPF-GOSISDBHSA-N NC1=NC=C(Br)N2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Br)N2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 UYNHCBOPZQTIPF-GOSISDBHSA-N 0.000 description 1
- VHMIVFAVDXZVOE-CYBMUJFWSA-N NC1=NC=C(C(F)(F)F)N2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound NC1=NC=C(C(F)(F)F)N2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 VHMIVFAVDXZVOE-CYBMUJFWSA-N 0.000 description 1
- YDFPBVNVSJBQCL-ZCFIWIBFSA-N NC1=NC=C(Cl)C2=C1C(Br)=NN2[C@@H]1CCCNC1 Chemical compound NC1=NC=C(Cl)C2=C1C(Br)=NN2[C@@H]1CCCNC1 YDFPBVNVSJBQCL-ZCFIWIBFSA-N 0.000 description 1
- KFHYWEPPMQWUIN-UHFFFAOYSA-N NC1=NC=C(Cl)N2C(C3CN(C(=O)C4(O)CCC4)CCO3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C(C3CN(C(=O)C4(O)CCC4)CCO3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 KFHYWEPPMQWUIN-UHFFFAOYSA-N 0.000 description 1
- AFLIOQQSISIKJR-MRXNPFEDSA-N NC1=NC=C(Cl)N2C([C@@H]3CCCN(C(=O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@@H]3CCCN(C(=O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 AFLIOQQSISIKJR-MRXNPFEDSA-N 0.000 description 1
- WGSKCDIJTLODJL-MRXNPFEDSA-N NC1=NC=C(Cl)N2C([C@@H]3CCCN(C=O)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@@H]3CCCN(C=O)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 WGSKCDIJTLODJL-MRXNPFEDSA-N 0.000 description 1
- IJYXJARRJFALNP-OAHLLOKOSA-N NC1=NC=C(Cl)N2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 IJYXJARRJFALNP-OAHLLOKOSA-N 0.000 description 1
- GICVOWQVNUJWTM-QGZVFWFLSA-N NC1=NC=C(Cl)N2C([C@H]3CN(C(=O)C4(O)CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@H]3CN(C(=O)C4(O)CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 GICVOWQVNUJWTM-QGZVFWFLSA-N 0.000 description 1
- LBEYVQFCJCEIMS-MRXNPFEDSA-N NC1=NC=C(Cl)N2C([C@H]3CN(CC(F)(F)F)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@H]3CN(CC(F)(F)F)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 LBEYVQFCJCEIMS-MRXNPFEDSA-N 0.000 description 1
- JFYNMYUQUMJLOM-QGZVFWFLSA-N NC1=NC=C(Cl)N2C([C@H]3CN(CCO)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@H]3CN(CCO)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 JFYNMYUQUMJLOM-QGZVFWFLSA-N 0.000 description 1
- AXADUSOGIZGHSI-OAHLLOKOSA-N NC1=NC=C(Cl)N2C([C@H]3CNCCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(Cl)N2C([C@H]3CNCCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 AXADUSOGIZGHSI-OAHLLOKOSA-N 0.000 description 1
- KWJPRUKEFHKNGE-GOSISDBHSA-N NC1=NC=C(F)N2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=C(F)N2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 KWJPRUKEFHKNGE-GOSISDBHSA-N 0.000 description 1
- MKRJEGVIAMYYHU-KOMQPUFPSA-N NC1=NC=CN2/C1=C(C1=CC(F)=C(C(=O)NC3=NC=CC=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2/C1=C(C1=CC(F)=C(C(=O)NC3=NC=CC=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 MKRJEGVIAMYYHU-KOMQPUFPSA-N 0.000 description 1
- BZSLNPURWCFGSK-XGAFWQRZSA-N NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC=CC(C4CC4)=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC=CC(C4CC4)=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 BZSLNPURWCFGSK-XGAFWQRZSA-N 0.000 description 1
- KIPHXMLKWLSPCH-SAABIXHNSA-N NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC=CC=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2/C1=C(C1=CC=C(C(=O)NC3=NC=CC=C3)C=C1)\N=C/2[C@H]1CC[C@H](O)CC1 KIPHXMLKWLSPCH-SAABIXHNSA-N 0.000 description 1
- GYIISBMEDBNVKB-UHFFFAOYSA-N NC1=NC=CN2C(C3CC34CCNCC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12.NC1=NC=CN2C(C3CC34CCNCC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CC34CCNCC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12.NC1=NC=CN2C(C3CC34CCNCC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 GYIISBMEDBNVKB-UHFFFAOYSA-N 0.000 description 1
- JXRGCTZPLAMBBB-UHFFFAOYSA-N NC1=NC=CN2C(C3CC4CCC3CN4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CC4CCC3CN4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 JXRGCTZPLAMBBB-UHFFFAOYSA-N 0.000 description 1
- QAQUZVKDPYZOPD-UHFFFAOYSA-N NC1=NC=CN2C(C3CC4CCC3N4C(=O)C3CCCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CC4CCC3N4C(=O)C3CCCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 QAQUZVKDPYZOPD-UHFFFAOYSA-N 0.000 description 1
- PMJXPEQGKMIZHB-UHFFFAOYSA-N NC1=NC=CN2C(C3CC4CCC3N4C(=O)OCC3=CC=CC=C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CC4CCC3N4C(=O)OCC3=CC=CC=C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 PMJXPEQGKMIZHB-UHFFFAOYSA-N 0.000 description 1
- OHLQHEYJAWLSGT-UHFFFAOYSA-N NC1=NC=CN2C(C3CCC(C(F)(F)F)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3F)=C12 Chemical compound NC1=NC=CN2C(C3CCC(C(F)(F)F)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3F)=C12 OHLQHEYJAWLSGT-UHFFFAOYSA-N 0.000 description 1
- DGGCSBQIYQEUII-UHFFFAOYSA-N NC1=NC=CN2C(C3CCC4=C(C3)C(C3CC3)=NN4)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(C3CCC4=C(C3)C(C3CC3)=NN4)=NC(Br)=C12 DGGCSBQIYQEUII-UHFFFAOYSA-N 0.000 description 1
- JXDURTNLGSPTCN-UHFFFAOYSA-N NC1=NC=CN2C(C3CCC4=C(C3)C(C3CC3)=NN4)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CCC4=C(C3)C(C3CC3)=NN4)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 JXDURTNLGSPTCN-UHFFFAOYSA-N 0.000 description 1
- ANDUAWQBNVMEEG-UHFFFAOYSA-N NC1=NC=CN2C(C3CCCC3)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(C3CCCC3)=NC(Br)=C12 ANDUAWQBNVMEEG-UHFFFAOYSA-N 0.000 description 1
- AXQUFNXXUFDTHI-UHFFFAOYSA-N NC1=NC=CN2C(C3CCCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CCCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 AXQUFNXXUFDTHI-UHFFFAOYSA-N 0.000 description 1
- QTIOIEKBRXIFLH-UHFFFAOYSA-N NC1=NC=CN2C(C3CCNCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CCNCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 QTIOIEKBRXIFLH-UHFFFAOYSA-N 0.000 description 1
- OYZQURHPTGJEGD-UHFFFAOYSA-N NC1=NC=CN2C(C3CCOC3)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(C3CCOC3)=NC(Br)=C12 OYZQURHPTGJEGD-UHFFFAOYSA-N 0.000 description 1
- HSIBTTLLIAZJOL-UHFFFAOYSA-N NC1=NC=CN2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 HSIBTTLLIAZJOL-UHFFFAOYSA-N 0.000 description 1
- VLKQJWCOIODGLA-UHFFFAOYSA-N NC1=NC=CN2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CS4)C=C3)=C12 Chemical compound NC1=NC=CN2C(C3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CS4)C=C3)=C12 VLKQJWCOIODGLA-UHFFFAOYSA-N 0.000 description 1
- RRHUZITXAXIDRF-HXUWFJFHSA-N NC1=NC=CN2C(N3CCC[C@@H](NC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(N3CCC[C@@H](NC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 RRHUZITXAXIDRF-HXUWFJFHSA-N 0.000 description 1
- LTLSLJCHBVBSQJ-CQSZACIVSA-N NC1=NC=CN2C(N3CCC[C@@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(N3CCC[C@@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 LTLSLJCHBVBSQJ-CQSZACIVSA-N 0.000 description 1
- UCRJZIFRAHGUDV-QGZVFWFLSA-N NC1=NC=CN2C(N3CCC[C@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(N3CCC[C@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 UCRJZIFRAHGUDV-QGZVFWFLSA-N 0.000 description 1
- DEZKGIGQHHJQPL-GOSISDBHSA-N NC1=NC=CN2C(N3CCC[C@H](CC(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(N3CCC[C@H](CC(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 DEZKGIGQHHJQPL-GOSISDBHSA-N 0.000 description 1
- LTLSLJCHBVBSQJ-AWEZNQCLSA-N NC1=NC=CN2C(N3CCC[C@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(N3CCC[C@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12 LTLSLJCHBVBSQJ-AWEZNQCLSA-N 0.000 description 1
- AFMFAKJOIOPAJW-UHFFFAOYSA-N NC1=NC=CN2C(N3CCOCC3)=NC(Br)=C12 Chemical compound NC1=NC=CN2C(N3CCOCC3)=NC(Br)=C12 AFMFAKJOIOPAJW-UHFFFAOYSA-N 0.000 description 1
- AQGFIHRKYGUVPX-UHFFFAOYSA-N NC1=NC=CN2C(N3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C(N3CCOCC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 AQGFIHRKYGUVPX-UHFFFAOYSA-N 0.000 description 1
- HWVXBURXNUAEHM-OAQYLSRUSA-N NC1=NC=CN2C([C@@H]3CCCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 HWVXBURXNUAEHM-OAQYLSRUSA-N 0.000 description 1
- RIZBNVTVOCBRML-HSZRJFAPSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C(=O)C4=CC=CO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C(=O)C4=CC=CO4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 RIZBNVTVOCBRML-HSZRJFAPSA-N 0.000 description 1
- OIKSOCWFZVIDCD-MRXNPFEDSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 OIKSOCWFZVIDCD-MRXNPFEDSA-N 0.000 description 1
- HITLUFKWUVDKAM-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 HITLUFKWUVDKAM-GOSISDBHSA-N 0.000 description 1
- JNJKCJGGKISVOM-LJQANCHMSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 JNJKCJGGKISVOM-LJQANCHMSA-N 0.000 description 1
- ZIUKSKPVXCWRBR-LJQANCHMSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CCC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4(O)CCC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 ZIUKSKPVXCWRBR-LJQANCHMSA-N 0.000 description 1
- UTDSJVUHNKDSIM-QGDQTTSCSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C45CC(C4)C5)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C45CC(C4)C5)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 UTDSJVUHNKDSIM-QGDQTTSCSA-N 0.000 description 1
- YNASLPGHYMJXRG-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=CSN=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=CSN=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 YNASLPGHYMJXRG-GOSISDBHSA-N 0.000 description 1
- BYDBACHGYQNBRU-LJQANCHMSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=NC=CN=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=NC=CN=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 BYDBACHGYQNBRU-LJQANCHMSA-N 0.000 description 1
- AFWPBGCGMRMFOV-QGZVFWFLSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=NSN=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4=NSN=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 AFWPBGCGMRMFOV-QGZVFWFLSA-N 0.000 description 1
- HHSHOHMHVVLFHW-JOCHJYFZSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 HHSHOHMHVVLFHW-JOCHJYFZSA-N 0.000 description 1
- MDASDNOKLRSGHZ-DUSLRRAJSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4(F)F)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4(F)F)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 MDASDNOKLRSGHZ-DUSLRRAJSA-N 0.000 description 1
- BZZHACDOSQVCSC-LJQANCHMSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 BZZHACDOSQVCSC-LJQANCHMSA-N 0.000 description 1
- LMPYLAUQJCSFCZ-HXUWFJFHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 LMPYLAUQJCSFCZ-HXUWFJFHSA-N 0.000 description 1
- IDSJWUZWWLPRJS-OOMBGRCJSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCC(N)CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCC(N)CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 IDSJWUZWWLPRJS-OOMBGRCJSA-N 0.000 description 1
- OYNNSRRYWLILFM-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 OYNNSRRYWLILFM-XMMPIXPASA-N 0.000 description 1
- NZMRYJOIMSYJTJ-VQCQRNETSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 NZMRYJOIMSYJTJ-VQCQRNETSA-N 0.000 description 1
- YUDFNJRMPVLXQD-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CN(C(=O)C5=CC=CC=C5)C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CN(C(=O)C5=CC=CC=C5)C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 YUDFNJRMPVLXQD-XMMPIXPASA-N 0.000 description 1
- KSRAMBYMCCVSFI-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CSC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)C4CSC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 KSRAMBYMCCVSFI-GOSISDBHSA-N 0.000 description 1
- SZVWMFXIPRWSEI-QGZVFWFLSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 SZVWMFXIPRWSEI-QGZVFWFLSA-N 0.000 description 1
- HNGIDAKOAWPIER-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC4CC4)C3)=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC4CC4)C3)=NC(C3=C(F)C=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 HNGIDAKOAWPIER-GOSISDBHSA-N 0.000 description 1
- JNSPPKRXKZRWAC-OAQYLSRUSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CC4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 JNSPPKRXKZRWAC-OAQYLSRUSA-N 0.000 description 1
- LPEKACHXJCLTPM-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CCC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CCC(F)(F)F)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 LPEKACHXJCLTPM-GOSISDBHSA-N 0.000 description 1
- RSQSXFRWMXXAGD-GOSISDBHSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 RSQSXFRWMXXAGD-GOSISDBHSA-N 0.000 description 1
- GDSWLWKYYIVCOH-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)N4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)N4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 GDSWLWKYYIVCOH-XMMPIXPASA-N 0.000 description 1
- CKFPAZIUFVTNNB-PQWJSQAQSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)NC45CC6CC(CC(C6)C4)C5)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)NC45CC6CC(CC(C6)C4)C5)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 CKFPAZIUFVTNNB-PQWJSQAQSA-N 0.000 description 1
- RKCNLHDTMAERQH-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)NC4=C(Cl)C=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)NC4=C(Cl)C=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 RKCNLHDTMAERQH-XMMPIXPASA-N 0.000 description 1
- PABLHZWQYKWSRO-RUZDIDTESA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)OC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)OC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 PABLHZWQYKWSRO-RUZDIDTESA-N 0.000 description 1
- KHVFFASAUMUKOL-UCBDWBPOSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12.NC1=NC=CN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12.NC1=NC=CN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 KHVFFASAUMUKOL-UCBDWBPOSA-N 0.000 description 1
- HUPSTXOOWSCBDA-BRIYGOEASA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC(Br)=C3C(Cl)=NC=CN23)C1.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC=C3C(Cl)=NC=CN32)C1 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(Br)=C12.NCC1=NC=CN=C1Cl.O=C(NCC1=NC=CN=C1Cl)[C@@H]1CCCN(C(=O)OCC2=CC=CC=C2)C1.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC(Br)=C3C(Cl)=NC=CN23)C1.O=C(OCC1=CC=CC=C1)N1CCC[C@@H](C2=NC=C3C(Cl)=NC=CN32)C1 HUPSTXOOWSCBDA-BRIYGOEASA-N 0.000 description 1
- DBGKTKAWLWVDRI-HSZRJFAPSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 DBGKTKAWLWVDRI-HSZRJFAPSA-N 0.000 description 1
- IRIKXASJUHYONF-QUCCMNQESA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@@H]4CC(F)(F)CN4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@@H]4CC(F)(F)CN4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 IRIKXASJUHYONF-QUCCMNQESA-N 0.000 description 1
- OOPYWFFMBSXMJX-FGZHOGPDSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@H](O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@H](O)CO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 OOPYWFFMBSXMJX-FGZHOGPDSA-N 0.000 description 1
- ISFPTMWNCQZGCA-IEBWSBKVSA-N NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@H]4CC(=O)N4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(C(=O)[C@H]4CC(=O)N4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 ISFPTMWNCQZGCA-IEBWSBKVSA-N 0.000 description 1
- ZBKQUOREBHOXQZ-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(CC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 ZBKQUOREBHOXQZ-XMMPIXPASA-N 0.000 description 1
- PAIPQYJTINDEOW-XMMPIXPASA-N NC1=NC=CN2C([C@@H]3CCCN(CC4=CC=CN4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CC4=CC=CN4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 PAIPQYJTINDEOW-XMMPIXPASA-N 0.000 description 1
- SQEGMOJKKVOJHQ-AREMUKBSSA-N NC1=NC=CN2C([C@@H]3CCCN(CC4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CC4CCCC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 SQEGMOJKKVOJHQ-AREMUKBSSA-N 0.000 description 1
- BEYXKZANUWBJBG-GBAXHLBXSA-N NC1=NC=CN2C([C@@H]3CCCN(CC4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CC4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C5CC5)=C4)C=C3)=C12 BEYXKZANUWBJBG-GBAXHLBXSA-N 0.000 description 1
- QKPIZQGMSSCDAS-RUZDIDTESA-N NC1=NC=CN2C([C@@H]3CCCN(CCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCN(CCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 QKPIZQGMSSCDAS-RUZDIDTESA-N 0.000 description 1
- SYKOWYYEJBBBJS-MRXNPFEDSA-N NC1=NC=CN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 SYKOWYYEJBBBJS-MRXNPFEDSA-N 0.000 description 1
- AQSNMDYUPCJNGD-DYESRHJHSA-N NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 AQSNMDYUPCJNGD-DYESRHJHSA-N 0.000 description 1
- CHQGOPNBKXJDLC-XMSQKQJNSA-N NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CCC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 CHQGOPNBKXJDLC-XMSQKQJNSA-N 0.000 description 1
- UKGREFCWHMMQJX-MMCXAJBUSA-N NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@@H](CC(=O)C4CCCO4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 UKGREFCWHMMQJX-MMCXAJBUSA-N 0.000 description 1
- LJAQEYXDWMNYKQ-SJLPKXTDSA-N NC1=NC=CN2C([C@@H]3CCC[C@@H](N)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@@H](N)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 LJAQEYXDWMNYKQ-SJLPKXTDSA-N 0.000 description 1
- AQSNMDYUPCJNGD-LAUBAEHRSA-N NC1=NC=CN2C([C@@H]3CCC[C@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@H](CC(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 AQSNMDYUPCJNGD-LAUBAEHRSA-N 0.000 description 1
- LJAQEYXDWMNYKQ-AEFFLSMTSA-N NC1=NC=CN2C([C@@H]3CCC[C@H](N)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@H](N)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 LJAQEYXDWMNYKQ-AEFFLSMTSA-N 0.000 description 1
- PFVVRGXTHDNTRW-NOZRDPDXSA-N NC1=NC=CN2C([C@@H]3CCC[C@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCC[C@H](NC(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 PFVVRGXTHDNTRW-NOZRDPDXSA-N 0.000 description 1
- VAUSARRRJQUNKG-FIWHBWSRSA-N NC1=NC=CN2C([C@@H]3CCN(C(=O)C4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCN(C(=O)C4CCOC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 VAUSARRRJQUNKG-FIWHBWSRSA-N 0.000 description 1
- AHVXOMFTHGJBFW-MRXNPFEDSA-N NC1=NC=CN2C([C@@H]3CCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 AHVXOMFTHGJBFW-MRXNPFEDSA-N 0.000 description 1
- HMNFMBLGZDPQEW-IBGZPJMESA-N NC1=NC=CN2C([C@@H]3CN(C(=O)C4CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CN(C(=O)C4CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 HMNFMBLGZDPQEW-IBGZPJMESA-N 0.000 description 1
- OZTWWLIIXKMFEY-SJORKVTESA-N NC1=NC=CN2C([C@@H]3CN[C@H](CO)CO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3CN[C@H](CO)CO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 OZTWWLIIXKMFEY-SJORKVTESA-N 0.000 description 1
- OTXDZDPXXOHQAN-QUCCMNQESA-N NC1=NC=CN2C([C@@H]3C[C@H](O)CN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@@H]3C[C@H](O)CN(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 OTXDZDPXXOHQAN-QUCCMNQESA-N 0.000 description 1
- UYIALWHPFFDCJL-LJQANCHMSA-N NC1=NC=CN2C([C@H]3CC34CCN(C(=O)CO)CC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CC34CCN(C(=O)CO)CC4)=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C12 UYIALWHPFFDCJL-LJQANCHMSA-N 0.000 description 1
- PIPVTJJSBLYWJI-REWPJTCUSA-N NC1=NC=CN2C([C@H]3CC[C@@H](CO)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CC[C@@H](CO)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)CC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 PIPVTJJSBLYWJI-REWPJTCUSA-N 0.000 description 1
- BCPPFUJXJZAKJS-AZUAARDMSA-N NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(C(=O)C4CC4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(F)=C4)C=C3)=C12 BCPPFUJXJZAKJS-AZUAARDMSA-N 0.000 description 1
- UDDIVHCVKCWBIP-PKOBYXMFSA-N NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(CCO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CC[C@H](C(F)(F)F)N(CCO)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 UDDIVHCVKCWBIP-PKOBYXMFSA-N 0.000 description 1
- KYSWEYNXIKPYBI-LJQANCHMSA-N NC1=NC=CN2C([C@H]3CN(C(=O)C4(N)CCC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CN(C(=O)C4(N)CCC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 KYSWEYNXIKPYBI-LJQANCHMSA-N 0.000 description 1
- XKCUKOZFIIGAML-QGZVFWFLSA-N NC1=NC=CN2C([C@H]3CN(C(=O)CO)CCO3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CN(C(=O)CO)CCO3)=NC(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)=C12 XKCUKOZFIIGAML-QGZVFWFLSA-N 0.000 description 1
- GXCALHHQCMVHBO-LJQANCHMSA-N NC1=NC=CN2C([C@H]3CN(C4COC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CN(C4COC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 GXCALHHQCMVHBO-LJQANCHMSA-N 0.000 description 1
- FMGACZPHSMCHFJ-HXUWFJFHSA-N NC1=NC=CN2C([C@H]3CN(CC4CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=CN2C([C@H]3CN(CC4CC4)CCO3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 FMGACZPHSMCHFJ-HXUWFJFHSA-N 0.000 description 1
- NQYDMXWCFMQLEE-IYARVYRRSA-N NC1=NC=CN2C1=C(C1=C3C=CC=CC3=C(C(=O)NC3=NC=CC=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2C1=C(C1=C3C=CC=CC3=C(C(=O)NC3=NC=CC=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 NQYDMXWCFMQLEE-IYARVYRRSA-N 0.000 description 1
- IDZSWDKISGYKMR-KOMQPUFPSA-N NC1=NC=CN2C1=C(C1=CC(Cl)=C(C(=O)NC3=NC=CC=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2C1=C(C1=CC(Cl)=C(C(=O)NC3=NC=CC=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 IDZSWDKISGYKMR-KOMQPUFPSA-N 0.000 description 1
- ZZXRVSDXOCEMNT-JCNLHEQBSA-N NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC4=C(COCC4)S3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC4=C(COCC4)S3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 ZZXRVSDXOCEMNT-JCNLHEQBSA-N 0.000 description 1
- MUKLLWUYFLJAOJ-SAIGFBBZSA-N NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC=CC(C4=CC=CC=C4)=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC=CC(C4=CC=CC=C4)=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 MUKLLWUYFLJAOJ-SAIGFBBZSA-N 0.000 description 1
- QNXSTOQRGRKAFZ-XYWHTSSQSA-N NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC=CC(N4CCCC4)=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 Chemical compound NC1=NC=CN2C1=C(C1=CC=C(C(=O)NC3=NC=CC(N4CCCC4)=C3)C=C1)N=C2[C@H]1CC[C@H](O)CC1 QNXSTOQRGRKAFZ-XYWHTSSQSA-N 0.000 description 1
- RUEOOHIBYIRGCY-HXUWFJFHSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCC2=C1C=NN2CCO Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCC2=C1C=NN2CCO RUEOOHIBYIRGCY-HXUWFJFHSA-N 0.000 description 1
- CZUMWIWICUZYBB-HXUWFJFHSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCC2=NN(CCO)C=C21 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCC2=NN(CCO)C=C21 CZUMWIWICUZYBB-HXUWFJFHSA-N 0.000 description 1
- OYHDQLCYUPNNEU-LJQANCHMSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CC2)C1 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CC2)C1 OYHDQLCYUPNNEU-LJQANCHMSA-N 0.000 description 1
- WUKZFVCBDVZJHM-HXUWFJFHSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CCC2)C1 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CCC2)C1 WUKZFVCBDVZJHM-HXUWFJFHSA-N 0.000 description 1
- KJYGKGFSCWUETM-FIWHBWSRSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CCCO2)C1 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@@H]1CCCN(C(=O)C2CCCO2)C1 KJYGKGFSCWUETM-FIWHBWSRSA-N 0.000 description 1
- CEPZPPWLYMJTKZ-SFHVURJKSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=C1C=NN2 Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=C1C=NN2 CEPZPPWLYMJTKZ-SFHVURJKSA-N 0.000 description 1
- RUEOOHIBYIRGCY-FQEVSTJZSA-N NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=C1C=NN2CCO Chemical compound NC1=NC=NC2=C1C(C1=CC=C(C(=O)NC3=NC=CC(C(F)(F)F)=C3)C=C1)=NN2[C@H]1CCCC2=C1C=NN2CCO RUEOOHIBYIRGCY-FQEVSTJZSA-N 0.000 description 1
- OVKWVFMBCQNKBO-UHFFFAOYSA-N NC1=NC=NN2C(C3CCCNC3)=CC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=NN2C(C3CCCNC3)=CC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 OVKWVFMBCQNKBO-UHFFFAOYSA-N 0.000 description 1
- DQEFLWAYAIJSME-QGZVFWFLSA-N NC1=NC=NN2C([C@@H]3CCCN(C(=O)C4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=NN2C([C@@H]3CCCN(C(=O)C4CC(F)(F)C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 DQEFLWAYAIJSME-QGZVFWFLSA-N 0.000 description 1
- NRPGGAYDLJRQIG-HBKJNALASA-N NC1=NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12.NC1=NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C12.NC1=NC=NN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12.NC1=NC=NN2C([C@@H]3CCCN(C(=O)OCC4=CC=CC=C4)C3)=NC(I)=C12.NC1=NC=NN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 NRPGGAYDLJRQIG-HBKJNALASA-N 0.000 description 1
- CNLWYKCKHUIPFT-OAHLLOKOSA-N NC1=NC=NN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 Chemical compound NC1=NC=NN2C([C@@H]3CCCNC3)=NC(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)=C12 CNLWYKCKHUIPFT-OAHLLOKOSA-N 0.000 description 1
- GOWCPJPPSYTKFN-OAQYLSRUSA-N NCCCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound NCCCCC(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 GOWCPJPPSYTKFN-OAQYLSRUSA-N 0.000 description 1
- CEPZPPWLYMJTKZ-GOSISDBHSA-N Nc1c(c(-c(cc2)ccc2C(Nc2cc(C(F)(F)F)ccn2)=O)n[n]2[C@H](CCC3)c4c3[nH]nc4)c2ncn1 Chemical compound Nc1c(c(-c(cc2)ccc2C(Nc2cc(C(F)(F)F)ccn2)=O)n[n]2[C@H](CCC3)c4c3[nH]nc4)c2ncn1 CEPZPPWLYMJTKZ-GOSISDBHSA-N 0.000 description 1
- RRHUZITXAXIDRF-FQEVSTJZSA-N Nc1ncc[n]2c(N(CCC3)C[C@H]3NC(C3CC3)=O)nc(-c(cc3)ccc3C(Nc3cc(C(F)(F)F)ccn3)=O)c12 Chemical compound Nc1ncc[n]2c(N(CCC3)C[C@H]3NC(C3CC3)=O)nc(-c(cc3)ccc3C(Nc3cc(C(F)(F)F)ccn3)=O)c12 RRHUZITXAXIDRF-FQEVSTJZSA-N 0.000 description 1
- PZXZTSSADHAKAT-VQFNDLOPSA-N Nc1ncc[n]2c1c(-c(cc1)ccc1C(Nc1cc(C(F)(F)F)ccn1)=O)nc2[C@@H]1[C@@H]2[C@H]1COC2 Chemical compound Nc1ncc[n]2c1c(-c(cc1)ccc1C(Nc1cc(C(F)(F)F)ccn1)=O)nc2[C@@H]1[C@@H]2[C@H]1COC2 PZXZTSSADHAKAT-VQFNDLOPSA-N 0.000 description 1
- PHRRMQJSEYFRMK-UHFFFAOYSA-N O=C(NC1=NC=CC=C1)C1=NC=C(B(O)O)C=C1 Chemical compound O=C(NC1=NC=CC=C1)C1=NC=C(B(O)O)C=C1 PHRRMQJSEYFRMK-UHFFFAOYSA-N 0.000 description 1
- ZCRHDDGIVRGRQG-UHFFFAOYSA-N O=C(O)C1CCC(C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1 Chemical compound O=C(O)C1CCC(C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1 ZCRHDDGIVRGRQG-UHFFFAOYSA-N 0.000 description 1
- AICPFFSPPXEEKL-UHFFFAOYSA-N O=C(O)C1CN(C(=O)OCC2=CC=CC=C2)CC(F)(F)C1 Chemical compound O=C(O)C1CN(C(=O)OCC2=CC=CC=C2)CC(F)(F)C1 AICPFFSPPXEEKL-UHFFFAOYSA-N 0.000 description 1
- OGINWCRPYOBYTO-CMFFWLDZSA-N O=C(O)[C@@H]1CC[C@H](C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@@H](C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1 Chemical compound O=C(O)[C@@H]1CC[C@H](C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@@H](C(F)(F)F)N(C(=O)OCC2=CC=CC=C2)C1 OGINWCRPYOBYTO-CMFFWLDZSA-N 0.000 description 1
- HGCPXPAUMNKCBR-CMFFWLDZSA-N O=C(O)[C@@H]1CC[C@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1 Chemical compound O=C(O)[C@@H]1CC[C@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1.O=C(O)[C@H]1CC[C@@H](C(F)F)N(C(=O)OCC2=CC=CC=C2)C1 HGCPXPAUMNKCBR-CMFFWLDZSA-N 0.000 description 1
- CBMWAKBYAHNXAQ-MPTDGOKMSA-N [2H]C([2H])([2H])C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound [2H]C([2H])([2H])C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 CBMWAKBYAHNXAQ-MPTDGOKMSA-N 0.000 description 1
- AHBFBRPGNOVEBK-QUHDWGKMSA-N [2H]C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 Chemical compound [2H]C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)C4(C)COC4)C3)N12 AHBFBRPGNOVEBK-QUHDWGKMSA-N 0.000 description 1
- BXAASMHLFNGBBY-GQWXLSTFSA-N [2H]C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)CCOC)C3)N12 Chemical compound [2H]C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=CC(C(F)(F)F)=CC=N4)C=C3)N=C([C@@H]3CCCN(C(=O)CCOC)C3)N12 BXAASMHLFNGBBY-GQWXLSTFSA-N 0.000 description 1
- POBRNRAUPAXUDU-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(B3OC(C)(C)C(C)(C)O3)C=C2)=NC=C1 POBRNRAUPAXUDU-UHFFFAOYSA-N 0.000 description 1
- MXPBIZOOBSJMCW-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCCC4)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCCC4)=N3)C=C2)=NC=C1 MXPBIZOOBSJMCW-UHFFFAOYSA-N 0.000 description 1
- ZZRVYTHWNHGRSJ-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC(C)(C)C4)=N3)C=C2)=NC=C1 ZZRVYTHWNHGRSJ-UHFFFAOYSA-N 0.000 description 1
- NRDMXNSYLYAQJJ-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC4)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOC4)=N3)C=C2)=NC=C1 NRDMXNSYLYAQJJ-UHFFFAOYSA-N 0.000 description 1
- MREAUYKXJOJZFI-UHFFFAOYSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C(C4CCOCC4)=N3)C=C2)=NC=C1 MREAUYKXJOJZFI-UHFFFAOYSA-N 0.000 description 1
- KCDQMZDRCXZGMY-MSEWRSJXSA-N [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)=NC=C1 Chemical compound [C-]#[N+]C1=CC(NC(=O)C2=CC=C(C3=C4C(N)=NC=CN4C([C@H]4CC[C@@H](OC)CC4)=N3)C=C2)=NC=C1 KCDQMZDRCXZGMY-MSEWRSJXSA-N 0.000 description 1
- PDJVPNICZGWNGS-GOSISDBHSA-N [H]C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 Chemical compound [H]C(=O)N1CCC[C@@H](C2=NC(C3=CC=C(C(=O)NC4=NC=CC=C4)C=C3)=C3C(N)=NC=CN23)C1 PDJVPNICZGWNGS-GOSISDBHSA-N 0.000 description 1
- IYPMLDGLHWXCOW-UHFFFAOYSA-N [H]C(O)(CC(C)C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 Chemical compound [H]C(O)(CC(C)C)C1=CN=C(N)C2=C(C3=CC=C(C(=O)NC4=NC=CC(C(F)(F)F)=C4)C=C3)N=C(C)N12 IYPMLDGLHWXCOW-UHFFFAOYSA-N 0.000 description 1
- XMLZDZKHIYBKRA-UHFFFAOYSA-N [H]C1(C2=NC(Br)=C3C(N)=NC=CN23)CCOC1.[H]C1(C2=NC(Br)=C3C(N)=NC=CN23)CCOC1 Chemical compound [H]C1(C2=NC(Br)=C3C(N)=NC=CN23)CCOC1.[H]C1(C2=NC(Br)=C3C(N)=NC=CN23)CCOC1 XMLZDZKHIYBKRA-UHFFFAOYSA-N 0.000 description 1
- NNCQDWJDCRVHEC-DWCPNZBPSA-N [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC4=C(CC(C)CC4)S3)C=C2)=C2C(N)=NC=CN12 Chemical compound [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC4=C(CC(C)CC4)S3)C=C2)=C2C(N)=NC=CN12 NNCQDWJDCRVHEC-DWCPNZBPSA-N 0.000 description 1
- PSMXQXJMRKIQKS-DZFIZOCASA-N [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C)=C3)C=C2)=C2C(N)=NC=CN12 Chemical compound [H][C@@]12COC[C@]1([H])[C@H]2C1=NC(C2=CC=C(C(=O)NC3=NC=CC(C)=C3)C=C2)=C2C(N)=NC=CN12 PSMXQXJMRKIQKS-DZFIZOCASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to 6-5 membered fused pyridine ring compounds, to pharmaceutical compositions comprising these compounds and to their use in therapy.
- the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
- Btk Bruton's Tyrosine Kinase
- B lymphocyte activation is key in the generation of adaptive immune responses. Derailed B lymphocyte activation is a hallmark of many autoimmune diseases and modulation of this immune response is therefore of therapeutic interest. Recently the success of B cell therapies in autoimmune diseases has been established. Treatment of rheumatoid arthritis (RA) patients with Rituximab (anti-CD20 therapy) is an accepted clinical therapy by now. More recent clinical trial studies show that treatment with Rituximab also ameliorates disease symptoms in relapsing remitting multiple sclerosis (RRMS) and systemic lupus erythematosus (SLE) patients. This success supports the potential for future therapies in autoimmune diseases targeting B cell immunity.
- RRMS multiple sclerosis
- SLE systemic lupus erythematosus
- Btk Bruton tyrosine kinase
- Btk in the regulation of the production of auto-antibodies in autoimmune diseases.
- regulation of Btk may affect BCR-induced production of pro-inflammatory cytokines and chemokines by B cells, indicating a broad potential for Btk in the treatment of autoimmune diseases.
- Btk inhibitors may also show potential in the treatment of allergic responses [Gilfillan et al, Immunological Reviews 288 (2009) pp 149-169].
- Btk is also reported to be implicated in RANKL-induced osteoclast differentiation [Shinohara et al, Cell 132 (2008) pp 794-806] and therefore may also be of interest for the treatment of bone resorption disorders.
- B cell malignancies Other diseases with an important role for dysfunctional B cells are B cell malignancies. Indeed anti-CD20 therapy is used effectively in the clinic for the treatment of follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia [Lim et al, Haematologica, 95 (2010) pp 135-143].
- the reported role for Btk in the regulation of proliferation and apoptosis of B cells indicates there is potential for Btk inhibitors in the treatment of B cell lymphomas as well. Inhibition of Btk seems to be relevant in particular for B cell lymphomas due to chronic active BCR signaling [Davis et al, Nature, 463 (2010) pp 88-94].
- kinase inhibitors e.g. Imiclazo[1,5-f][1,2,4]triazine compounds have been described in WO2005097800 and WO2007064993; Imidazo[1,5-a]pyrazine compounds have been described in WO2005037836 and WO2001019828 as IGF-1R enzyme inhibitors.
- Btk inhibitors are not selective over Src-family kinases. With dramatic adverse effects reported for knockouts of Src-family kinases, especially for double and triple knockouts, this is seen as prohibitive for the development of Btk inhibitors that are not selective over the Src-family kinases.
- Lyn-deficient mice exhibit autoimmunity mimicking the phenotype of human lupus nephritis.
- Fyn-deficient mice also show pronounced neurological defects.
- Lyn knockout mice also show an allergic-like phenotype, indicating Lyn as a broad negative regulator of the IgE-mediated allergic response by controlling mast cell responsiveness and allergy-associated traits [Odom et al, J. Exp. Med., 199 (2004) pp 1491-1502].
- aged Lyn knock-out mice develop severe splenomegaly (myeloid expansion) and disseminated monocyte/macrophage tumors [Harder et al, Immunity, 15 (2001) pp 603-615].
- mice Female Src knockout mice are infertile due to reduced follicle development and ovulation [Roby et al, Endocrine, 26 (2005) pp 169-176].
- the double knockouts Src ⁇ / ⁇ Fyn ⁇ / ⁇ and Src ⁇ / ⁇ Yes ⁇ / ⁇ show a severe phenotype with effects on movement and breathing.
- the triple knockouts Src ⁇ / ⁇ Fyn ⁇ / ⁇ Yes ⁇ / ⁇ die at day 9.5 [Klinghoffer et al, EMBO J., 18 (1999) pp 2459-2471].
- mice die at birth, with surviving mice developing osteopetrosis, extramedullary hematopoiseis, anemia, leukopenia [Lowell et al, Blood, 87 (1996) pp 1780-1792].
- an inhibitor that inhibits multiple or all kinases of the Src-family kinases simultaneously may cause serious adverse effects.
- the present invention provides compounds which inhibit Btk activity, their use for treatment of Btk mediated diseases and disorders, in particular autoimmune diseases and inflammatory diseases, as well as pharmaceutical compositions comprising such compounds and pharmaceutical carriers.
- the object of the present invention is to provide 6-5 membered fused pyridine ring compounds, to pharmaceutical compositions comprising these compounds and to their use in therapy.
- the present invention relates to the use of 6-5 membered fused pyridine ring compounds in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.
- Btk Bruton's Tyrosine Kinase
- the present invention provides 6-5 membered fused pyridine ring compounds according to Formula I or pharmaceutically acceptable salts thereof
- the attachment point is at the last group.
- a circle in a ring of Formula I indicates that the ring is aromatic.
- the nitrogen if present in W, X, Y or Z, may carry a hydrogen.
- substituted means that one or more hydrogens on the designated atom/atoms is/are replaced with a selection from the indicated group, provided that the designated atom's normal valency under the existing circumstances is not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- Stable compound or “stable structure” is defined as a compound or structure that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
- the term pharmaceutically acceptable salt is well known in the art. They may be obtained during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable mineral acid such as hydrochloric acid, phosphoric acid, or sulfuric acid, or with an organic acid such as for example ascorbic acid, citric acid, tartaric acid, lactic acid, maleic acid, malonic acid, fumaric acid, glycolic acid, succinic acid, propionic acid, acetic acid, methanesulfonic acid, and the like.
- the acid function can be reacted with an organic or a mineral base, like sodium hydroxide, potassium hydroxide or lithium hydroxide.
- the invention relates to a compound according to Formula I wherein:
- B 1 is C(R 7 ), B 2 is C(R 8 ), B 3 is C(R 9 ), and B 4 is C(R 10 ); or
- B 1 is N
- B 2 is N
- B 3 is C(R 9 )
- B 4 is C(R 10 );
- B 1 is N
- B 2 is C(R 8 )
- B 3 is N
- B 4 is C(R 10 );
- B 1 is N
- B 2 is C(R 8 )
- B 3 is C(R 9 )
- B 4 is N;
- B 1 is C(R 7 ), B 2 is C(R 8 ), B 3 is N, and B 4 is N; or
- B 1 is C(R 7 ), B 2 is N, B 3 is C(R 9 ), and B 4 is N.
- the invention relates to a compound of Formula I wherein ring K is defined as: B 1 is C(R 7 ), B 2 is C(R 8 ), B 3 is C(R 9 ), and B 4 is C(R 10 ) and wherein R 7 , R 8 , R 9 and R 10 each are H or halogen.
- the invention relates to a compound according to Formula I wherein ring L is selected from the group consisting of pyridyl, pyrimidyl, pyridazyl, triazinyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, thiadiazolyl, and isothiazolyl.
- the invention relates to a compound according to Formula I wherein ring L is selected from the group consisting of pyridyl, pyrimidyl, and thiazolyl.
- the invention relates to a compound according to Formula I wherein R 5 is selected from the group consisting of hydrogen, fluorine, chlorine, CN, cyclopropyl, (1-3C)alkyl and (1-2C) alkoxy; the (1-3C)alkyl group of which is optionally substituted with one or more halogen.
- the invention relates to a compound according to Formula I wherein R 5 is selected from the group consisting of hydrogen, fluorine, methyl, ethyl, propyl, cyclopropyl, methoxy and trifluoromethyl.
- the invention relates to a compound according to Formula I wherein R 1 is selected from the group consisting of R 21 C(O), R 22 NHC(O), R 23 C(O)NH, R 25 SO2, (3-7C)cycloalkyl(1-4C)alkyl, (6-10C)aryl (1-4C)alkyl, (1-6C)alkyl, (1-5C)heteroaryl(1-4C)alkyl, halo(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-4C)alkoxy(1-6C)alkyl, and (1-6C)alkoxyl.
- R 1 is selected from the group consisting of R 21 C(O), R 22 NHC(O), R 23 C(O)NH, R 25 SO2, (3-7C)cycloalkyl(1-4C)alkyl, (6-10C)aryl (1-4C)alkyl, (1-6C)alkyl, (1-5C)heteroaryl(1-4C)alkyl, halo(1-6C)alkyl
- the invention relates to a compound according to Formula I wherein R 1 is selected from the group consisting of R 21 C(O), R 22 NHC(O), R 23 C(O)NH, (6-10C)aryl(1-4C)alkyl, (1-5C)heteroaryl(1-4C)alkyl, halo(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-4C)alkoxy(1-6C)alkyl, and (1-6C)alkoxyl.
- R 1 is selected from the group consisting of R 21 C(O), R 22 NHC(O), R 23 C(O)NH, (6-10C)aryl(1-4C)alkyl, (1-5C)heteroaryl(1-4C)alkyl, halo(1-6C)alkyl, hydroxy(1-6C)alkyl, (1-4C)alkoxy(1-6C)alkyl, and (1-6C)alkoxyl.
- the preferred (6-10C)aryl(1-4C)alkyl is phenyl-methylene and the preferred (1-5C)heteroaryl(1-4C)alkyl is pyrazol-methylene.
- the invention relates to a compound according to Formula I wherein R 1 is selected from the group consisting of R 21 C(O), R 22 NHC(O), and R 23 C(O)NH.
- T is O, S or CH2;
- a 6 is C or N
- Z is 0, 1 or 2.
- R 21 is selected from the group consisting of di[hydroxy](1-6C)alkyl, di[(1-6C)alkyl]amino(1-6C)alkyl, amino(3-7C)cycloalkyl, (6-10C)aryloxy, (6-10C)arylcarbonyl(2-5C)heterocycloalkyl, (3-7C)cycloalkylcarbonyl(1-5C)heterocycloalkyl, (3-7C)cycloalkyl, (3-6C)cycloalkoxy, (3-10C)cycloalkylamino, (3-10C)cycloalkyl, (1-6C)alkylsulfonyl(2-5C)heterocycloalkyl, (1-6C)alkylcarbonyl(2-5C)heterocycloalkyl, (1-6C)alkylamino, (1-6C)alkoxy, (1-5C)heteroarylcarbonyl, (1
- R 21 is selected from the group consisting of (3-7C)cycloalkylcarbonyl(1-5C)heterocycloalkyl, (3-7C)cycloalkyl, (3-6C)cycloalkoxy, (3-10C)cycloalkylamino, (3-10C)cycloalkyl, (1-6C)alkylsulfonyl(2-5C)heterocycloalkyl, (1-6C)alkylcarbonyl(2-5C)heterocycloalkyl, (1-6C)alkylamino, (1-6C)alkoxy, (1-5C)heteroarylcarbonyl, (1-5C)heteroaryl(1-4C)alkyl, (1-5C)heterocycloalkyl, (1-4C)thioalkyl(1-6C)alkyl, di[(1-4C)alkyl]aminocarbonyl, (1-4C)alkoxy[(2-4C)alkoxy] m (1-6C)alkyl, (
- R 21 is selected from the group consisting of (3-7C)cycloalkyl, (3-6C)cycloalkoxy, (1-6C)alkylsulfonyl(2-5C)heterocycloalkyl, (1-4C)thioalkyl(1-6C)alkyl, (1-4C)alkylsulfonyl(1-6C)alkyl, (1-4C)alkoxy(1-6C)alkyl, (3-7C)cycloalkoxy, (1-6C)alkyl, and (1-5C)heteroaryl.
- R 21 may optionally be substituted with R 211 .
- R 21 may optionally be substituted with R 211 and substituted R 21 is selected from the group consisting of
- the invention relates to a compound according to Formula I wherein R 22 is selected from the group consisting of (3-7C)cycloalkyl(1-4C)alkyl, (3-7C)cycloalkyl, (3-7C)cycloalkoxy(1-4C)alkyl, (3-6C)cycloalkoxy, (1-6C)alkyl, (1-6C)alkoxy, (1-4C)thioalkyl(1-6C)alkyl, (1-4C)alkylsulfonyl(1-6C)alkyl, and (1-4C)alkoxy(1-6C)alkyl.
- R 22 may optionally be substituted with R 221 .
- R 22 is selected from the group consisting of (3-7C)cycloalkyl, (3-7C)cycloalkoxy(1-4C)alkyl, (3-6C)cycloalkoxy, (1-6C)alkyl, and (1-4C)alkoxy(1-6C)alkyl.
- R 22 may optionally be substituted with R 221 .
- R 22 may optionally be substituted with R 221 and R 22 is selected from the group consisting of
- the invention in another aspect relates to a compound according to Formula I wherein R 23 is selected from the group consisting of (6-10C)aryl(1-6C)alkoxy, (3-7C)cycloalkyl, (3-7C)cycloalkoxy, (1-6C)alkylamino, (1-6C)alkyl, and (1-4C)alkoxy(1-6C)alkyl.
- R 23 may optionally be substituted with R 231 .
- R 23 is selected from the group consisting of (3-7C)cycloalkyl, (3-7C)cycloalkoxy, and (1-4C)alkoxy(1-6C)alkyl and R 23 may optionally be substituted with R 231 .
- R 23 is selected from the group consisting of
- R 23 may optionally be substituted with R 231 .
- the invention relates to a compound according to Formula I wherein R 24 is selected from the group consisting of (3-7C)cycloalkyl and (1-6C)alkyl and R 24 may optionally be substituted with R 241 .
- R 24 is selected from the group consisting of
- R 24 may optionally be substituted with R 241 .
- the invention relates to a compound according to Formula I wherein R 25 is selected from the group consisting of (3-7C)cycloalkyl and (1-6C)alkyl and R 25 may optionally be substituted with R 251 .
- R 25 is selected from the group consisting of
- R 25 may optionally be substituted with R 251 .
- the invention relates to a compound according to Formula I wherein optional substituents R 211 , R 221 , R 231 , R 241 , and R 251 are independently selected from the group consisting of: one or more halogen, CF 3 , OCF 3 , oxo, hydroxy, cyano, (1-6C)alkyl, (3-7C)cycloalkoxy, di[(1-6C)alkyl]amino, (1-4C)akoxy(1-6C)alkyl, (1-5C)heteroaryl, and (2-5C)heterocycloalkyl and R 21 , R 22 , R 23 , R 24 , and R 25 may optionally be substituted with one to four substituents R 211 , R 221 , R 231 , R 241 , and R 251 , respectively.
- optional substituents R 211 , R 221 , R 231 , R 241 , and R 251 are independently selected from the group consisting of F, hydroxyl, (1-3C)alkyl, and dimethylamino.
- the invention relates to a compound according to Formula I wherein R 11 is selected from the group consisting of H, 2 H, F, Cl, Br, Me, C 2 H 3 , ethyl, cyclopropyl and vinyl.
- R 11 is H.
- the invention relates to a compound according to Formula I wherein A 1 -A 4 are C or N and bicyclic ring system E-G is selected from the group consisting of
- the invention relates to a compound according to Formula I wherein A 1 -A 4 are C or N and bicyclic ring system E-G is
- the invention relates to a compound having Formula Ia
- the invention also relates to those compounds wherein all specific definitions for A 1 -A 6 , B 1 -B 4 , X, Y, Z, R 3 , R 4 , R 5 and R x , and all substituent groups in the various aspects of the inventions defined here above occur in any combination within the definition of the 6-5 membered fused pyridine ring compounds of Formula I or pharmaceutically acceptable salts thereof.
- the invention relates to a compound according to Formula I or a pharmaceutically acceptable salt or solvate thereof selected from the group consisting of:
- Another aspect of the invention is a compound having Formula I or a pharmaceutically acceptable salt or solvate thereof selected from the group consisting of:
- the invention relates to the compounds of Formula I or pharmaceutically acceptable salts or solvates thereof selected from the group consisting of:
- the invention relates to 4-(8-amino-3-((cis)-1-(3-methoxypropanoyl)-6-methylpiperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-cyclopropylpyridin-2-yl)benzamide.
- the invention relates to 4-(8-amino-3-((cis)-1-(cyclobutanecarbonyl)-6-methylpiperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-cyclopropylpyridin-2-yl)benzamide.
- the invention relates to (cis)-5-(8-amino-1-(4-(4-(trifluoromethyl)pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)-N-ethyl-2-methylpiperidine-1-carboxamide.
- the invention relates to (R)-4-(8-amino-3-(1-(3-methoxypropanoyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide.
- the invention relates to 4-(8-amino-3-((cis)-6-methyl-1-(tetrahydrofuran-2-carbonyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide.
- the 6-5 membered fused pyridine ring compounds of the invention having Formula I inhibit the Btk kinase activity. All compounds of the invention have an EC50 of 10 ⁇ M or lower. In another aspect the invention relates to compounds of Formula I which have an EC50 of less than 100 nM. In yet another aspect the invention relates to compounds of Formula I which have an EC50 of less than 10 nM.
- EC50 means the concentration of the test compound that is required for 50% inhibition of its maximum effect in vitro.
- the invention relates to compounds of Formula I or pharmaceutically acceptable salts thereof, which have an IC50 of less than 100 nM. In yet another aspect the invention relates to the compounds of Formula I or pharmaceutically acceptable salts thereof, which have an IC50 of less than 10 nM.
- IC50 means the concentration of the test compound that is required for 50% inhibition of its maximum effect in vitro.
- IMAP Immobilized Metal Assay for Phosphochemicals
- IMAP is a homogeneous fluorescence polarization (FP) assay based on affinity capture of phosphorylated peptide substrates.
- IMAP uses fluorescein-labeled peptide substrates that, upon phosphorylation by a protein kinase, bind to so-called IMAP nanoparticles, which are derivatized with trivalent metal complexes. Binding causes a change in the rate of the molecular motion of the peptide, and results in an increase in the FP value observed for the fluorescein label attached to the substrate peptide (Gaudet et al. A homogeneous fluorescence polarization assay adaptable for a range of protein serine/threonine and tyrosine kinases. J. Biomol. Screen (2003) 8, 164-175).
- the Btk activity can also be determined in B cell lines such as Ramos cells or in primary cell assays, e.g PBMC or whole blood from human, monkey, rat or mouse or isolated splenocytes from monkey, rat or mouse Inhibition of Btk activity can be investigated measuring anti-IgM-induced MIP1 ⁇ production (Ramos, PBMC, splenocytes), H 2 O 2 -induced Btk and PLC ⁇ 2 phosphorylation (Ramos cells), or anti-IgM-induced B cell proliferation or CD86 expression on primary B cells (PBMC and splenocytes).
- B cell lines such as Ramos cells or in primary cell assays, e.g PBMC or whole blood from human, monkey, rat or mouse or isolated splenocytes from monkey, rat or mouse
- Inhibition of Btk activity can be investigated measuring anti-IgM-induced MIP1 ⁇ production (Ramos, PBMC, splenocytes), H 2 O
- Regulation of Btk activity can also be determined on human, monkey, rat or mouse mast cells following activation Fc ⁇ R induced degranulation, cytokine production and CD63 induced cell surface expression.
- regulation of Btk activity can be determined on CD14+ monocytes differentiated following treatment with M-CSF to osteoclasts and activated with RANKL.
- mice can be euthanized 3 h following compound administration.
- Spleens can be extracted from the treated mice for splenocyte isolation.
- Splenocytes can be plated in 96 well culture plates and stimulated with anti-IgM, without further addition of compounds.
- Anti-IgM-induced B cell stimulation and inhibition thereof by Btk inhibitors can be measured by B cell proliferation, MIP1 ⁇ production or CD86 expression on CD19+ splenocyte B cells.
- Efficacy of Btk inhibitors can also be investigated in the mouse collagen induced arthritis model using a therapeutic protocol with start of treatment following onset of disease, measuring disease score, X-ray analysis of bone destruction, cartilage breakdown and histology of joints
- Efficacy of Btk inhibitors on the regulation of activated mast cells can be investigated in vivo using the passive cutaneous anaphylaxis model.
- Btk inhibitors The effect of Btk inhibitors on bone resorption in vivo can be investigated using the rat OVX model.
- ovariectomized animals develop symptoms of osteoporosis that may be regulated using a Btk inhibitor.
- the compounds of Formula I can form salts which are also within the scope of this invention.
- Reference to a compound of Formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated.
- the term “salt(s)”, as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases.
- zwitterions inner salts may be formed and are included within the term “salt(s)” as used herein.
- salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.
- Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like.
- Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl amines, and salts with amino acids such as arginine, lysine and the like.
- alkali metal salts such as sodium, lithium, and potassium salts
- alkaline earth metal salts such as calcium and magnesium salts
- salts with organic bases for example, organic amines
- organic amines such as dicyclohexylamines, t-butyl amines
- salts with amino acids such as arginine, lysine and the like.
- Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (e.g., methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (e.g., dimethyl, diethyl, and dibutyl sulfates), long chain halides (e.g., decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (e.g., benzyl and phenethyl bromides), and others.
- lower alkyl halides e.g., methyl, ethyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates e.g., dimethyl, diethyl, and dibutyl sulfates
- long chain halides e.g., decyl, lauryl, and
- the compounds of Formula I may have the ability to crystallize in more than one form, a characteristic known as polymorphism, and it is understood that such polymorphic forms (“polymorphs”) are within the scope of Formula I.
- Polymorphism generally can occur as a response to changes in temperature or pressure or both and can also result from variations in the crystallization process.
- Polymorphs can be distinguished by various physical characteristics known in the art such as x-ray diffraction patterns, solubility and melting point.
- the compounds of Formula I may contain asymmetric or chiral centers, and, therefore, exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of Formula I as well as mixtures thereof, including racemic mixtures, form part of the present invention.
- the present invention embraces all geometric and positional isomers. For example, if a compound of Formula (I) incorporates a double bond or a fused ring, both the cis- and trans-forms, as well as mixtures, are embraced within the scope of the invention.
- Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods well known to those skilled in the art, such as, for example, by chromatography and/or fractional crystallization.
- Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers and converting (e.g. hydrolyzing) the individual diastereomers to the corresponding pure enantiomers.
- an appropriate optically active compound e.g. chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
- some of the compounds of Formula I may be atropisomers (e.g. substituted biaryls) and are considered as part of this invention.
- Enantiomers can also be separated by use of chiral HPLC column.
- All stereoisomers for example, geometric isomers, optical isomers and the like
- of the present compounds including those of the salts, solvates, esters and prodrugs of the compounds as well as the salts, solvates and esters of the prodrugs, such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention, as are positional isomers.
- Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers.
- the chiral centers of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations.
- the use of the terms “salt”, “solvate”, “ester”, “prodrug” and the like, is intended to equally apply to the salt, solvate, ester and prodrug of enantiomers, stereoisomers, rotamers, tautomers, positional isomers, racemates or prodrugs of the inventive compounds.
- prodrugs means a compound (e.g, a drug precursor) that is transformed in vivo to yield a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms (e.g. by metabolic or chemical processes), such as, for example, through hydrolysis in blood.
- prodrugs is provided by T. Higuchi and W. Stella, “Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
- the compounds having Formula I or the pharmaceutically acceptable salts or solvates thereof may form hydrates or solvates. It is known to those of skill in the art that charged compounds form hydrated species when lyophilized with water, or form solvated species when concentrated in a solution with an appropriate organic solvent.
- the compounds of this invention include the hydrates or solvates of the compounds listed.
- One or more compounds of the invention having Formula I or the pharmaceutically acceptable salts or solvates thereof may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms.
- “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H 2 O.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I.
- different isotopic forms of hydrogen (H) include protium ( 1 H) and deuterium ( 2 H).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
- Certain isotopically-labelled compounds of Formula I are useful in compound and/or substrate tissue distribution assays. Tritiated (i.e., 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements) and hence may be preferred in some circumstances.
- Isotopically labelled compounds of Formula I can generally be prepared by following procedures analogous to those disclosed in the Schemes and/or in the Examples hereinbelow, by substituting an appropriate isotopically labeled reagent for a non-isotopically labeled reagent.
- the compounds having Formula I and pharmaceutical compositions thereof can be used to treat or prevent a variety of conditions or diseases mediated by Bruton's Tyrosine kinase (Btk).
- Such conditions and diseases include, but are not limited to: (1) arthritis, including rheumatoid arthritis, juvenile arthritis, psoriatic arthritis and osteoarthritis; (2) asthma and other obstructive airways diseases, including chronic asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, adult respiratory distress syndrome, recurrent airway obstruction, and chronic obstruction pulmonary disease including emphysema; (3) autoimmune diseases or disorders, including those designated as single organ or single cell-type autoimmune disorders, for example Hashimoto's thyroiditis, autoimmune hemolytic anemia, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune orchitis, Goodpasture's disease,
- B-ALL marginal zone B cell lymphoma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt lymphoma, mediastinal large B-cell lymphoma), Hodgkin lymphoma, NK and T cell lymphomas
- TEL-Syk and ITK-Syk fusion driven tumors myelomas including multiple myeloma, myeloproliferative disorders kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma including oral and metastatic melanoma, Kaposi's sarcoma, proliferative diabetic retinopathy, and angiogenic-associated disorders including solid tumors, and pancreatic cancer
- diabetes including Type I diabetes and complications from diabetes
- eye diseases, disorders or conditions including autoimmune diseases of the eye, keratoconjunctivitis, vernal conjunctivitis, uveitis including uveitis associated with Behcet's
- the invention thus provides compounds of Formula (I) and salts, solvates and physiologically functional derivatives thereof for use in therapy, and particularly in the treatment of diseases and conditions mediated by inappropriate Btk activity.
- the inappropriate Btk activity referred to herein is any Btk activity that deviates from the normal Btk activity expected in a particular mammalian subject.
- Inappropriate Btk activity may take the form of, for instance, an abnormal increase in activity, or an aberration in the timing and or control of Btk activity.
- Such inappropriate activity may result then, for example, from overexpression or mutation of the protein kinase leading to inappropriate or uncontrolled activation.
- the present invention is directed to methods of regulating, modulating, or inhibiting Btk for the prevention and/or treatment of disorders related to unregulated or inappropriate Btk activity.
- the present invention provides a method of treatment of a mammal suffering from a disorder mediated by Btk activity, which comprises administering to said mammal an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, solvate, or a physiologically functional derivative thereof.
- the present invention provides for the use of a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, in the preparation of a medicament for the treatment of a disorder mediated by Btk activity.
- said disorder mediated by Btk activity is asthma.
- said disorder is rheumatoid arthritis.
- said disorder is cancer.
- said disorder is ocular conjunctivitis.
- Yet another aspect of the present invention provides a method for treating diseases caused by or associated with Fc receptor signaling cascades, including FceRI and/or FcgRI-mediated degranulation as a therapeutic approach towards the treatment or prevention of diseases characterized by, caused by and/or associated with the release or synthesis of chemical mediators of such Fc receptor signaling cascades or degranulation.
- Fc receptor signaling cascades including FceRI and/or FcgRI-mediated degranulation
- Btk is known to play a critical role in immunotyrosine-based activation motif (ITAM) signaling, B cell receptor signaling, T cell receptor signaling and is an essential component of integrin beta (1), beta (2), and beta (3) signaling in neutrophils.
- ITAM immunotyrosine-based activation motif
- compounds of the present invention can be used to regulate Fc receptor, ITAM, B cell receptor and integrin signaling cascades, as well as the cellular responses elicited through these signaling cascades.
- cellular responses include respiratory burst, cellular adhesion, cellular degranulation, cell spreading, cell migration, phagocytosis, calcium ion flux, platelet aggregation and cell maturation.
- a further aspect of the invention resides in the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to be used for the treatment of Btk-mediated diseases or Btk-mediated conditions.
- a further aspect of the invention resides in the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to be used for the treatment of chronic B cell disorders in which T cells play a prominent role.
- the invention resides in the use of a compound of Formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament to be used for the treatment of Btk-mediated diseases or conditions.
- diseases or conditions include, but are not limited to, the treatment of B cell lymphomas resulting from chronic active B cell receptor signaling.
- the compounds according to the invention may be used in therapies to treat or prevent diseases Bruton's Tyrosine Kinase (Btk) mediated disorders.
- Btk mediated disorders or Btk mediated condition as used herein mean any disease state or other deleterious condition in which B cells, mast cells, myeloid cells or osteoclasts play a central role.
- diseases include but are not limited to, immune, autoimmune and inflammatory diseases, allergies, infectious diseases, bone resorption disorders and proliferative diseases.
- Immune, autoimmune and inflammatory diseases that may be treated or prevented with the compounds of the present invention include rheumatic diseases (e.g. rheumatoid arthritis, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deforming arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis), glomerulonephritis (with or without nephrotic syndrome), Goodpasture's syndrome, (and associated glomerulonephritis and pulmonary hemorrhage), atherosclerosis, autoimmune hematologic disorders (e.g.
- hemolytic anemia aplasic anemia, idiopathic thrombocytopenia, chronic idiopathic thrombocytopenic purpura (ITP), and neutropenia
- autoimmune gastritis e.g.
- ulcerative colitis and Crohn's disease irritable bowel syndrome
- host versus graft disease allograft rejection, chronic thyroiditis
- Graves' disease Sjorgren's disease, scleroderma, diabetes (type I and type II), active hepatitis (acute and chronic), pancreatitis, primary billiary cirrhosis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosis, psoriasis, atopic dermatitis, dermatomyositis, contact dermatitis, eczema, skin sunburns, vasculitis (e.g.
- Behcet's disease ANCA-associated and other vasculitudes, chronic renal insufficiency, Stevens-Johnson syndrome, inflammatory pain, idiopathic sprue, cachexia, sarcoidosis, Guillain-Barré syndrome, uveitis, conjunctivitis, kerato conjunctivitis, otitis media, periodontal disease, Addison's disease, Parkinson's disease, Alzheimer's disease, diabetes, septic shock, myasthenia gravis, pulmonary interstitial fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, chronic inflammatory pulmonary disease (e.g. chronic obstructive pulmonary disease) and other inflammatory or obstructive disease on airways.
- chronic inflammatory pulmonary disease e.g. chronic
- Allergies that may be treated or prevented include, among others, allergies to foods, food additives, insect poisons, dust mites, pollen, animal materials and contact allergans, type I hypersensitivity allergic asthma, allergic rhinitis, allergic conjunctivitis.
- Infectious diseases that may be treated or prevented include, among others, sepsis, septic shock, endotoxic shock, sepsis by Gram-negative bacteria, shigellosis, meningitis, cerebral malaria, pneumonia, tuberculosis, viral myocarditis, viral hepatitis (hepatitis A, hepatitis B and hepatitis C), HIV infection, retinitis caused by cytomegalovirus, influenza, herpes, treatment of infections associated with severe burns, myalgias caused by infections, cachexia secondary to infections, and veterinary viral infections such as lentivirus, caprine arthritic virus, visna-maedi virus, feline immunodeficiency virus, bovine immunodeficiency virus or canine immunodeficiency virus.
- Bone resorption disorders that may be treated or prevented include, among others, osteoporosis, osteoarthritis, traumatic arthritis, gouty arthritis and bone disorders related with multiple myeloma.
- Proliferative diseases that may be treated or prevented include, among others, non-Hodgkin lymphoma (in particular the subtypes diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)), B cell chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL) with mature B cell, ALL in particular.
- non-Hodgkin lymphoma in particular the subtypes diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL)
- B cell chronic lymphocytic leukemia and acute lymphoblastic leukemia (ALL) with mature B cell, ALL in particular.
- ALL acute lymphoblastic leukemia
- the compounds of Formula I or pharmaceutically acceptable salts may be used for the treatment of B cell lymphomas resulting from chronic active B cell receptor signaling.
- compositions in which at least one compound of Formula I or a pharmaceutically acceptable salt thereof is administered in combination with at least one other active agent.
- the other active agent is an anti-inflammatory agent, an immunosuppressant agent, or a chemotherapeutic agent.
- Anti-inflammatory agents include but are not limited to NSAIDs, non-specific and COX-2 specific cyclooxygenase enzyme inhibitors, gold compounds, corticosteroids, methotrexate, tumor necrosis factor receptor (TNF) receptors antagonists, immunosuppressants and methotrexate.
- NSAIDs include, but are not limited to, ibuprofen, flurbiprofen, naproxen and naproxen sodium, diclofenac, combinations of diclofenac sodium and misoprostol, sulindac, oxaprozin, diflunisal, piroxicam, indomethacin, etodolac, fenoprofen calcium, ketoprofen, sodium nabumetone, sulfasalazine, tolmetin sodium, and hydroxychloroquine.
- NSAIDs also include COX-2 specific inhibitors such as celecoxib, valdecoxib, lumiracoxib and/or etoricoxib.
- the anti-inflammatory agent is a salicylate.
- Salicylates include by are not limited to acetylsalicylic acid or aspirin, sodium salicylate, and choline and magnesium salicylates.
- the anti-inflammatory agent may also be a corticosteroid.
- the corticosteroid may be cortisone, dexamethasone, methylprednisolone, prednisolone, prednisolone sodium phosphate, or prednisone.
- the anti-inflammatory agent is a gold compound such as gold sodium thiomalate or auranofin.
- the invention also includes embodiments in which the anti-inflammatory agent is a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
- a metabolic inhibitor such as a dihydrofolate reductase inhibitor, such as methotrexate or a dihydroorotate dehydrogenase inhibitor, such as leflunomide.
- At least one anti-inflammatory agent is an anti-C5 monoclonal antibody (such as eculizumab or pexelizumab), a TNF antagonist, such as entanercept, or infliximab, which is an anti-TNF alpha monoclonal antibody.
- an anti-C5 monoclonal antibody such as eculizumab or pexelizumab
- TNF antagonist such as entanercept, or infliximab
- Still other embodiments of the invention pertain to combinations in which at least one active agent is an immunosuppressant agent, such as an immunosuppressant compound chosen from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.
- an immunosuppressant agent such as an immunosuppressant compound chosen from methotrexate, leflunomide, cyclosporine, tacrolimus, azathioprine, and mycophenolate mofetil.
- B-cells and B-cell precursors expressing BTK have been implicated in the pathology of B-cell malignancies, including, but not limited to, B-cell lymphoma, lymphoma (including Hodgkin's and non-Hodgkin's lymphoma), hairy cell lymphoma, multiple myeloma, chronic and acute myelogenous leukemia and chronic and acute lymphocytic leukemia.
- BTK has been shown to be an inhibitor of the Fas/APO-1 (CD-95) death inducing signaling complex (DISC) in B-lineage lymphoid cells.
- DISC Fas/APO-1
- the fate of leukemia/lymphoma cells may reside in the balance between the opposing proapoptotic effects of caspases activated by DISC and an upstream anti-apoptotic regulatory mechanism involving BTK and/or its substrates (Vassilev et al., J. Biol. Chem. 1998, 274, 1646-1656).
- BTK inhibitors are useful as chemosensitizing agents, and, thus, are useful in combination with other chemotherapeutic agents, in particular, drugs that induce apoptosis.
- chemotherapeutic agents include topoisomerase I inhibitors (camptothecin or topotecan), topoisomerase II inhibitors (e.g. daunomycin and etoposide), alkylating agents (e.g. cyclophosphamide, melphalan and BCNU), tubulin directed agents (e.g. taxol and vinblastine), and biological agents (e.g. antibodies such as anti CD20 antibody, IDEC 8, immunotoxins, and cytokines).
- topoisomerase I inhibitors camptothecin or topotecan
- topoisomerase II inhibitors e.g. daunomycin and etoposide
- alkylating agents e.g. cyclophosphamide, melphalan and BCNU
- tubulin directed agents e
- Btk activity has also been associated with some leukemias expressing the bcr-abl fusion gene resulting from translocation of parts of chromosome 9 and 22. This abnormality is commonly observed in chronic myelogenous leukemia. Btk is constitutively phosphorylated by the bcr-abl kinase which initiates downstream survival signals which circumvents apoptosis in bcr-abl cells. (N. Feldhahn et al. J. Exp. Med. 2005 201(11):1837-1852).
- the invention further provides a pharmaceutical composition, which comprises a compound of Formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- a pharmaceutical composition which comprises a compound of Formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- the compounds of the Formula (I) and salts, solvates and physiological functional derivatives thereof are as described above.
- the carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- a process for the preparation of a pharmaceutical composition including admixing a compound of the Formula (I), or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.
- compositions of the present invention may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
- a unit may contain, for example, 5 ⁇ g to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound of the Formula (I), depending on the condition being treated, the route of administration and the age, weight and condition of the patient.
- Such unit doses may therefore be administered more than once a day.
- Preferred unit dosage compositions are those containing a daily dose or sub-dose (for administration more than once a day), as herein above recited, or an appropriate fraction thereof, of an active ingredient.
- such pharmaceutical compositions may be prepared by any of the methods well known in the pharmacy art.
- compositions of the present invention may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, topical, inhaled, nasal, ocular, sublingual, subcutaneous, local or parenteral (including intravenous and intramuscular) route, and the like, all in unit dosage forms for administration.
- Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).
- Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like.
- the present invention provides a pharmaceutical composition adapted for administration by the oral route, for treating, for example, rheumatoid arthritis.
- the present invention provides a pharmaceutical composition adapted for administration by the nasal route, for treating, for example, allergic rhinitis.
- the present invention provides a pharmaceutical composition adapted for administration by the inhaled route, for treating, for example, asthma, Chronic Obstructive Pulmonary disease (COPD) or Acute Respiratory Distress Syndrome (ARDS).
- COPD Chronic Obstructive Pulmonary disease
- ARDS Acute Respiratory Distress Syndrome
- the present invention provides a pharmaceutical composition adapted for administration by the ocular route, for treating, diseases of the eye, for example, conjunctivitis.
- the present invention provides a pharmaceutical composition adapted for administration by the parenteral (including intravenous) route, for treating, for example, cancer.
- the pharmaceutical composition of the invention may be presented in unit-dose or multi-dose containers, e.g. injection liquids in predetermined amounts, for example in sealed vials and ampoules, and may also be stored in a freeze dried (lyophilized) condition requiring only the addition of sterile liquid carrier, e.g. water, prior to use.
- sterile liquid carrier e.g. water
- the active agent may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories.
- the active agent can be applied as a fluid composition, e.g. as an injection preparation, in the form of a solution, suspension, emulsion, or as a spray, e.g. a nasal spray.
- solid dosage units For making solid dosage units, the use of conventional additives such as fillers, is colorants, polymeric binders and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. Suitable carriers with which the active agent of the invention can be administered as solid compositions include lactose, starch, cellulose derivatives and the like, or mixtures thereof, used in suitable amounts. For parenteral administration, aqueous suspensions, isotonic saline solutions and sterile injectable solutions may be used, containing pharmaceutically acceptable dispersing agents and/or wetting agents, such as propylene glycol or butylene glycol.
- compositions of the present invention which are adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.
- Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
- Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation.
- a disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
- suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
- Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets.
- a powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- a binder such as carboxymethylcellulose, an aliginate, gelatin, or polyvinyl pyrrolidone
- a solution retardant such as paraffin
- a resorption accelerator such as a quaternary salt
- an absorption agent such as bentonite, kaolin or dicalcium phosphate.
- the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen.
- the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
- the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil.
- the lubricated mixture is then compressed into tablets.
- the compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
- a clear or opaque protective coating consisting of a sealing coat of shellac, a coating of
- Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of the compound.
- Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle.
- Suspensions can be formulated by dispersing the compound in a non-toxic vehicle.
- Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.
- dosage unit compositions for oral administration can be microencapsulated.
- the formulation can also be prepared to prolong or sustain the release, for example, by coating or embedding particulate material in polymers, wax or the like.
- the compounds of Formula (I), and salts, solvates and physiological functional derivatives thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- the compounds of Formula (I) and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- the compounds may also be coupled with soluble polymers as targetable drug carriers.
- Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues.
- the compounds may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Dosage forms for inhaled administration may conveniently be formulated as aerosols or dry powders.
- the compound or salt of Formula (I) is in a particle-size-reduced form, and more preferably the size-reduced form is obtained or obtainable by micronisation.
- the preferable particle size of the size-reduced (e.g. micronised) compound or salt or solvate is defined by a D50 value of about 0.5 to about 10 microns (for example as measured using laser diffraction).
- Aerosol formulations can comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent. Aerosol formulations can be presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device or inhaler. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve (metered dose inhaler) which is intended for disposal once the contents of the container have been exhausted.
- a metering valve metered dose inhaler
- the dosage form comprises an aerosol dispenser
- it preferably contains a suitable propellant under pressure such as compressed air, carbon dioxide or an organic propellant such as a hydrofluorocarbon (HFC).
- HFC propellants include 1,1,1,2,3,3,3-heptafluoropropane and 1,1,1,2-tetrafluoroethane.
- the aerosol dosage forms can also take the form of a pump-atomiser.
- the pressurised aerosol may contain a solution or a suspension of the active compound. This may require the incorporation of additional excipients e.g. co-solvents and/or surfactants to improve the dispersion characteristics and homogeneity of suspension formulations. Solution formulations may also require the addition of co-solvents such as ethanol.
- Other excipient modifiers may also be incorporated to improve, for example, the stability and/or taste and/or fine particle mass characteristics (amount and/or profile) of the formulation.
- the pharmaceutical composition is a dry powder inhalable composition.
- a dry powder inhalable composition can comprise a powder base such as lactose, glucose, trehalose, mannitol or starch, the compound of Formula (I) or salt or solvate thereof (preferably in particle-size-reduced form, e.g. in micronised form), and optionally a performance modifier such as L-leucine or another amino acid, and/or metals salts of stearic acid such as magnesium or calcium stearate.
- the dry powder inhalable composition comprises a dry powder blend of lactose and the compound of Formula (I) or salt thereof.
- the lactose is preferably lactose hydrate e.g. lactose monohydrate and/or is preferably inhalation-grade and/or fine-grade lactose.
- the particle size of the lactose is defined by 90% or more (by weight or by volume) of the lactose particles being less than 1000 microns (micrometres) (e.g. 10-1000 microns e.g. 30-1000 microns) in diameter, and/or 50% or more of the lactose particles being less than 500 microns (e.g. 10-500 microns) in diameter. More preferably, the particle size of the lactose is defined by 90% or more of the lactose particles being less than 300 microns (e.g.
- the particle size of the lactose is defined by 90% or more of the lactose particles being less than 100-200 microns in diameter, and/or 50% or more of the lactose particles being less than 40-70 microns in diameter. It is preferable that about 3 to about 30% (e.g. about 10%) (by weight or by volume) of the particles are less than 50 microns or less than 20 microns in diameter.
- a suitable inhalation-grade lactose is E9334 lactose (10% fines) (Borculo Domo Ingredients, Hanzeplein 25, 8017 J D Zwolle, Netherlands).
- a pharmaceutical composition for inhaled administration can be incorporated into a plurality of sealed dose containers (e.g. containing the dry powder composition) mounted longitudinally in a strip or ribbon inside a suitable inhalation device.
- the container is rupturable or peel-openable on demand and the dose of e.g. the dry powder composition can be administered by inhalation via the device such as the DISKUS® device (GlaxoSmithKline).
- Dosage forms for ocular administration may be formulated as solutions or suspensions with excipients suitable for ophthalmic use.
- Dosage forms for nasal administration may conveniently be formulated as aerosols, solutions, drops, gels or dry powders.
- compositions adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of metered, dose pressurized aerosols, nebulizers or insufflators.
- the compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof may be formulated as a fluid formulation for delivery from a fluid dispenser.
- a fluid dispenser may have, for example, a dispensing nozzle or dispensing orifice through which a metered dose of the fluid formulation is dispensed upon the application of a user-applied force to a pump mechanism of the fluid dispenser.
- Such fluid dispensers are generally provided with a reservoir of multiple metered doses of the fluid formulation, the doses being dispensable upon sequential pump actuations.
- the dispensing nozzle or orifice may be configured for insertion into the nostrils of the user for spray dispensing of the fluid formulation into the nasal cavity.
- a fluid dispenser of the aforementioned type is described and illustrated in WO-A-2005/044354, the entire content of which is hereby incorporated herein by reference.
- the dispenser has a housing which houses a fluid discharge device having a compression pump mounted on a container for containing a fluid formulation.
- the housing has at least one finger-operable side lever which is movable inwardly with respect to the housing to cam the container upwardly in the housing to cause the pump to compress and pump a metered dose of the formulation out of a pump stem through a nasal nozzle of the housing.
- a particularly preferred fluid dispenser is of the general type illustrated in FIGS. 30-40 of WO-A-2005/044354.
- the invention further includes a pharmaceutical composition of a compound of Formula I or pharmaceutically acceptable salts thereof, as hereinbefore described, in combination with packaging material suitable for said composition, said packaging material including instructions for the use of the composition for the use as hereinbefore described.
- Injectable Suspension mg/ml Compound of Formula Ia 10 Methylcellulose 5.0 Tween 80 0.5 Benzyl alcohol 9.0 Benzalkonium chloride 1.0 Water for injection to a total volume of 1 ml
- Tablet mg/tablet Compound of Formula Ia 25 Microcrystalline Cellulose 415 Providone 14.0 Pregelatinized Starch 43.5 Magnesium Stearate 2.5 500
- Aerosol Per canister Compound of Formula Ia 24 mg Lecithin, NF Liquid Concentrate 1.2 mg Trichlorofluoromethane, NF 4.025 gm Dichlorodifluoromethane, NF 12.15 gm
- the compound of the present invention when administered in combination with other therapeutic agents normally administered by the inhaled, intravenous, oral or intranasal route, that the resultant pharmaceutical composition may be administered by the same routes.
- compositions may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
- a therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the animal, the precise condition requiring treatment and its severity, the particular compound having Formula I, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian.
- an effective amount of a compound of Formula (I) for the treatment of diseases or conditions associated with inappropriate Btk activity will generally be in the range of 5 ⁇ g to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 5 ⁇ g to 10 mg/kg body weight per day.
- This amount may be given in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same.
- An effective amount of a salt or solvate, thereof, may be determined as a proportion of the effective amount of the compound of Formula (I) per se.
- a dosage for humans preferably contains 0.0001-25 mg of a compound of Formula I or pharmaceutically acceptable salts thereof per kg body weight.
- the desired dose may be presented as one dose or as multiple subdoses administered at appropriate intervals throughout the day, or, in case of female recipients, as doses to be administered at appropriate daily intervals throughout the menstrual cycle.
- the dosage as well as the regimen of administration may differ between a female and a male recipient.
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula I or pharmaceutically acceptable salt thereof in admixture with pharmaceutically acceptable auxiliaries and optionally other therapeutic agents.
- the auxiliaries must be “acceptable” in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipients thereof.
- the invention further includes a pharmaceutical composition comprising at least one compound of Formula I or pharmaceutically acceptable salts thereof in combination with at least one other therapeutically active agent.
- Combination therapies according to the present invention thus comprise the administration of at least one compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, or a physiologically functional derivative thereof, and the use of at least one other pharmaceutically active agent.
- the compound(s) of Formula (I) and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately this may occur simultaneously or sequentially in any order.
- the amounts of the compound(s) of Formula (I) and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect.
- a compound of Formula I may be combined with one or more other active agents such as: (1) TNF- ⁇ inhibitors such as infliximab (Remicade®), etanercept (Enbrel®), adalimumab (Humira®), certolizumab pegol (Cimzia®), and golimumab (Simponi®); (2) non-selective COX-I/COX-2 inhibitors (such as piroxicam, diclofenac, propionic acids such as naproxen, flubiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, etodolac, azapropazone, pyrazolones such as phen
- the present invention also provides for “triple combination” therapy, comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof together with beta 2 -adrenoreceptor agonist and an anti-inflammatory corticosteroid.
- this combination is for treatment and/or prophylaxis of asthma, COPD or allergic rhinitis.
- the beta 2 -adrenoreceptor agonist and/or the anti-inflammatory corticosteroid can be as described above and/or as described in WO 03/030939 A1.
- triple a compound of Formula (I) or a pharmaceutically acceptable salt thereof in combination with the components of Advair® (salmeterol xinafoate and fluticasone propionate), Symbicort® (budesonide and formoterol fumarate), or Dulera® (mometasone furoate and formoterol).
- Advair® simeterol xinafoate and fluticasone propionate
- Symbicort® budesonide and formoterol fumarate
- Dulera® mitasone furoate and formoterol
- a compound of Formula I may be combined with one or more of an anticancer agents.
- an anticancer agents can be found in Cancer Principles and Practice of Oncology by V. T. Devita and S. Hellman (editors), 6 th edition (Feb. 15, 2001), Lippincott Williams & Wilkins Publishers. A person of ordinary skill in the art would be able to discern which combinations of agents would be useful based on the particular characteristics of the drugs and the cancer involved.
- Such anti-cancer agents include, but are not limited to, the following: (1) estrogen receptor modulator such as diethylstibestral, tamoxifen, raloxifene, idoxifene, LY353381, LY117081, toremifene, fluoxymestero, and SH646; (2) other hormonal agents including aromatase inhibitors (e.g., aminoglutethimide, tetrazole anastrozole, letrozole and exemestane), luteinizing hormone release hormone (LHRH) analogues, ketoconazole, goserelin acetate, leuprolide, megestrol acetate and mifepristone; (3) androgen receptor modulator such as finasteride and other 5 ⁇ -reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole, and abiraterone acetate; (4) retinoid receptor modulator such as be
- inhibitors of inherent multidrug resistance including inhibitors of p-glycoprotein (P-gp), such as LY335979, XR9576, OC144-093, R101922, VX853 and PSC833 (valspodar); (10) inhibitor of cell proliferation and survival signaling such as inhibitors of EGFR (for example gefitinib and erlotinib), inhibitors of ERB-2 (for example trastuzumab), inhibitors of IGF1R such as MK-0646 (dalotuzumab), inhibitors of CD20 (rituximab), inhibitors of cytokine receptors, inhibitors of MET, inhibitors of PI3K family kinase (for example LY294002), serine/threonine kinases (including but not limited to inhibitors of Akt such as described in (WO 03/086404, WO 03/086403, WO 03/086394, WO 03/08
- Cytotoxic/cytostatic agents refer to compounds which cause cell death or inhibit cell proliferation primarily by interfering directly with the cell's functioning or inhibit or interfere with cell mytosis, including alkylating agents, tumor necrosis factors, intercalators, hypoxia activatable compounds, microtubule inhibitors/microtubule-stabilizing agents, inhibitors of mitotic kinesins, inhibitors of histone deacetylase, inhibitors of kinases involved in mitotic progression, antimetabolites; biological response modifiers; hormonal/anti-hormonal therapeutic agents, haematopoietic growth factors, monoclonal antibody targeted therapeutic agents, topoisomerase inhibitors, proteasome inhibitors and ubiquitin ligase inhibitors.
- cytotoxic agents include, but are not limited to, sertenef, cachectin, chlorambucil, cyclophosphamide, ifosfamide, mechlorethamine, melphalan, uracil mustard, thiotepa, busulfan, carmustine, lomustine, streptozocin, tasonermin, lonidamine, carboplatin, altretamine, dacarbazine, procarbazine, prednimustine, dibromodulcitol, ranimustine, fotemustine, nedaplatin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosilate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, lobaplatin, satraplatin, profiromycin, cisplatin, irofulven, dexifos
- hypoxia activatable compound is tirapazamine.
- proteasome inhibitors include but are not limited to lactacystin and bortezomib.
- microtubule inhibitors/microtubule-stabilising agents include vincristine, vinblastine, vindesine, vinzolidine, vinorelbine, vindesine sulfate, 3′,4′-didehydro-4′-deoxy-8′-norvincaleukoblastine, podophyllotoxins (e.g., etoposide (VP-16) and teniposide (VM-26)), paclitaxel, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, BMS184476, vinflunine, cryptophycin, anhydrovinblastine, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258, the epothilones (see for example U.S. Pat
- topoisomerase inhibitors are topotecan, hycaptamine, irinotecan, rubitecan, 6-ethoxypropionyl-3′,4′-O-exo-benzylidene-chartreusin, lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNPI1100, BN80915, BN80942, etoposide phosphate, teniposide, sobuzoxane, 2′-dimethylamino-2′-deoxy-etoposide, GL331, N-[2-(dimethylamino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxamide, asulacrine, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]-phenanth
- inhibitors of mitotic kinesins include, but are not limited to inhibitors of KSP, inhibitors of MKLP1, inhibitors of CENP-E, inhibitors of MCAK, inhibitors of Kif14, inhibitors of Mphosph1 and inhibitors of Rab6-KIFL.
- histone deacetylase inhibitors include, but are not limited to, vorinostat, trichostatin A, oxamflatin, PXD101, MG98, valproic acid and scriptaid.
- “Inhibitors of kinases involved in mitotic progression” include, but are not limited to, inhibitors of aurora kinase, inhibitors of Polo-like kinases (PLK; in particular inhibitors of PLK-1), inhibitors of bub-1 and inhibitors of bub-R1.
- PLK Polo-like kinases
- An example of an “aurora kinase inhibitor” is VX-680.
- Antiproliferative agents includes antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231, and INX3001, and antimetabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluridine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2′-deoxy-2′-methylidenecytidine, 2′-fluoromethylene-2′-deoxycytidine, N6-[4-deoxy-4-[N2-[2,4-tetradecadienoyl]glycylamino]-L-glycero-
- Non-limiting examples of suitable agents used in cancer therapy include, but are not limited to, abarelix; aldesleukin; alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; anastrozole; arsenic trioxide; asparaginase; azacitidine; bendamustine; bevacuzimab; bexarotene; bleomycin; bortezomib; busulfan; calusterone; capecitabine; carboplatin; carmustine; cetuximab; chlorambucil; cisplatin; cladribine; clofarabine; cyclophosphamide; cytarabine; dacarbazine; dactinomycin, actinomycin D; dalteparin; darbepoetin alfa; dasatinib; daunorubicin; degarelix; den
- the other therapeutic ingredient(s) may be used in the form of salts, for example as alkali metal or amine salts or as acid addition salts, or prodrugs, or as esters, for example lower alkyl esters, or as solvates, for example hydrates, to optimise the activity and/or stability and/or physical characteristics, such as solubility, of the therapeutic ingredient. It will be clear also that, where appropriate, the therapeutic ingredients may be used in optically pure form.
- compositions comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.
- These combinations are of particular interest in respiratory diseases and are conveniently adapted for inhaled or intranasal delivery.
- the individual compounds of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical compositions.
- the individual compounds will be administered simultaneously in a combined pharmaceutical composition.
- Appropriate doses of known therapeutic agents will be readily appreciated by those skilled in the art.
- the 8-amino-imidazo[1,5-a]pyrazine, 4-amino-imidazo[1,5-f][1,2,4]triazine, 4-amino-pyrazolo[3,4-d]pyrimidine and 4-amino-pyrrolo[1,2-f][1,2,4]triazine derivatives of the present invention can be prepared by methods well known in the art of organic chemistry. See, for example, J. March, ‘ Advanced Organic Chemistry’ 4 th Edition, John Wiley and Sons. During synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This is achieved by means of conventional protecting groups, such as those described in T. W. Greene and P. G. M. Wutts ‘ Protective Groups in Organic Synthesis’ 3 rd Edition, John Wiley and Sons, 1999. The protective groups are optionally removed at a convenient subsequent stage using methods well known in the art.
- the products of the reactions are optionally isolated and purified, if desired, using conventional techniques, but not limited to, filtration, distillation, crystallization, chromatography and the like. Such materials are optionally characterized using conventional means, including physical constants and spectral data.
- Reduction of 3-chloropyrazine-2-carbonitrile (II) can be accomplished by hydrogenation in the presence of a suitable catalyst system and solvent, for example Raney-Nickel to provide (3-chloropyrazin-2-yl)methanamine (III). This can then be reacted either with an appropriately amine protected amino acid where A5 is equivalent to CH and X is equivalent to OH.
- a suitable catalyst system and solvent for example Raney-Nickel
- the reaction of HO(O)CC(R 3 ,R 4 )R x can be carried out in a solvent such as DMF, THF or DCM in the presence of a base such as DIPEA, N-methylmorpholine, 4-DMAP or triethylamine and in the presence of a coupling reagent such as PyBOP, TBTU, EDCI or HATU to form N-((3-chloropyrazin-2-yl)methyl)amide (IV).
- a coupling reagent such as PyBOP, TBTU, EDCI or HATU
- NH(R 3 ,R 4 )R x can be activated with trichloromethyl chloroformate or phosgene to introduce COX, where X is equivalent to a leaving group.
- 8-Aminoimidazo[1,5-a]pyrazine derivatives can be prepared from compounds VI using ammonia(gas) in isopropanol at elevated temperature in a pressure vessel (>4 atm).
- Compounds of Formula IX can be prepared from compounds of Formula VII using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system, for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an an organic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent system like combinations of dioxane and water.
- cleaving the protective group of compounds with the Formula IX give the unprotected amine or carboxylic acid which after functionalisation, using methods well known in the art, provided compounds of Formula I.
- the compounds like COXA 5 (R 3 ,R 4 )R x are either commercially available or they can be readily prepared using methods well known to the skilled organic chemist, to introduce protecting groups like benzyloxycarbonyl or tert-butyloxycarbonyl.
- Palladium catalysts and conditions to form either the pinacol esters or to couple the boronic acids or pinacol esters with the 1-bromoimidazo[1,5-a]pyrazin-8-amine are well known to the skilled organic chemist—see, for example, Ei-ichi Negishi (Editor), Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, 2002.
- Starting material 3-amino-6-(aminomethyl)-1,2,4-triazin-5(4H)-one (X) can be prepared via a condensation reaction of ethyl bromopyruvate, dibenzylamine, and aminoguanidine carbonate, followed by debenzylation via hydrogenation over Pd—C catalyst [Mitchel, W. L. et al, J. Heterocycl. Chem. 21, (1984), pp 697].
- the amine can be reacted with an appropriately amine protected amino acid using an activating agent.
- R x (R 3 ,R 4 )A 5 C(O)OH can be carried out in a solvent such as water, THF, DMF or MeCN or combinations of these solvents in the presence of a base such as DIPEA, sodium hydrogen carbonate, N-methylmorpholine, 4-DMAP or triethylamine to form N-((3-amino-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)methyl)amide (XI).
- a base such as DIPEA, sodium hydrogen carbonate, N-methylmorpholine, 4-DMAP or triethylamine to form N-((3-amino-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)methyl)amide (XI).
- Cyclisation of the amino-triazinone (XI) can be performed using condensation reagents like phosphorousoxychloride under heating conditions to provide the 2-amino-imidazo[1,5-f][1,2,4]triazin-4(3H)-one derivatives XII. Subsequent iodination can be accomplished using iodine or N-iodosuccinimide in a suitable solvent like DCM or DMF at appropriate temperature to obtain compounds of Formula XIII.
- Removal of the 2-amino group in the 2-aminoimidazo[1,5-f][1,2,4]triazin-4(3H)-one derivatives XIII can be performed using t-butyl nitrite in solvents like DMF/THF at room temperature to form imidazo[1,5-f][1,2,4]triazin-4(3H)-one derivatives XIV.
- 4-Amino-imidazo[1,5-f][1,2,4]triazine derivatives XV can be prepared from compounds XIV using phosphorousoxychloride, 1,2,4-triazole in pyridine and subsequent ammonolysis with ammonia(gas) in isopropanol at room temperature.
- Compounds of Formula XVI can be prepared from compounds of Formula XV using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system, for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an inorganic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent system like combinations of dioxane and water.
- cleaving the protective group of compounds with the Formula XVI give the unprotected amine which, after functionalisation, using methods well known in the art, provided compounds of Formula XVII.
- An example of such protective strategy is the use of the benzyloxycarbonyl protecting group to protect the amine from the amino acids used, and after deprotection with 33% HBr/HOAc or conc. HCl gave the resulting amines.
- R x (R 3 ,R 4 )A 5 C(O)OH are either commercially available or they can be readily prepared using methods well known to the skilled organic chemist, to introduce protecting groups like benzyloxycarbonyl or tert-butyloxycarbonyl or to introduce activating groups like succinic esters in the presence of carbodiimides in solvents like dioxane.
- Palladium catalysts and conditions to form either the pinacol esters or to couple the boronic acids or pinacol esters with the 5-iodoimidazo[1,5-f][1,2,4]triazin-4-amine are well known to the skilled organic chemist—see, for example, Ei-ichi Negishi (Editor), Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, 2002.
- 4-Amino-pyrazolo[3,4-d]pyrimidine compounds of Formula XVIII, wherein R 1 -R x have the previously defined meanings, can be prepared by the general synthetic route shown in Scheme III.
- Compounds of Formula XXII can be to prepared from 3-bromo-4-amino-pyrazolo[3,4-d]pyrimidine-1-yl derivatives XXI using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system, for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an anorganic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent system like combinations of dioxane and water.
- a suitable palladium catalyst system for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an anorganic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent
- cleaving the protective group of compounds with the Formula XXII give the unprotected amine which, after functionalisation, using methods well known in the art, provided compounds of Formula XVIII.
- An example of such protective strategy is the use of the tert-butyloxycarbonyl protecting group to protect the amine from the amines used, and after deprotection in acidic solutions like HCl in for example cyclic or non-cyclic ethers gave the resulting amines.
- the compounds HOA 5 (R 3 ,R 4 )R x are either commercially available or they can be readily prepared using methods well known to the skilled organic chemist, to introduce protecting groups like benzyloxycarbonyl or tert-butyloxycarbonyl.
- Palladium catalysts and conditions to form either the pinacol esters or to couple the boronic acids or pinacol esters with the 4-amino-3-bromopyrazolo[3,4-d]pyrimidine are well known to the skilled organic chemist—see, for example, Ei-ichi Negishi (Editor), Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for Organic Synthesis, John Wiley and Sons, 2002.
- 4-Amino-pyrrolo[1,2-f][1,2,4]triazine compounds of Formula XXIII, wherein R 1 -R x have the previously defined meanings, can be prepared by the general synthetic route shown in Scheme IV.
- Starting material 7-bromopyrrolo[1,2-f][1,2,4]triazin-4-amine can be prepared via a condensation reaction of commercially available 1-amino-1H-pyrrole-2-carbonitrile and formamidine acetate, followed by bromination with bromodan [Dixon, J. L. et al, WO2007064931, pp 163-164].
- the reaction of B(OH) 2 A 5 (R 3 ,R 4 )R x or its corresponding pinacol ester can be carried out in a solvent such as dioxane using an inorganic base like potassium carbonate, cesium carbonate or potassium phosphate, in the presence of a suitable palladium catalyst system, for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0).
- a suitable palladium catalyst system for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0).
- a suitable Pd catalyst system for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0).
- Compounds of Formula XXVII can be prepared from compounds of Formula XXVI using an appropriate boronic acid or pinacol ester (VIII), in the presence of a suitable palladium catalyst system, for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an an organic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent system like combinations of dioxane and water.
- a suitable palladium catalyst system for example bis(diphenylphosphino)ferrocene palladium(II)chloride complex or tetrakis(triphenylphosphine)palladium(0) in the presence of an an organic base like potassium carbonate, cesium carbonate or potassium phosphate in a suitable solvent system like combinations of dioxane and water.
- cleaving the protective group of compounds with the Formula XXVII gives the unprotected amine which, after functionalisation, using methods well known in the art, provided compounds of Formula XXIII.
- An example of such protective strategy is the use of the tert-butyloxycarbonyl protecting group to protect the functionality amine from the boronic acids or esters used. Deprotection in acidic solutions like HCl in, for example, cyclic or non-cyclic ethers gave the resulting amines.
- Compounds (I) can also be constructed by coupling of DMB-protected intermediate XXIV to an appropriately substituted boronic acid or ester using suitable palladium coupling conditions as described in previous schemes, to provide a appropriately functionalized intermediates, which may then undergo amide bond forming reactions to afford intermediates XXV.
- Pyrrolopyrimidine compounds of Formula XXVIII, wherein R 1 -R x have the previously defined meanings can be prepared using the general synthetic route shown in Scheme VII.
- Pyrrolopyrimidines can be obtained commercially, or prepared using methods known to those skilled in the art.
- One such approach involves reaction of commercially available 5-bromo-4-chloro-7H-pyrrolopyrimidine with an appropriate alcohol XXX using Mitsunobu coupling reagents such as triphenylphosphine and DEAD, in an appropriate solvent such as THF, to afford intermediate XXXI, which can be converted to the amine XXXII using ammonia in an appropriate solvent such as isopropanol at elevated temperatures in a sealed tube.
- the intermediate XXXII can then be modified using analogous procedures to those described for imidazopyrazine compounds in Schemes I-VI to obtain compounds XXXIII.
- Pyrazolopyridine compounds of Formula XXXVII, wherein R 1 -R x have the previously defined meanings can be prepared by the general synthetic route shown in scheme VIII.
- Commercially available 4-chloro-1H-pyrazolo[4,3-c]pyridine can be converted to bromide XXXIV using a brominating agent such as NBS in a solvent such as MeCN.
- Intermediate XXXIV can then be converted to XXXV using Mitsunobu coupling reagents such as triphenylphosphine and DEAD in a solvent such as THF or DCM, which can in turn be converted to aminoheterocycle XXXVI by reaction with 2,4-dimethoxybenzylamine in an appropriate solvent such as MeCN in presence of a base such as DIPEA, followed by removal of the DMB group using methods known by those skilled in the art, such as TFA containing triethylsilanei.
- Intermediate XXXVI can then be coupled to an appropriate boronic acid or pinacol ester VIII using analogous procedures outlined for imidazopyrazine compounds in Schemes I-VI to obtain compounds XXXVII.
- the compounds like B(OH) 2 A 5 (R 3 ,R 4 )R x are either commercially available or they can be readily prepared using methods well known to the skilled organic chemist, to introduce protecting groups like benzyloxycarbonyl or tert-butyloxycarbonyl.
- Palladium catalysts and conditions to form either the pinacol esters or to couple the boronic acids or pinacol esters with the 4-amino-pyrrolo[1,2-f][1,2,4]triazine are well known to the skilled organic chemist—see, for example, Ei-ichi Negishi (Editor), Armin de Meijere (Associate Editor), Handbook of Organopalladium Chemistry for to Organic Synthesis, John Wiley and Sons, 2002.
- the present invention also includes within its scope all stereoisomeric forms of the 6-5 membered fused pyridine ring compounds according to the present invention resulting, for example, because of configurational or geometrical isomerism.
- stereoisomeric forms are enantiomers, diastereoisomers, cis and trans isomers etc.
- azepane-2-carboxylic acid is used as amino acid, there exists a mixture of two enantiomers.
- the present invention includes the aforementioned stereoisomers substantially free, i.e., associated with less than 5%, preferably less than 2% and in particular less than 1% of the other stereoisomer. Mixtures of stereoisomers in any proportion, for example a racemic mixture comprising substantially equal amounts of two enantiomers are also included within the scope of the present invention.
- chiral compounds For chiral compounds, methods for asymmetric synthesis whereby the pure stereoisomers are obtained are well known in the art, e.g. synthesis with chiral induction, synthesis starting from chiral intermediates, enantioselective enzymatic conversions, separation of stereoisomers using chromatography on chiral media. Such methods are described in Chirality in Industry (edited by A. N. Collins, G. N. Sheldrake and J. Crosby, 1992; John Wiley). Likewise methods for synthesis of geometrical isomers are also well known in the art.
- the 6-5 membered fused pyridine ring compounds of the present invention which can be in the form of a free base, may be isolated from the reaction mixture in the form of a pharmaceutically acceptable salt.
- the pharmaceutically acceptable salts may also be obtained by treating the free base of Formula I with an organic or inorganic acid such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and ascorbic acid.
- an organic or inorganic acid such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, propionic acid, glycolic acid, maleic acid, malonic acid, methanesulphonic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, and
- the 6-5 membered fused pyridine ring compounds of the present invention also exist as amorphous forms. Multiple crystalline forms are also possible. All the physical forms are included within the scope of the present invention.
- solvates Preparation of solvates is generally known.
- M. Caira et al, J. Pharmaceutical Sci., 93(3), 601-611 (2004) describe the preparation of the solvates of the antifungal fluconazole in ethyl acetate as well as from water.
- Similar preparations of solvates, hemisolvate, hydrates and the like are described by E. C. van Tonder et al, AAPS PharmSciTech., 5(1), article 12 (2004); and A. L. Bingham et al, Chem. Commun. 603-604 (2001).
- a typical, non-limiting, process involves dissolving the inventive compound in desired amounts of the desired solvent (organic or water or mixtures thereof) at a higher than ambient temperature, and cooling the solution at a rate sufficient to form crystals which are then isolated by standard methods.
- Analytical techniques such as, for example IR spectroscopy, show the presence of the solvent (or water) in the crystals as a solvate (or hydrate).
- Mass Spectrometry Electron Spray spectra were recorded on the Applied Biosystems API-165 single quad mass spectrometer in alternating positive and negative ion mode using Flow Injection. The mass range was 120-2000 Da and scanned with a step rate of 0.2 Da. and the capillary voltage was set to 5000 V. N2-gas was used for nebulisation.
- Method H LC-MS Column Agilent TC-C18, 50 ⁇ 2.1 mm, 5 ⁇ m Mobile Phase A: H 2 O (0.1% TFA) B: CH3CN (0.05% TFA) Stop Time: 4.5 min Time(min) B % 0 1 0.4 1 3.4 90 3.9 100 Gradient 3.91 1 Sample injection volume 2 ⁇ l Flow Rate 0.8 ml/min Wavelength 220 nm Oven Tem. 50° C. MS polarity ESI POS
- Method L LC-MS Column Agilent TC-C18, 50 ⁇ 2.1 mm, 5 ⁇ m Mobile Phase A: H 2 O (0.1% TFA) B: MeCN (0.05% TFA) Stop Time: 4.5 min Time(min) B % 0 1 0.4 1 3.4 90 3.9 100 Gradient 3.91 1 Sample injection volume 2 ⁇ l Flow Rate 0.8 ml/min Wavelength 220 nm Oven Temp. 50° C. MS polarity ESI POS
- Preparative HPLC was conducted on a column (50 ⁇ 10 mm ID, 5 ⁇ m, Xterra Prep MS C18) at a flow rate of 5 ml/min, injection volume 500 ⁇ l, at room temperature and UV Detection at 210 nm.
- N-Bromosuccinimide (15.09 g, 85 mmol) was added to a stirred solution of (trans)-4-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclohexyl acetate (85 mmol, 30 g) in DMF (90 mL). The reaction was stirred 1.5 h at rt. The reaction was quenched with sat. NaHCO 3 (aq) and subsequently extracted with DCM (3 ⁇ ).
- This intermediate was prepared, in an analogous manner as described for intermediate 1, from cis-4-hydroxycyclohexanecarboxylic acid to obtain the title compound (796 mg, 102%).
- This intermediate was prepared, in an analogous manner as described for intermediate 1, from tetrahydro-2h-pyran-4-carboxylic acid to obtain the title compound (3.9 g, 54.2%).
- This intermediate was prepared in an analogous manner as described for Intermediate 1, from (1R,5S,6R)-3-oxabicyclo[3.1.0]hexane-6-carboxylic acid to obtain the title compound (3.1 g, 97%).
- This intermediate was prepared in an analogous manner as described for Intermediate 1, from 2,2-dimethyltetrahydro-2h-pyran-4-carboxylic acid to obtain the title compound (10.25 g, 53.3%).
- This intermediate was prepared in an analogous manner as described for Intermediate 1, from cyclopentanecarboxylic acid to obtain the title compound (275 mg, 58.8%).
- reaction mixture was stirred overnight at rt.
- the reaction was washed with 20 mL sat. Na 2 CO 3 solution, 20 mL water, 20 mL brine, dried (Na 2 SO 4 ), filtered and concentrated.
- the residue was purified using silica gel chromatography (EtOAc:heptane 10:90 to 30:70) to give the title compound (1.50 g, 55.5%).
- This compound was prepared in an analogous manner as described in Intermediate V, starting from commercially available 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid and 2 tert-butyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate, to afford the title compound (1.30 g, 71.2%).
- N-(4-cyclopropoxypyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide was prepared following the procedure of intermediate AF.
- 1 H NMR (400 MHz, CHLOROFORM-d) ⁇ 9.12 (br.
- N-Bromosuccinimide (1.329 g, 7.47 mmol) was added to a stirred solution of (R)-benzyl 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate (7.47 mmol, 2.77 g) in DMF (40 mL). The reaction was stirred 1 h at room temperature. The reaction was quenched with 50 mL sat. Na 2 S 2 O 3 (aq) and ethyl acetate (50 mL). Brine (50 mL) was added and the mixture was then separated. The aqueous layer was extracted with ethyl acetate.
- This intermediate was prepared in an analogous manner as described for intermediate 8, from (R)-1-Cbz-pyrrolidine-3-carboxylic acid to obtain (R)-benzyl 3-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate. Subsequent reaction with N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide and deprotection with 33% HBr/HOAc was performed as described for intermediate 9 afforded the title compound (1.49 g, 99%)
- This intermediate was prepared in an analogous manner as described for intermediate 8, from 1-[(benzyloxy)carbonyl]piperidine-4-carboxylic acid to obtain benzyl 4-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)piperidine-1-carboxylate. Subsequent reaction with N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide and deprotection with 33% HBr/HOAc as described for intermediate 9 afforded the title compound (314 mg, 95%).
- This intermediate was prepared in an analogous manner as described for intermediate 8, from Cbz-DL-3-aminoisobutyric acid to obtain benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)propylcarbamate. Subsequent reaction with 4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide (Intermediate D) and deprotection with 33% HBr/HOAc as described for intermediate 9 afforded the title compound (130 mg, 84%).
- This intermediate was prepared in an analogous manner as described for intermediate 8, from 7-(benzyloxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (prepared as described by Otani, Y. et. Al. in Tetrahedron 62 (2006) 11635) to obtain benzyl 2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)-7-azabicyclo[2.2.1]heptane-7-carboxylate.
- This intermediate was prepared in an analogous manner as described for Intermediate 8, from commercially available cis-3-(((benzyloxy)carbonyl)amino)cyclohexanecarboxylic acid to obtain benzyl(cis)-3-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)cyclohexyl-carbamate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/233,478 US20140221333A1 (en) | 2011-07-19 | 2012-07-19 | Btk inhibitors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161509446P | 2011-07-19 | 2011-07-19 | |
EP11174570A EP2548877A1 (de) | 2011-07-19 | 2011-07-19 | 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren |
EP11174570.9 | 2011-07-19 | ||
US14/233,478 US20140221333A1 (en) | 2011-07-19 | 2012-07-19 | Btk inhibitors |
PCT/CN2012/000971 WO2013010380A1 (en) | 2011-07-19 | 2012-07-19 | Btk inhibitors |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/000971 A-371-Of-International WO2013010380A1 (en) | 2011-07-19 | 2012-07-19 | Btk inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/250,978 Continuation US9718828B2 (en) | 2011-07-19 | 2016-08-30 | BTK Inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140221333A1 true US20140221333A1 (en) | 2014-08-07 |
Family
ID=44545515
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/233,478 Abandoned US20140221333A1 (en) | 2011-07-19 | 2012-07-19 | Btk inhibitors |
US15/250,978 Active US9718828B2 (en) | 2011-07-19 | 2016-08-30 | BTK Inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/250,978 Active US9718828B2 (en) | 2011-07-19 | 2016-08-30 | BTK Inhibitors |
Country Status (11)
Country | Link |
---|---|
US (2) | US20140221333A1 (de) |
EP (2) | EP2548877A1 (de) |
JP (1) | JP2014520866A (de) |
KR (1) | KR20140068020A (de) |
CN (1) | CN103917545A (de) |
AU (1) | AU2012286426A1 (de) |
BR (1) | BR112014001279A2 (de) |
CA (1) | CA2841899A1 (de) |
MX (1) | MX2014000747A (de) |
RU (1) | RU2014106020A (de) |
WO (1) | WO2013010380A1 (de) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016079693A1 (en) * | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
WO2016109220A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
WO2016109223A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
US9975897B2 (en) | 2014-06-11 | 2018-05-22 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase |
US9981975B2 (en) | 2016-03-28 | 2018-05-29 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
US10342780B2 (en) | 2015-12-16 | 2019-07-09 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
US10399990B2 (en) | 2015-09-16 | 2019-09-03 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
CN110291080A (zh) * | 2016-12-21 | 2019-09-27 | 安塞塔制药公司 | 布鲁顿酪氨酸激酶的咪唑并吡嗪抑制剂 |
US10435375B2 (en) * | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
US11180496B2 (en) | 2017-07-12 | 2021-11-23 | Daewoong Pharmaceutical Co., Ltd. | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same |
WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
EP2710005B1 (de) | 2011-05-17 | 2016-10-05 | Principia Biopharma Inc. | Tyrosinkinase-hemmer |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
CN106243113B (zh) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
EP2548877A1 (de) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
WO2013113097A1 (en) | 2012-01-31 | 2013-08-08 | Beta Pharma Canada Inc. | Cyclic molecules as bruton's tyrosine kinase inhibitors |
MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
WO2014031784A1 (en) | 2012-08-23 | 2014-02-27 | Alios Biopharma, Inc. | Compounds for the treatment of paramoxyvirus viral infections |
PL3181567T3 (pl) | 2012-09-10 | 2019-09-30 | Principia Biopharma Inc. | Związki pyrazolopirymidonowe jako inhibitory kinazy |
KR20150061651A (ko) | 2012-09-26 | 2015-06-04 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ire1의 조절 |
WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20140206681A1 (en) * | 2013-01-23 | 2014-07-24 | Ronald M. Kim | Btk inhibitors |
AR094812A1 (es) * | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
EP2970300B1 (de) * | 2013-03-15 | 2018-05-16 | Boehringer Ingelheim International GmbH | Heteroaromatische verbindungen als btk inhibitoren |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
MX367085B (es) | 2013-07-31 | 2019-08-05 | Merck Patent Gmbh | Piridinas, pirimidinas y pirazinas como inhibidores de tirosina cinasa de bruton e inhibidores y usos de las mismas. |
CN114716426A (zh) * | 2013-08-21 | 2022-07-08 | 詹森生物制药有限公司 | 抗病毒化合物 |
BR112016006978A2 (pt) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton |
EP3076974A1 (de) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutische kombination aus einem pi3k-hemmer und einem btk-hemmer |
US9382246B2 (en) | 2013-12-05 | 2016-07-05 | Pharmacyclics Llc | Inhibitors of Bruton's tyrosine kinase |
EP3079683A4 (de) | 2013-12-13 | 2017-12-20 | Dana-Farber Cancer Institute, Inc. | Verfahren zur behandlung eines lymphoplasmazytischen lymphoms |
US9908872B2 (en) | 2013-12-13 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
WO2015095099A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US9834554B2 (en) | 2013-12-20 | 2017-12-05 | Merck Sharp & Dohme Corp. | BTK inhibitors |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
TW201613860A (en) | 2014-02-13 | 2016-04-16 | Incyte Corp | Cyclopropylamines as LSD1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
SG10201806849WA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
EP3626714A1 (de) | 2014-02-13 | 2020-03-25 | Incyte Corporation | Cyclopropylamine als lsd1-inhibitoren |
CN112353806A (zh) | 2014-02-21 | 2021-02-12 | 普林斯匹亚生物制药公司 | Btk抑制剂的盐和固体形式 |
MX2016011674A (es) | 2014-03-12 | 2017-04-27 | Novartis Ag | Combinacion que comprende un inhibidor de btk y un inhibidor de akt. |
WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
CA2959602A1 (en) * | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
LT3179991T (lt) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai |
RU2658821C1 (ru) * | 2014-08-18 | 2018-06-25 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль моноциклического производного пиридина и ее кристалл |
AU2015335788B2 (en) | 2014-10-22 | 2020-07-30 | Dana-Farber Cancer Institute, Inc. | Thiazolyl-containing compounds for treating proliferative diseases |
AR102871A1 (es) * | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
EA036269B1 (ru) | 2014-12-18 | 2020-10-21 | Принсипиа Биофарма Инк. | Лечение пузырчатки |
WO2016106628A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106627A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016106652A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Biarylether imidazopyrazine btk inhibitors |
WO2016106624A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Tertiary alcohol imidazopyrazine btk inhibitors |
WO2016106625A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Btk inhibitors |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
PE20180455A1 (es) | 2015-04-03 | 2018-03-05 | Incyte Corp | Compuestos heterociclicos como inhibidores de lsd1 |
WO2016161571A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | Indazole and azaindazole btk inhibitors |
EP3603672A1 (de) | 2015-05-26 | 2020-02-05 | MorphoSys AG | Kombination aus einem anti-cd19-antikörper und einem bruton-tyrosinkinase-inhibitor und verwendungen davon |
WO2016192074A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
MA50817B1 (fr) | 2015-07-02 | 2021-10-29 | Acerta Pharma Bv | Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
ITUB20152576A1 (it) * | 2015-07-29 | 2017-01-29 | Laboratorio Chimico Int S P A | Procedimento per la preparazione di ibrutinib e nuovo intermedio di sintesi. |
SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
EP3371189A1 (de) | 2015-11-06 | 2018-09-12 | Acerta Pharma B.V. | Imidazopyrazinhemmer der bruton-tyrosinkinase |
SG11201804152RA (en) | 2015-11-19 | 2018-06-28 | Incyte Corp | Heterocyclic compounds as immunomodulators |
US20180371321A1 (en) * | 2015-12-11 | 2018-12-27 | Merck Patent Gmbh | Polymerisable compounds and the use thereof in liquid-crystal displays |
WO2017112730A1 (en) | 2015-12-22 | 2017-06-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10626116B2 (en) * | 2016-01-05 | 2020-04-21 | Jiangsu Hengrui Medicine Co., Ltd. | Crystalline form of BTK kinase inhibitor and preparation method thereof |
US10793566B2 (en) * | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
CN105732638B (zh) * | 2016-01-22 | 2018-01-30 | 成都倍特药业有限公司 | 一种具有螺环或桥环结构的布鲁顿酪氨酸激酶抑制剂及其制备方法 |
CA3021678A1 (en) | 2016-04-22 | 2017-10-26 | Incyte Corporation | Formulations of an lsd1 inhibitor |
ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
PL3472167T3 (pl) * | 2016-06-20 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
MX2018016056A (es) | 2016-06-29 | 2019-07-04 | Principia Biopharma Inc | Formulaciones de liberacion modificada de 2-[3-[4-amino-3-(2-fluor o-4-fenoxi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbo nil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enenitrilo. |
EP3480199B1 (de) * | 2016-06-30 | 2021-03-17 | Hangzhou Bangshun Pharmaceutical Co., Ltd. | Imidazopyridinaminphenylderivate und verwendung davon |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
KR20190112263A (ko) | 2016-12-12 | 2019-10-04 | 멀티비르 인코포레이티드 | 암 및 감염성 질환의 치료 및 예방을 위한 바이러스 유전자 치료요법 및 면역 체크포인트 억제제를 포함하는 방법 및 조성물 |
US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3558973B1 (de) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridinderivate als immunmodulatoren |
BR112019012993A2 (pt) | 2016-12-22 | 2019-12-03 | Incyte Corp | derivados de benzo-oxazol como imunomoduladores |
CN106588937B (zh) * | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
TWI754011B (zh) | 2017-02-24 | 2022-02-01 | 美商基利科學股份有限公司 | 布魯頓氏酪胺酸激酶之抑制劑 |
US10314844B2 (en) | 2017-02-24 | 2019-06-11 | Gilead Sciences, Inc. | Inhibitors of Bruton's tyrosine kinase |
JP7219902B2 (ja) | 2017-03-22 | 2023-02-09 | スジョウ・バイジブゴン・ファーマスーティカル・テクノロジー・カンパニー・リミテッド | ブルトン型チロシンキナーゼ阻害剤 |
CN109111446B (zh) * | 2017-06-22 | 2021-11-30 | 上海度德医药科技有限公司 | 一种具有药物活性的杂芳基化合物 |
WO2019013562A1 (ko) * | 2017-07-12 | 2019-01-17 | 주식회사 대웅제약 | 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물 |
CN109305944B (zh) * | 2017-07-28 | 2022-09-02 | 深圳睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CA3074139A1 (en) | 2017-09-01 | 2019-03-07 | Richard M. Keenan | Compounds and compositions for ire1 inhibition |
CN107602564B (zh) * | 2017-09-20 | 2019-08-30 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
EA037031B1 (ru) * | 2017-10-06 | 2021-01-28 | Асерта Фарма Б.В. | Имидазопиразиновые ингибиторы тирозинкиназы брутона |
JP7133023B2 (ja) * | 2018-01-17 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Pi4kiiiベータ阻害剤 |
CN108478580A (zh) * | 2018-03-05 | 2018-09-04 | 浙江大学 | 依鲁替尼在制备抗重症肝炎药物中的应用 |
MX2020008610A (es) | 2018-03-28 | 2020-09-21 | Eisai R&D Man Co Ltd | Agente terapeutico para carcinoma hepatocelular. |
CA3099994A1 (en) | 2018-05-11 | 2019-11-04 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
CN109053780B (zh) * | 2018-07-05 | 2020-09-29 | 浙江合聚生物医药有限公司 | 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法 |
WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN113365631A (zh) * | 2019-01-18 | 2021-09-07 | 杭州邦顺制药有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药(上海)有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
WO2021008441A1 (zh) * | 2019-07-12 | 2021-01-21 | 正大天晴药业集团股份有限公司 | 含有5-氮杂螺庚烷的btk抑制剂 |
AR119624A1 (es) | 2019-08-09 | 2021-12-29 | Incyte Corp | Sales de un inhibidor de pd-1 / pd-l1 |
CN110563733A (zh) * | 2019-09-12 | 2019-12-13 | 安帝康(无锡)生物科技有限公司 | 作为选择性btk抑制剂的咪唑并吡嗪类化合物 |
RS65239B1 (sr) | 2019-09-26 | 2024-03-29 | Jumbo Drug Bank Co Ltd | Derivati 4-fluoro-1h-pirazolo[3,4-c]piridina kao selektivni inhibitori brutonove tirozin kinaze (btk) za lečenje b-ćelijskih limfoma i autoimunih bolesti |
KR20220062366A (ko) * | 2019-09-26 | 2022-05-16 | 센젠 타겟알엑스, 아이엔씨. | 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도 |
JP2022549375A (ja) | 2019-09-30 | 2022-11-24 | インサイト・コーポレイション | 免疫調節剤としてのピリド[3,2-d]ピリミジン化合物 |
CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
MX2022005651A (es) | 2019-11-11 | 2022-07-27 | Incyte Corp | Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1). |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
TW202233616A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | 用於製備pd-1/pd-l1抑制劑以及其鹽及結晶形式之方法 |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
BR112023023065A2 (pt) * | 2021-05-05 | 2024-01-30 | Biogen Ma Inc | Compostos para direcionar a degradação da tirosina quinase de bruton |
CN113968860B (zh) * | 2021-11-05 | 2023-06-06 | 杭州医学院 | 一种可逆btk抑制剂及其合成方法和应用 |
CN114213416B (zh) * | 2021-11-05 | 2023-06-06 | 杭州医学院 | 一种恶唑并[4,5-b]吡啶结构的不可逆BTK抑制剂及其应用 |
WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
CN117164591A (zh) * | 2022-05-26 | 2023-12-05 | 中国医学科学院药物研究所 | 吡咯并嘧啶类化合物,其制备方法及制药用途 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT95899A (pt) | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
DK0903348T4 (da) | 1995-11-17 | 2008-10-20 | Biotechnolog Forschung Gmbh | Epothilonderivater og fremstilling deraf |
AU756699B2 (en) | 1996-12-03 | 2003-01-23 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
KR20020063854A (ko) | 1999-09-17 | 2002-08-05 | 애보트 게엠베하 운트 콤파니 카게 | 치료제로서의 키나제 억제제 |
US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
CN1390219A (zh) * | 1999-09-17 | 2003-01-08 | 艾博特股份有限两合公司 | 作为治疗剂的吡唑并嘧啶类 |
WO2002083139A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
WO2002083140A1 (en) | 2001-04-10 | 2002-10-24 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2002252614B2 (en) | 2001-04-10 | 2006-09-14 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
AU2002251266A1 (en) | 2001-04-10 | 2002-10-28 | Merck Sharp And Dohme Limited | Inhibitors of akt activity |
GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
US6998391B2 (en) | 2002-02-07 | 2006-02-14 | Supergen.Inc. | Method for treating diseases associated with abnormal kinase activity |
CA2480880C (en) | 2002-04-08 | 2011-03-22 | Merck & Co., Inc. | Inhibitors of akt activity |
AU2003226250B2 (en) | 2002-04-08 | 2007-08-16 | Merck Sharp & Dohme Corp. | Inhibitors of Akt activity |
US7273869B2 (en) | 2002-04-08 | 2007-09-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
JP4394960B2 (ja) | 2002-04-08 | 2010-01-06 | メルク エンド カムパニー インコーポレーテッド | Akt活性阻害薬 |
UA83509C2 (en) | 2003-10-15 | 2008-07-25 | Оси Фармасьютикалз, Инк. | Imidazopyrazines as tyrosine kinase inhibitors |
PT1699512E (pt) | 2003-11-03 | 2012-09-11 | Glaxo Group Ltd | Dispositivo distribuidor de fluido |
EA012873B1 (ru) | 2004-04-02 | 2009-12-30 | Оси Фармасьютикалз, Инк. | 6,6-бициклические кольцевые замещенные гетеробициклические ингибиторы протеинкиназ |
JP4954086B2 (ja) | 2004-12-08 | 2012-06-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 1h−ピロロ[2,3−b]ピリジン |
PT1951724E (pt) | 2005-11-17 | 2011-08-02 | Osi Pharm Inc | Inibidores mtor fundidos bicíclicos |
PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
AR057960A1 (es) | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
AU2006320440B2 (en) | 2005-12-02 | 2012-04-05 | Bayer Healthcare Llc | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis |
JP4675801B2 (ja) | 2006-03-06 | 2011-04-27 | 日本メナード化粧品株式会社 | Ror活性化剤 |
EP1996193A2 (de) | 2006-03-13 | 2008-12-03 | OSI Pharmaceuticals, Inc. | Kombinierte behandlung mit einem egfr-kinase-hemmber und einem wirkstoff, der tumorzellen für die wirkung von egfr-kinase-hemmern sensibilisiert |
SI2526771T1 (sl) | 2006-09-22 | 2017-06-30 | Pharmacyclics Llc | Inhibitorji Bruton tirozin kinaze |
US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
EP2560007A1 (de) | 2007-03-28 | 2013-02-20 | Pharmacyclics, Inc. | Identifikation von Inhibitoren der Bruton Tyrosin Kinase |
WO2009076170A2 (en) | 2007-12-13 | 2009-06-18 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
EP2181710A1 (de) | 2008-10-28 | 2010-05-05 | Phenex Pharmaceuticals AG | Liganden zur Modulation der Orphan-Rezeptor-Gamma (NR1F3) Aktivität |
US9095592B2 (en) | 2008-11-07 | 2015-08-04 | The Research Foundation For The State University Of New York | Bruton's tyrosine kinase as anti-cancer drug target |
JP5656976B2 (ja) * | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
JP5764145B2 (ja) * | 2010-02-08 | 2015-08-12 | メルク・シャープ・エンド・ドーム・ベー・フェー | 8−メチル−1−フェニル−イミダゾル[1,5−a]ピラジン化合物 |
UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
PT2578585T (pt) | 2010-05-31 | 2016-09-23 | Ono Pharmaceutical Co | Derivado de purinona como inibidor da quinase btk |
CA3154024C (en) | 2010-06-03 | 2024-02-27 | Pharmacyclics Llc | Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma |
US20120053189A1 (en) | 2010-06-28 | 2012-03-01 | Pharmacyclics, Inc. | Btk inhibitors for the treatment of immune mediated conditions |
WO2012158843A2 (en) | 2011-05-17 | 2012-11-22 | The Regents Of The University Of California | Kinase inhibitors |
AU2012275275A1 (en) | 2011-06-28 | 2014-01-23 | Pharmacyclics Llc | Methods and compositions for inhibition of bone resorption |
EA201490265A1 (ru) | 2011-07-13 | 2014-12-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
CN106243113B (zh) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
CA2841887A1 (en) | 2011-07-19 | 2013-01-24 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors |
EP2548877A1 (de) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Gliedrige kondensierte Pyridinyl)benzamide als BTK-Inhibitoren |
EA201892766A1 (ru) | 2011-10-19 | 2019-08-30 | Фармасайкликс Элэлси | ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk) |
US20140212425A1 (en) | 2011-12-05 | 2014-07-31 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US20140206681A1 (en) | 2013-01-23 | 2014-07-24 | Ronald M. Kim | Btk inhibitors |
CN105073115A (zh) | 2013-03-14 | 2015-11-18 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合 |
WO2014143807A2 (en) | 2013-03-15 | 2014-09-18 | Stromatt Scott | Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders |
CN111317821A (zh) | 2013-04-08 | 2020-06-23 | 药品循环有限责任公司 | 依鲁替尼联合疗法 |
WO2015018522A1 (en) | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
-
2011
- 2011-07-19 EP EP11174570A patent/EP2548877A1/de not_active Withdrawn
-
2012
- 2012-07-19 RU RU2014106020/04A patent/RU2014106020A/ru not_active Application Discontinuation
- 2012-07-19 EP EP12814549.7A patent/EP2734529B1/de active Active
- 2012-07-19 BR BR112014001279A patent/BR112014001279A2/pt not_active IP Right Cessation
- 2012-07-19 CN CN201280045511.4A patent/CN103917545A/zh active Pending
- 2012-07-19 WO PCT/CN2012/000971 patent/WO2013010380A1/en active Application Filing
- 2012-07-19 AU AU2012286426A patent/AU2012286426A1/en not_active Abandoned
- 2012-07-19 CA CA2841899A patent/CA2841899A1/en not_active Abandoned
- 2012-07-19 MX MX2014000747A patent/MX2014000747A/es unknown
- 2012-07-19 KR KR1020147003924A patent/KR20140068020A/ko not_active Application Discontinuation
- 2012-07-19 JP JP2014520495A patent/JP2014520866A/ja not_active Withdrawn
- 2012-07-19 US US14/233,478 patent/US20140221333A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/250,978 patent/US9718828B2/en active Active
Non-Patent Citations (3)
Title |
---|
Akinleye et al. Journal of Hematology & Oncology 2013, 6:59 * |
Chakravarty et al. Clinical Immunology (2013) 148, 66-78. * |
Whang et al., Drug Discovery Today, pages 1-5, 2014. * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10538524B2 (en) | 2014-06-11 | 2020-01-21 | Loxo Oncology Inc. | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase |
US9975897B2 (en) | 2014-06-11 | 2018-05-22 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase |
US10196397B2 (en) | 2014-11-19 | 2019-02-05 | Sun Pharmaceutical Industries Limited | Process for the preparation of ibrutinib |
WO2016079693A1 (en) * | 2014-11-19 | 2016-05-26 | Sun Pharmaceutical Industries Limited | A process for the preparation of ibrutinib |
US10087188B2 (en) | 2014-12-31 | 2018-10-02 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine Btk inhibitors |
US10040805B2 (en) | 2014-12-31 | 2018-08-07 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,5-a]pyrazines as Btk inhibitors |
WO2016109223A1 (en) | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016109220A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Imidazopyrazine analogs with 3-tertiary carbon substitutions as btk inhibitors |
US10435375B2 (en) * | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
EP4116303A1 (de) | 2015-09-16 | 2023-01-11 | Loxo Oncology, Inc. | Pyrazolopyrimidinderivate als btk-inhibitoren zur krebsbehandlung |
US10611766B2 (en) | 2015-09-16 | 2020-04-07 | Loxo Oncology Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
US10399990B2 (en) | 2015-09-16 | 2019-09-03 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
US10399989B2 (en) | 2015-09-16 | 2019-09-03 | Loxo Oncology, Inc. | Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer |
US10918622B2 (en) | 2015-12-16 | 2021-02-16 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
US10464905B2 (en) | 2015-12-16 | 2019-11-05 | Loxo Oncology Inc. | Compounds useful as kinase inhibitors |
US10342780B2 (en) | 2015-12-16 | 2019-07-09 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
US10695323B2 (en) | 2015-12-16 | 2020-06-30 | Loxo Oncology, Inc. | Compounds useful as kinase inhibitors |
EP3782994A1 (de) | 2015-12-16 | 2021-02-24 | Loxo Oncology, Inc. | Als kinaseinhibitoren geeignete verbindungen |
US11471441B2 (en) | 2015-12-16 | 2022-10-18 | Loxo Oncology Inc. | Compounds useful as kinase inhibitors |
US11826351B2 (en) | 2015-12-16 | 2023-11-28 | Loxo Oncology Inc. | Compounds useful as kinase inhibitors |
US9981975B2 (en) | 2016-03-28 | 2018-05-29 | Incyte Corporation | Pyrrolotriazine compounds as tam inhibitors |
CN110291080A (zh) * | 2016-12-21 | 2019-09-27 | 安塞塔制药公司 | 布鲁顿酪氨酸激酶的咪唑并吡嗪抑制剂 |
US11180496B2 (en) | 2017-07-12 | 2021-11-23 | Daewoong Pharmaceutical Co., Ltd. | 1H-pyrazolopyridine derivative and pharmaceutical composition comprising the same |
WO2019090269A1 (en) * | 2017-11-06 | 2019-05-09 | Peng Wang | Processes to produce acalabrutinib |
WO2022240920A1 (en) | 2021-05-14 | 2022-11-17 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
EP2734529B1 (de) | 2018-09-05 |
CA2841899A1 (en) | 2013-01-24 |
US20170008899A1 (en) | 2017-01-12 |
AU2012286426A1 (en) | 2014-01-30 |
KR20140068020A (ko) | 2014-06-05 |
RU2014106020A (ru) | 2015-08-27 |
EP2734529A1 (de) | 2014-05-28 |
JP2014520866A (ja) | 2014-08-25 |
EP2734529A4 (de) | 2015-06-03 |
EP2548877A1 (de) | 2013-01-23 |
CN103917545A (zh) | 2014-07-09 |
WO2013010380A1 (en) | 2013-01-24 |
MX2014000747A (es) | 2014-10-15 |
US9718828B2 (en) | 2017-08-01 |
BR112014001279A2 (pt) | 2018-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9718828B2 (en) | BTK Inhibitors | |
US9481682B2 (en) | Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors | |
US9446130B2 (en) | BTK inhibitors | |
US9637486B2 (en) | Btk inhibitors | |
US9834554B2 (en) | BTK inhibitors | |
US10040805B2 (en) | Substituted imidazo[1,5-a]pyrazines as Btk inhibitors | |
US10214546B2 (en) | Btk inhibitors | |
US20170349593A1 (en) | Btk inhibitors | |
WO2014113932A1 (en) | Btk inhibitors | |
WO2016109221A1 (en) | Btk inhibitors | |
US10130630B2 (en) | BTK inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COOPER, ALAN B.;KIM, RONALD M.;BOGA, SOBHANA BABU;AND OTHERS;SIGNING DATES FROM 20140204 TO 20140226;REEL/FRAME:033326/0232 |
|
AS | Assignment |
Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WUXI APPTEC (SHANGHAI) CO., LTD.;REEL/FRAME:033329/0773 Effective date: 20140123 Owner name: WUXI APPTEC (SHANGHAI) CO., LTD., CHINA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WU, HAO;LIU, SHILAN;YANG, CHUNDAO;REEL/FRAME:033329/0766 Effective date: 20131231 Owner name: MERCK SHARP & DOHME B.V., NETHERLANDS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DE MAN, ADRIANUS PETRUS ANTONIUS;STERRENBURG, JAN-GERARD;RAAIJMAKERS, HANS C.A.;AND OTHERS;SIGNING DATES FROM 20131223 TO 20140203;REEL/FRAME:033329/0735 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |